

별첨 2

배제문헌

문헌배제사유

1. 사전에 정의한 연구대상자에 대한 연구가 아닌 연구
2. 사전에 정의한 중재검사를 수행하지 않은 연구
3. 건강인을 대조군으로 비교한 연구
4. 사전에 정의한 참고표준검사를 수행하지 않은 연구
5. 사전에 정의한 연구결과를 하나 이상 보고하지 않은 연구
6. 사전에 정의한 연구설계에 해당하지 않는 연구
7. 원저가 아닌 연구(종설, letter, comment 등)
8. 동물실험 또는 전임상시험 연구
9. 한국어나 영어로 출판되지 않은 문헌
10. 중복문헌

연번	서지정보	배제 사유
1	Amaxilati DA, M.Daniels, T.Carroll, M.Patel, J. Do blood biomarkers perform better than traditional methods for identifying adults with cystic fibrosis and liver fibrosis? Journal of Cystic Fibrosis. 2020;19 (Supplement 2):S4.	7
2	An HSC, Y. H.Song, M. K.Lee, S. Y.Kim, G. B.Bae, E. J. Early development of hepatic fibrosis after Fontan procedure: A non-invasive study of a subclinical liver disease. International Journal of Cardiology. 2020.	1
3	Are VSV, R.Vilar-Gomez, E.Chalasanani, N. Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis. Clinical Gastroenterology and Hepatology. 2020.	7
4	Asphaug LT, M.Krag, A.Melberg, H. O. Cost-Effectiveness of Noninvasive Screening for Alcohol-Related Liver Fibrosis. Hepatology. 2020;71(6):2093-104.	4
5	Azzaroli FM, G.Marchesini, G.Brodosi, L.Petroni, M. L. Fatty liver in pregnancy: a narrative review of two distinct conditions. Expert Review of Gastroenterology and Hepatology. 2020;14(2):127-35.	7
6	Bradshaw DG, Y.Verma, S.Abramowicz, I.Bremner, S.Perry, N. Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone. BMJ Open. 2020;10 (7) (no pagination)(e035596).	3

연번	서지정보	배제 사유
7	Clough GFC, A. J.Thanaj, M.Scorletti, E.Calder, P. C.Byrne, C. D. Dysregulated Neurovascular Control Underlies Declining Microvascular Functionality in People With Non-alcoholic Fatty Liver Disease (NAFLD) at Risk of Liver Fibrosis. <i>Frontiers in Physiology</i> . 2020;11 (no pagination)(551).	3
8	Foncea CGP, A.Lupusoru, R.Moga, T. V.Danila, M.Sirli, R.Sporea, I. Non-Invasive Techniques for Screening of Significant Liver Fibrosis and Steatosis in Patients with Alcohol Use Disorder. <i>Gastroenterology</i> . 2020;158 (6 Supplement 1):S-1437.	7
9	Fragkos KCB, M. C. P.Kumar, S.Caselton, L.Menys, A.Bainbridge, A.Taylor, S. A.Torrealdea, F.Kumagai, T.Di Caro, S.Rahman, F.Macnaughtan, J.Chouhan, M. D.Mehta, S. Serum scoring and quantitative magnetic resonance imaging in intestinal failure-associated liver disease: A feasibility study. <i>Nutrients</i> . 2020;12(7):1-21.	1
10	Fragkos KCPB, M. C.Kumar, S.Caselton, L.Menys, A.Bainbridge, A.Taylor, S. A.Torrealdea, F.Kumagai, T.Di Caro, S.Rahman, F.Macnaughtan, J.Chouhan, M. D.Mehta, S. Serum Scoring and Quantitative Magnetic Resonance Imaging in Intestinal Failure-Associated Liver Disease: A Feasibility Study. <i>Nutrients</i> . 2020;12(7):19.	6
11	Hadeifi AD, D.Trepo, E.Moreno, C. Noninvasive diagnosis in alcohol-related liver disease. <i>Health Science Reports</i> . 2020;3(1):e146.	7
12	Harrison SAR, S. J.Paredes, A. H.Trotter, J. F.Bashir, M. R.Guy, C. D.Banerjee, R.Jaros, M. J.Owers, S.Baxter, B. A.Ling, L.DePaoli, A. M. NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis. <i>Hepatology</i> . 2020;71(4):1198-212.	1
13	Jacobson IM, A. J.Lawitz, E.Gane, E.Conway, B.Ruane, P. J.Younes, Z.Chen, F.Camargo, M.Chokkalingam, A.Gaggar, A.Myers, R. P.Lu, W. Y.Leggett, B.Calleja, J. L.Agarwal, K.Reddy, K. R.Mangia, A. Long-term course of cirrhosis regression: Lessons from patients with HCV cirrhosis following successful sofosbuvir-based treatment. <i>Hepatology International</i> . 2020;14 (Supplement 1):S164.	7
14	Karsdal MAD, S. J.Holm Nielsen, S.Bager, C.Rasmussen, D. G. K.Loomba, R.Surabattula, R.Villesen, I. F.Luo, Y.Shevell, D.Gudmann, N. S.Nielsen, M. J.George, J.Christian, R.Leeming, D. J.Schuppan, D. Collagen biology and non-invasive biomarkers of liver fibrosis. <i>Liver International</i> . 2020;40(4):736-50.	7
15	Keller LME, S.Li, C.Winter, L.Kerecman, J.Goodman, Z.Mittal, N.Blanco, C. L. Association of novel markers of liver disease with neonatal liver disease in premature baboons, <i>Papio sp.</i> <i>PLoS ONE</i> . 2020;15 (3) (no pagination)(e0228985).	5
16	Koutoukidis DAJ, S. A.Aveyard, P.Astbury, N. M. The Effect of Moderate Weight Loss on a Non-Invasive Biomarker of Liver Fibrosis: A Randomised Controlled Trial. <i>Obesity Facts</i> . 2020;13(2):144-51.	1
17	Madsen BST, M.Detlefsen, S.Sorensen, M. D.Kjaergaard, M.Moller, L. S.Rasmussen, D. N.Schlosser, A.Holmskov, U.Trebicka, J.Sorensen, G. L.Krag, A.Galaxy consortium. Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar-associated protein 4. <i>Liver International</i> . 2020;40(7):1701-12.	2
18	Madsen BST, M.Detlefsen, S.Sorensen, M. D.Kjaergaard, M.Moller, L. S.Rasmussen, D. N.Schlosser, A.Holmskov, U.Trebicka, J.Sorensen, G. L.Krag, A. Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar-associated protein 4. <i>Liver International</i> . 2020;40(7):1701-12.	6
19	Mjelle ABF, G.Gilja, O. H.Vesterhus, M. Liver Elastography in Primary Sclerosing Cholangitis Patients Using Three Different Scanner Systems. <i>Ultrasound in Medicine and Biology</i> . 2020;46(8):1854-64.	1

연번	서지정보	배제 사유
20	Nagelkerke SCJD, L. G.Benninga, M. A.Koot, B. G. P.Tabbers, M. M. The prevalence of liver fibrosis according to non-invasive tools in a pediatric home parenteral nutrition cohort. <i>Clinical Nutrition</i> . 2020.	1
21	Nct. Balloon-Assisted Maturation of Autogenous Arteriovenous Fistulae. https://clinicaltrials.gov/show/NCT04263116 . 2020.	1
22	Nct. Combination With Inhibitor of Neutrophil Elastase (All-trans Retinoic Acid) and Isotretinoin May Enhances Neutralizing Antibodies in COVID -19 Infected Patients Better Than COVID-19 Inactivated Vaccines. https://clinicaltrials.gov/show/NCT04396067 . 2020.	1
23	Nct. The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin Resistance. https://clinicaltrials.gov/show/NCT04315350 . 2020.	1
24	Patel KH, S. A.Elkhashab, M.Trotter, J. F.Herring, R.Rojter, S. E.Kayali, Z.Wong, V. W.Greenbloom, S.Jayakumar, S.Shiffman, M. L.Freilich, B.Lawitz, E. J.Gane, E. J.Harting, E.Xu, J.Billin, A. N.Chung, C.Djedjos, C. S.Subramanian, G. M.Myers, R. P.Middleton, M. S.Rinella, M.Noureddin, M. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. <i>Hepatology</i> . 2020;72(1):58-71.	5
25	Patel KH, S. A.Elkhashab, M.Trotter, J. F.Herring, R.Rojter, S. E.Kayali, Z.Wong, V. W. S.Greenbloom, S.Jayakumar, S.Shiffman, M. L.Freilich, B.Lawitz, E. J.Gane, E. J.Harting, E.Xu, J.Billin, A. N.Chung, C.Djedjos, C. S.Subramanian, G. M.Myers, R. P.Middleton, M. S.Rinella, M.Noureddin, M. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. <i>Hepatology</i> . 2020;72(1):58-71.	6
26	Patel KS, G. Limitations of non-invasive tests for assessment of liver fibrosis. <i>JHEP Reports : Innovation in Hepatology / EASL</i> . 2020;2(2):100067.	7
27	Patel PJC, D.Rhodes, F.Srivastava, A.Rosenberg, W. A review of the clinical utility of the Enhanced Liver Fibrosis test in multiple aetiologies of chronic liver disease. <i>Annals of Clinical Biochemistry</i> . 2020;57(1):36-43.	7
28	Ratziu VS, A.Harrison, S. A.Wong, V. W.Francque, S.Goodman, Z.Aithal, G. P.Kowdley, K. V.Seyedkazemi, S.Fischer, L.Loomba, R.Abdelmalek, M. F.Tacke, F. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> . 2020;13:13.	5
29	Ratziu VS, A.Harrison, S. A.Wong, V. W. S.Francque, S.Goodman, Z.Aithal, G. P.Kowdley, K. V.Seyedkazemi, S.Fischer, L.Loomba, R.Abdelmalek, M. F.Tacke, F. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> . 2020.	6
30	Sherman KEA-H, E. A.Ehman, R. L.Rouster, S. D.Campa, A.Martinez, S. S.Huang, Y.Zarini, G. G.Hernandez, J.Teeman, C.Tamargo, J.Liu, Q.Mandler, R.Baum, M. K. Validation and Refinement of Noninvasive Methods to Assess Hepatic Fibrosis: Magnetic Resonance Elastography Versus Enhanced Liver Fibrosis Index. <i>Digestive Diseases and Sciences</i> . 2020;65(4):1252-7.	10
31	Simbrunner BM, R.Scheiner, B.Schwabl, P.Bucsics, T.Stadlmann, A.Bauer, D. J. M.Paternostro, R.Eigenbauer, E.Pinter, M.Stattermayer, A. F.Trauner, M.Mandorfer, M.Reiberger, T. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. <i>Liver International</i> . 2020;40(7):1713-24.	4
32	Sumida YS, T.Mitsumoto, Y.Katayama, T.Umemura, A.Yamaguchi, K.Itoh, Y.Yoneda, M.Okanoue, T. Epidemiology: Pathogenesis, and diagnostic strategy of diabetic liver disease in Japan. <i>International Journal of Molecular Sciences</i> . 2020;21(12):1-18.	7

연번	서지정보	배제 사유
33	Sumida YY, M.Seko, Y.Ishiba, H.Hara, T.Toyoda, H.Yasuda, S.Kumada, T.Hayashi, H.Kobayashi, T.Imajo, K.Yoneda, M.Tada, T.Kawaguchi, T.Eguchi, Y.Oeda, S.Takahashi, H.Tomita, E.Okanoue, T.Nakajima, A.Japan Study Group Of Nafld, Jsg-Nafld. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Diagnostics</i> . 2020;10(8):10.	7
34	Takashi KY, O.Atsushi, N. A novel 3-step approach for predicting advanced fibrosis in nonalcoholic fatty liver disease. <i>Hepatology International</i> . 2020;14 (Supplement 1):S351.	7
35	Tien PCD, M.Roque, A.Price, J. MRE and ELF in Liver Fibrosis Assessment: Are Two Better Than One? <i>Digestive Diseases and Sciences</i> . 2020;65(4):928-30.	7
36	Trauner MG, Y.Jiang, Z.Chung, C.Subramanian, G. M.Myers, R. P.Gulamhusein, A.Kowdley, K. V.Levy, C.Goodman, Z.Manns, M. P.Muir, A. J.Bowlus, C. L. Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. <i>JHEP Reports</i> . 2020;2 (1) (no pagination)(100060).	1
37	Trembling PMA, S.Gentry-Maharaj, A.Parkes, J.Ryan, A.Tanwar, S.Burnell, M.Harris, S.Menon, U.Rosenberg, W. M. The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease. <i>BMC Gastroenterology</i> . 2020;20 (1) (no pagination)(104).	1
38	Trivedi PJM, A. J.Levy, C.Bowlus, C. L.Manns, M.Lu, X.Crans, G.Chung, C.Subramanian, G. M.Myers, R. P.Goodman, Z.Chalasani, N.Vierling, J. M.Guha, I. N.Hirschfield, G. M. Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. <i>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</i> . 2020;21.	1
39	Vali YL, J.Boursier, J.Spijker, R.Loffler, J.Verheij, J.Brosnan, M. J.Bocskei, Z.Anstee, Q. M.Bossuyt, P. M.Zafarmand, M. H.Litmus systematic review team. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> . 2020;73(2):252-62.	7
40	Vali YL, J.Boursier, J.Spijker, R.Loffler, J.Verheij, J.Brosnan, M. J.Bocskei, Z.Anstee, Q. M.Bossuyt, P. M.Zafarmand, M. H.Pavlidis, M.Levick, C.Duffin, K.Hyde, C.Bauer, T.Bedossa, P.Leeming, D.Daly, A.Hanf, R.Ortiz, P.Oresic, M.Schuppan, D.Hanauer, G.Chen, Y.Shumbayawonda, E.Bjerring, P. N.Zwinderman, K. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> . 2020;73(2):252-62.	6
41	Vo HDH, K. A.Mauch, T. J. Diagnostic performance of non-invasive tests for evaluation of hepatic graft fibrosis in pediatric liver transplantation: A scoping review. <i>Transplantation Reviews</i> . 2020;(no pagination)(100568).	7
42	Wan JW, E.Ben Mkaddem, S.Mabire, M.Choinier, P. M.Picq, O.Thibault-Sogorb, T.Hegde, P.Pishvaie, D.Bens, M.Broer, L.Gilgenkrantz, H.Moreau, R.Saveanu, L.Codogno, P.Monteiro, R. C.Lotersztajn, S. LC3-associated phagocytosis protects against inflammation and liver fibrosis via immunoreceptor inhibitory signaling. <i>Science Translational Medicine</i> . 2020;12(539):15.	5
43	Wan JW, E.Mkaddem, S. B.Mabire, M.Choinier, P. M.Picq, O.Thibault-Sogorb, T.Hegde, P.Pishvaie, D.Bens, M.Broer, L.Gilgenkrantz, H.Moreau, R.Saveanu, L.Codogno, P.Monteiro, R. C.Lotersztajn, S. LC3-associated phagocytosis protects against inflammation and liver fibrosis via immunoreceptor inhibitory signaling. <i>Science Translational Medicine</i> . 2020;12 (539) (no pagination)(eaaw8523).	6

연번	서지정보	배제 사유
44	Wang YY, J. M.Pan, A.Koh, W. P. Tissue inhibitor matrix metalloproteinase 1 and risk of type 2 diabetes in a Chinese population. <i>BMJ Open Diabetes Research and Care</i> . 2020;8 (1) (no pagination)(e001051).	1
45	Wong VWST, W. Y.Goh, G. B. B.Cheng, P. N.Lawitz, E. J.Younossi, Z. M.Vuppalanchi, R.Bzowej, N. H.Younes, Z.Alkhouiri, N.Wang, Y.Kersey, K.Li, G.Camargo, M.Myers, R. P.Djedjos, S.Harrison, S. A.Goodman, Z.Trauner, M. H.Romero-Gomez, M.Anstee, Q. M.Sarin, S.Nguyen, M. H.Okanoue, T. Race does not affect the performance of routinely available noninvasive tests for the discrimination of advanced fibrosis due to nonalcoholic steatohepatitis (NASH) in the phase 3 STELLAR trials of selonsertib. <i>Hepatology International</i> . 2020;14 (Supplement 1):S317.	7
46	Yang QW, J.Hao, X.Kong, D.Yu, X.Jiang, T.Xi, J.Cai, W.Luo, Y.Jing, X.et al., Improving B-mode ultrasound diagnostic performance for focal liver lesions using deep learning: a multicentre study. <i>Ebiomedicine</i> . 2020;56.	2
47	Yeung JG, B.Endozo, R.Hall, A.Wan, S.Groves, A.Taylor, S. A.Bandula, S. Equilibrium CT texture analysis for the evaluation of hepatic fibrosis: Preliminary evaluation against histopathology and extracellular volume fraction. <i>Journal of Personalized Medicine</i> . 2020;10 (2) (no pagination)(46).	4
48	Younossi ZMC, K. E.Alkhouiri, N.Noureddin, M.Jacobson, I.Lam, B.Clement, S.Basu, R.Gordon, S.Ravendhra, N.Puri, P.Rinella, M.Scudera, P.Singal, A. K.Henry, L. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. <i>Alimentary Pharmacology and Therapeutics</i> . 2020;52(3):513-26.	2
49	Abdel-hameed EAR, S. D.Sherman, K. E. Validation of Non-Invasive Biomarkers of Liver Disease in a Cohort of Hiv/Hcv Coinfection. <i>Gastroenterology</i> . 2019;156 (6 S1):S-1051.	7
50	Abeysekera KO, J.Fernandes, G.Hammerton, G.Portal, A.Heron, J.Gordon, F.Hickman, M. Diagnostic accuracy of non-invasive liver fibrosis markers in young adults within the alspac population-based cohort. <i>Gut</i> . 2019;68 (Supplement 2):A111-A2.	7
51	Abignano GB, J.Bissell, L. A.Dumitru, R. B.Eng, S.Allanore, Y.Avouac, J.Bosello, S.Denton, C. P.Distler, O.Ferraccioli, G.Jordan, S.Matucci-Cerinic, M.Ong, V.Messenger, M.Hutchinson, M.Buch, M. H.Emery, P.Del Galdo, F. European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. <i>Rheumatology (Oxford, England)</i> . 2019;58(2):254-9.	1
52	Actn. TWO BIRDS - Intensive lifestyle and medication to help improve diabetes and fatty liver disease through weight loss. http://www.who.int/trialssearch/Trial2.aspx?TrialID=ACTRN12619000931178 . 2019.	1
53	Aida KN, K.Kajitani, K.Tamura, A.Kobayashi, T.Yukawa, H.Kanazawa, T.Kobayashi, Y.Takahashi, N.Nakagawa, E.Ito, H.Hayashi, F.Makita, T.Inada, T.Tanaka, M. Measurement of liver fibrosis marker: Type IV collagen 7S among patients with acute heart failure and its relationship with the Enhanced Liver Fibrosis (ELF) score. <i>European Heart Journal</i> . 2019;40 (Supplement 1):1580.	7
54	Alkhouiri NY, Z. M.Lawitz, E.Wong, V. W. S.Gomez, M. R.Okanoue, T.Trauner, M.Chen, G.Wang, L.Kersey, K.Li, G.Myers, R.Djedjos, S.Harrison, S.Goodman, Z.Anstee, Q. Impact of age on routinely available non-invasive tests for the discrimination of advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib. <i>Journal of Hepatology</i> . 2019;70 (1):e754-e5.	7

연번	서지정보	배제 사유
55	Anstee QML, E. J.Alkhour, N.Wong, V. W. S.Romero-Gomez, M.Okanoue, T.Trauner, M.Kersey, K.Li, G.Han, L.Jia, C.Wang, L.Chen, G.Subramanian, G. M.Myers, R. P.Djedjos, C. S.Kohli, A.Bzowej, N.Younes, Z.Sarin, S.Shiffman, M. L.Harrison, S. A.Afdhal, N. H.Goodman, Z.Younessi, Z. M. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> . 2019;70(5):1521-30.	6
56	Arrebola-Ramirez MMR-E, M.Dayaldasani-Khialani, A.Rodriguez-Garcia, E.Morcillo-Jimenez, E.Bocanegra-Viniegra, M.Rodrigo-Lopez, J. M.Jimenez-Perez, M. Fibroscan and ELF score in the study of fibrosis in obese patients with chronic liver disease: A preliminary study. <i>Clinica Chimica Acta</i> . 2019;493 (Supplement 1):S360-S1.	7
57	Ashfaq-Khan MA, M.Qureshi, M. A.Senkowski, M. S.Yen-Weng, S.Strand, S.Kim, Y. O.Pickert, G.Schattenberg, J. M.Schuppan, D. Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver disease. <i>Scientific reports</i> . 2019;9(1):17463.	2
58	Baldo DCD, A.Ferraz, M. L. G.Andrade, L. E. C. Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies. <i>Autoimmunity Highlights</i> . 2019;10 (1) (no pagination)(10).	1
59	Bossen LV, M.Hov, J.Moller, H. J.Boberg, K.Karlsen, T.Gronbaek, H. Serum markers of macrophage activation CD163 and Mannose receptor predict transplant-free survival in primary sclerosing cholangitis. <i>Journal of Hepatology</i> . 2019;70 (1 Supplement):e385-e6.	7
60	Chen HL, Z.Klimov, S.Farris, A. B.Jiang, Y. A novel non-invasive technology for liver fibrosis detection. <i>Journal of Hepatology</i> . 2019;70 (1 Supplement):e116.	7
61	Chen LZ, T.Wu, N.O'Brien, A.Venter, J.Ceci, L.Kyritsi, K.Onori, P.Gaudio, E.Sybenga, A.Xie, L.Wu, C.Fabris, L.Invernizzi, P.Zawieja, D.Liangpunsakul, S.Meng, F.Francis, H.Alpini, G.Huang, Q.Glaser, S. Pinealectomy or light exposure exacerbates biliary damage and liver fibrosis in cholestatic rats through decreased melatonin synthesis. <i>Biochimica et Biophysica Acta - Molecular Basis of Disease</i> . 2019;1865(6):1525-39.	5
62	Cococcia SG, P.Caprioli, F.Pastorelli, L.Mazza, S.Lenti, M. V.Delliponti, M.Vecchi, M.Pinzi, M.Rosenberg, W.Di Sabatino, A. Inflammatory bowel diseases do not affect Enhanced Liver Fibrosis test reliability in assessing liver fibrosis. <i>United European Gastroenterology Journal</i> . 2019;7 (8 Supplement):191.	7
63	Connoley DP, P.Hogan, B.Tanwar, S.Rhodes, F.Parkes, J.Sievert, W.Rosenberg, W. The utility of the enhanced liver fibrosis test in alcoholic liver disease. <i>Journal of Hepatology</i> . 2019;70 (1 Supplement):e815.	7
64	Corpechot CR, A.Lemoinne, S.Farid, G.Belkacem, K. B.Poupon, R.Chazouilleres, O.Cales, P. Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with an improvement of fibrometer and fibrometer-VCTE, two high-accuracy non-invasive fibrosis tests extensively validated in frequent chronic liver diseases. <i>Journal of hepatology</i> . 2019;70(1):e387-.	7
65	Crossan CM, A.Srivastava, A.Thorburn, D.Rosenberg, W.Pinzi, M.Longworth, L.Tsochatzis, E. A. Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis. <i>Liver International</i> . 2019;39(11):2052-60.	1
66	Day JP, P.Parkes, J.Rosenberg, W. Derivation and Performance of Standardized Enhanced Liver Fibrosis (ELF) Test Thresholds for the Detection and Prognosis of Liver Fibrosis. <i>The Journal of Applied Laboratory Medicine</i> . 2019;3(5):815-26.	4

연번	서지정보	배제 사유
67	Dempster NS, K.Klimm, F.Baldry, E.Gerogiannis, I.Tandon, A.Tan, G.Cobbold, J. F. L.Awad, S.Gillies, R.Sgromo, B.Aithal, G. P.Macdonald, I.James, T.Fryer, E.Ryan, J.Iskander, I.Hodson, L.Damin, D.Tomlinson, J. Asymptomatic cirrhosis is common in bariatric surgical patients, associated with adverse postoperative outcomes and can be better predicted by machine learning algorithms rather than existing non-invasive biomarkers. <i>Hepatology</i> v70 suppl1 2019. 2019;70 (Supplement 1):124A-5A.	7
68	Dhillon AKK, A. E.Kummen, M.Boberg, K. M.Elferink, R. P. O.Karlsen, T. H.Beuers, U.Vesterhus, M.Hov, J. R. Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis. <i>Scientific Reports</i> . 2019;9(1):8450.	1
69	Eaton JEN, K. M.Gossard, A. A.Carey, E. J.Tabibian, J. H.Lindor, K. D.LaRusso, N. F. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study. <i>Scandinavian Journal of Gastroenterology</i> . 2019;54(5):633-9.	1
70	Eguchi YW, G.Lee, I. H.Akhtar, O.Jia, R.Sumida, Y. Non-invasive tests (NITS) for the diagnosis of non-alcoholic fatty liver and steatohepatitis (NAFLD/NASH) with advanced fibrosis (AF) in Japan—a targeted literature review. <i>Hepatology International</i> . 2019;13 (Supplement 1):S195-S6.	7
71	Gunes Yegin ED, S. S.Ture Ozdemir, F.Kombak, E. F.Ataizi-Celikel, C.Ozdogan, O. C. Appraising diagnostic performance of ELF test by pathological staging and digital quantification of liver fibrosis. <i>Annals of Hepatology</i> . 2019;18(6):833-40.	1
72	Han DHH, A. M.Choi, G. H.Choi, J. S. The meaning of Enhanced Liver Fibrosis (ELF) score as a predictive factor for HCC patient after liver resection. <i>Hpb</i> . 2019;21 (Supplement 2):S364-S5.	7
73	Harrison SAL, E. J.Wong, V. W. S.Anstee, Q. M.Trauner, M. H.Romero-Gomez, M.Bhandari, B.Abdelmalek, M. F.Sanyal, A. J.Patel, K.Leroy, V.Bureau, C.Sasso, M.Fournier, C. D.Sandrin, L.Han, L.Li, G.Kersey, K.Camargo, M.Djedjos, S.Myers, R. P.Goodman, Z.Younossi, Y. Currently available noninvasive tests accurately stage fibrosis in patients with nonalcoholic steatohepatitis (NASH). <i>Hepatology</i> v70 suppl1 2019. 2019;70 (Supplement 1):1349A-50A.	7
74	Harrison SAW, V. W. S.Okanoue, T.Bzowej, N.Vuppalanchi, R.Younes, Z.Kohli, A.Sarin, S. K.Henry, Z.Alkhoury, N.Shiffman, M. L.Li, G.Kersey, K.Zhu, Y.Jia, C.Subramanian, G. M.Djedjos, C. S.Myers, R. P.Gunn, N. T.Sheikh, A. M.Anstee, Q. M.Romero-Gomez, M.Trauner, M. H.Goodman, Z. D.Lawitz, E. J.Younossi, Z. M. Safety and efficacy of selonsertib for the treatment of bridging fibrosis or compensated cirrhosis due to nonalcoholic steatohepatitis (NASH): Results of the phase 3 stellar studies. <i>Hepatology</i> v70 suppl1 2019. 2019;70 (Supplement 1):45A-6A.	7
75	Harrison SAW, Vw- S.Okanoue, T.Bzowej, N.Vuppalanchi, R.Younes, Z.Kohli, A.Sarin, S. K.Henry, Z.Alkhoury, N.et al.,. Safety and efficacy of selonsertib for the treatment of bridging fibrosis or compensated cirrhosis due to nonalcoholic steatohepatitis (NASH): results of the phase 3 stellar studies. <i>Hepatology</i> v70 suppl1 2019. 2019;70:45A-6A.	7
76	Hashim AG, J.Mengozzi, M.Astbury, S.Macken, L.Aithal, G. P.Verma, S. Significant association of fibrosis and hepatocyte senescence biomarkers and cytokine profile with liver stiffness measurement amongst homeless individuals with liver disease in the community. <i>Hepatology</i> v70 suppl1 2019. 2019;70 (Supplement 1):1236A.	7
77	Hirschfield GMC, O.Drenth, J. P.Thorburn, D.Harrison, S. A.Landis, C. S.Mayo, M. J.Muir, A. J.Trotter, J. F.Leeming, D. J.Karsdal, M. A.Jaros, M. J.Ling, L.Kim, K. H.Rossi, S. J.Somarathne, R. M.DePaoli, A. M.Beuers, U. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. <i>Journal of Hepatology</i> . 2019;70(3):483-93.	1

연번	서지정보	배제 사유
78	Holstege A. What is new in diagnosis of liver fibrosis and cirrhosis?. [German]. <i>Verdauungskrankheiten</i> . 2019;37(6):260-9.	7
79	Iman IF, G.Teo, Y.Polak, M.Arden-Jones, M. The accuracy of the enhanced liver fibrosis test in detecting liver fibrosis in dermatology patients. <i>British Journal of Dermatology</i> . 2019;181 (Supplement 1):37-8.	7
80	Ishidair HS, A.Furuta, N.Nohisa, Y.Takemura, M.Saito, K.Shirakam, Y.Itou, H. Changes of liver fibrosis markers in patients with treatment by antiviral therapy. [Japanese]. <i>Japanese Journal of Clinical Chemistry</i> . 2019;48(2):137-43.	8
81	Jacobson IMM, A. J.Lawitz, E. J.Gane, E. J.Conway, B.Ruane, P. J.Younes, Z.Chen, F.Camargo, M.Chokkalingam, A.Djedjos, S.Gaggar, A.Myers, R. P.Leggett, B. A.Calleja, J. L.Agarwal, K.Reddy, K. R.Mangia, A. Course of cirrhosis regression: lessons from patients with HCV cirrhosis following successful sofosbuvir-based treatment. <i>Hepatology v70 suppl1 2019</i> . 2019;70 (Supplement 1):339A.	7
82	Javed ZP, M.Deshmukh, H.Kilpatrick, E. S.Mann, V.Corless, L.Abouda, G.Rigby, A. S.Atkin, S. L.Sathyapalan, T. A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome. <i>Nutrients</i> . 2019;11 (1) (no pagination)(188).	1
83	Jayakumar SM, M. S.Lawitz, E. J.Mantry, P. S.Caldwell, S. H.Arnold, H.Mae Diehl, A.Ghalib, R.Elkhatab, M.Abdelmalek, M. F.Kowdley, K. V.Stephen Djedjos, C.Xu, R.Han, L.Mani Subramanian, G.Myers, R. P.Goodman, Z. D.Afdhal, N. H.Charlton, M. R.Sirlin, C. B.Loomba, R. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. <i>Journal of Hepatology</i> . 2019;70(1):133-41.	6
84	Jayakumar SM, M. S.Lawitz, E. J.Mantry, P. S.Caldwell, S. H.Arnold, H.Mae Diehl, A.Ghalib, R.Elkhatab, M.Abdelmalek, M. F.et al.,. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib. <i>Journal of hepatology</i> . 2019;70(1):133-41.	2
85	Keogh KV, P.Clark, P. Discordance among non-invasive measures of liver fibrosis in a remote hepatitis C clinic. <i>Journal of Gastroenterology and Hepatology</i> . 2019;34 (Supplement 2):70.	7
86	Kim HYK, C. W.Kim, S. G.Kim, S. U.Kwon, J. H.Lee, J. H.Yim, H. J.Cheong, J. Y. Efficacy and safety of tenofovir with and without UDCA in chronic hepatitis B: Interim analysis of phase 2 randomized, double-blinded, placebo-controlled study. <i>Hepatology International</i> . 2019;13 (Supplement 1):S53.	7
87	Kumar MP, A. S.Kumar, A.Dahale, A.Sachdeva, S.Sakhuja, P. Efficacy of enhanced liver fibrosis score & transient elastography for assessment of the severity of fibrosis in chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology</i> . 2019;34 (Supplement 3):697.	6
88	Kumar MP, A. S.Kumar, A.Sachdeva, S.Dahale, A.Sakhuja, P. Efficacy of enhanced liver fibrosis score and transient elastography for assessment of severity of fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> . 2019;70 (1 Supplement):e197.	6
89	Kumar MP, A. S.Kumar, A. Efficacy of enhanced liver fibrosis score and transient elastography for assessment of the severity of fibrosis in chronic hepatitis C. <i>Turkish Journal of Gastroenterology</i> . 2019;30 (Supplement 3):S538.	7

연번	서지정보	배제 사유
90	Lampertico PY, Z. M.Lawitz, E. J.Alkhour, N.Wong, V. W. S.Romero-Gomez, M.Okanoue, T.Trauner, M.Kersey, K.Li, G.Subramanian, G. M.Myers, R. P.Djedjos, C. S.Han, L.Chen, G.Nguyen, T.Kohli, A.Bzowej, N.Younes, Z.Sarin, S.Shiffman, M. L.Harrison, S. A.Goodman, Z.Afdhal, N. H.Stepanova, M.Anstee, Q. M. Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials. <i>Digestive and Liver Disease</i> . 2019;51 (Supplement 1):e25-e6.	7
91	Liang LYW, V. W. S.Tse, K. Y.Chan, H. L. Y.Wong, G. L. H. Enhanced liver fibrosis (ELF) score improves the accuracy of LSM-HCC score for predicting hepatocellular carcinoma (HCC) in patients with chronic hepatitis B received antiviral treatment. <i>Hepatology International</i> . 2019;13 (Supplement 1):S9-S10.	6
92	Liang LYW, V. W.Tse, Y. K.Yip, T. C.Lui, G. C.Chan, H. L.Wong, G. L. Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. <i>Alimentary Pharmacology & Therapeutics</i> . 2019;49(12):1509-17.	1
93	Liang LYW, V. W. S.Tse, Y. K.Yip, T. C. F.Lui, G. C. Y.Chan, H. L. Y.Wong, G. L. H. Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> . 2019;49(12):1509-17.	7
94	Lin BM, Y.Wu, S.Liu, Y.Liu, L.Wu, L. Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis. <i>OMICS A Journal of Integrative Biology</i> . 2019;23(4):181-9.	7
95	Liu YL, T.Zhang, C.Xu, J.Xue, Z.Busuttill, R. W.Xu, N.Xia, Q.Kupiec-Weglinski, J. W.Ji, H. Activation of YAP attenuates hepatic damage and fibrosis in liver ischemia-reperfusion injury. <i>Journal of Hepatology</i> . 2019;71(4):719-30.	1
96	Lovero RS, A.Todeschini, A.Ruta, R.Marsico, S.Calamita, A.Genco, R.Varraso, L.Di Leo, A.Di Serio, F. Accuracy of new biomarkers for assessing liver fibrosis in chronic liver disease (CLD). <i>Clinica Chimica Acta</i> . 2019;493 (Supplement 1):S367-S8.	7
97	Luznik IAS, B.Jansa, K. Enhanced liver fibrosis test in a group of patients with alcohol abuse. [Slovene]. <i>Zdravniški Vestnik</i> . 2019;88(5-6):213-24.	8
98	Madsen BT, M.Detlefsen, S.Kjargaard, M.Moller, L. S.Rasmussen, D. N.Schlosser, A.Holmskov, U.Trebicka, J.Sorensen, G. L.Krag, A. Human microfibrillar-associated protein 4 expressed in the liver and serum in alcoholic liver disease predicts liver fibrosis severity with accuracy similar to transient elastography and enhanced liver fibrosis test. <i>Journal of Hepatology</i> . 2019;70 (1):e280.	7
99	Madsen BT, M.Detlefsen, S.Kjaergaard, M.Moller, L. S.Rasmussen, D. N.Schlosser, A.Holmskov, U.Trebicka, J.Sorensen, G. L.Krag, A. Human microfibrillar-associated protein 4 expressed in the liver and serum in alcoholic liver disease predicts liver fibrosis severity with accuracy similar to transient elastography and enhanced liver fibrosis test. <i>Journal of Hepatology</i> . 2019;70 (1 Supplement):e280.	7
100	Medina PGM, M. G.Martinez, R. M. L.Segura, A. R.Frias, F. R. Combination of FIB-4 and ELF to evaluate liver fibrosis in HCV-infected patients. <i>Clinica Chimica Acta</i> . 2019;493 (Supplement 1):S547.	7
101	Mikolajczyk-Korniak NB, T.Tronina, O.Durlik, M. Non-invasive diagnostic methods of liver fibrosis in liver transplant recipients. <i>Transplant International</i> . 2019;32 (Supplement 2):207.	7
102	Moreno CM, S.Szabo, G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. <i>Journal of Hepatology</i> . 2019;70(2):273-83.	7

연번	서지정보	배제 사유
103	Muir AJL, C.Janssen, H. L. A.Montano-Loza, A. J.Shiffman, M. L.Caldwell, S.Luketic, V.Ding, D.Jia, C.McColgan, B. J.McHutchison, J. G.Mani Subramanian, G.Myers, R. P.Manns, M.Chapman, R.Afdhal, N. H.Goodman, Z.Eksteen, B.Bowlus, C. L.Gs-Us- Investigators. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. <i>Hepatology</i> . 2019;69(2):684-98.	6
104	Muir AJL, C.Janssen, H. L. A.Montano-Loza, A. J.Shiffman, M. L.Caldwell, S.Luketic, V.Ding, D.Jia, C.McColgan, B. J.McHutchison, J. G.Mani Subramanian, G.Myers, R. P.Manns, M.Chapman, R.Afdhal, N. H.Goodman, Z.Eksteen, B.Bowlus, C. L. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. <i>Hepatology</i> . 2019;69(2):684-98.	6
105	Muir AJL, C.Janssen, H. L. A.Montano-Loza, A. J.Shiffman, M. L.Caldwell, S.Luketic, V.Ding, D.Jia, C.McColgan, B. J.et al.,. Simtuzumab for Primary Sclerosing Cholangitis: phase 2 Study Results With Insights on the Natural History of the Disease. <i>Hepatology (Baltimore, Md)</i> . 2019;69(2):684-98.	1
106	Nct. CRT-P or CRT-D in Dilated Cardiomyopathy. https://clinicaltrials.gov/show/NCT04139460 . 2019.	1
107	Nishimura NG, S.Zamboni, F.Farci, P. Identification of the intrahepatic cellular source of CHI3L1, a secreted protein associated with agerelated liver fibrosis progression. <i>Hepatology v70 suppl1</i> 2019. 2019;70 (Supplement 1):1125A-6A.	7
108	Pan QF, J. G. Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches. <i>Hepatobiliary and Pancreatic Diseases International</i> . 2019;18(1):1-3.	7
109	Pandeyarajan VG, R. G.Alkhour, N.Noureddin, M. Screening for nonalcoholic fatty liver disease in the primary care clinic. <i>Gastroenterology and Hepatology</i> . 2019;15(7):357-65.	2
110	Park HJL, S. S.Park, B.Yun, J.Sung, Y. S.Shim, W. H.Shin, Y. M.Kim, S. Y.Lee, S. J.Lee, M. G. Radiomics Analysis of Gadoteric Acid-enhanced MRI for Staging Liver Fibrosis. <i>Radiology</i> . 2019;290(2):380-7.	2
111	Patel KY, Z. M.Lawitz, E.Alkhour, N.Wong, V. W. S.Romero-Gomez, M.Okanoue, T.Trauner, M.Kersey, K.Li, G.Subramanian, M.Myers, R.Djedjos, S.Han, L.Chen, G.Nguyen, T.Kohli, A.Bzowej, N.Younes, Z.Sarin, S.Shiffman, M. L.Harrison, S. A.Goodman, Z.Afdhal, N.Stepanova, M.Anstee, Q. M. Algorithms using non-invasive tests can accurately identify patients with advanced fibrosis due to NASH: Data from the STELLAR clinical trials. <i>Canadian Liver Journal</i> . 2019;2 (2):92-3.	7
112	Rhodes FC, S.Vergis, N.Thursz, M. R.Atkinson, S.Tanwar, S.Rosenberg, W. M. An algorithm combining hyaluronic acid, procollagen III amino-terminal peptide and the Glasgow alcoholic hepatitis score in a single number predicts 90-day mortality in alcohol related hepatitis. <i>Hepatology v70 suppl1</i> 2019. 2019;70 (Supplement 1):817A-8A.	7
113	Rozovski UH, D. M.Li, P.Liu, Z.Manshour, T.Veletic, I.Jain, P.Ferrajoli, A.Burger, J. A.Bose, P.et al.,. Constitutively activated STAT3 induces the production of PTX3 that contributes to the induction of bone marrow reticulin fibrosis in patient with CLL. <i>Blood</i> . 2019;134.	7
114	Saffioti FR, D.Vesterhus, M.Hov, J. R.Rosenberg, W.Pinzani, M.Pereira, S. P.Boberg, K. M.Thorburn, D. Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis. <i>European Journal of Clinical Investigation</i> . 2019;49 (5) (no pagination)(e13088).	1
115	Sanyal AJH, S. A.Ratziu, V.Abdelmalek, M. F.Diehl, A. M.Caldwell, S.Shiffman, M. L.Aguilar Schall, R.Jia, C.McColgan, B.Djedjos, C. S.McHutchison, J. G.Subramanian, G. M.Myers, R. P.Younossi, Z.Muir, A. J.Afdhal, N. H.Bosch, J.Goodman, Z. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> . 2019;70(6):1913-27.	3

연번	서지정보	배제 사유
116	Sherman KEA-H, E.Rouster, S. D.Shata, M. T. M.Blackard, J. T.Safaie, P.Kroner, B.Preiss, L.Horn, P. S.Kottiril, S. Improvement in Hepatic Fibrosis Biomarkers Associated with Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade. <i>Clinical Infectious Diseases</i> . 2019;68(11):1911-8.	1
117	Sherman KM, H. L.Abdel-Hameed, E. A.Rouster, S. D.Shata, M. T. M. TLR7 gene polymorphisms influence development of hepatic fibrosis in HCV/HIV coinfection. <i>Open Forum Infectious Diseases</i> . 2019;6 (Supplement 2):S188-S9.	7
118	Simbrunner BM, R.Schwabl, P.Scheiner, B.Bucsics, T.Pinter, M.Stadlmann, A.Bauer, D. J.Mandorfer, M.Trauner, M.Reiberger, T. Enhanced liver fibrosis score is an accurate non-invasive predictor of clinically significant and high-risk portal hypertension. <i>Journal of Hepatology</i> . 2019;70 (1):e681-e2.	7
119	Simbrunner BM, R.Schwabl, P.Scheiner, B.Bucsics, T.Pinter, M.Stadlmann, A.Bauer, D. J. M.Mandorfer, M.Trauner, M.Reiberger, T. Enhanced liver fibrosis score is an accurate non-invasive predictor of clinically significant and high-risk portal hypertension. <i>Journal of Hepatology</i> . 2019;70 (1 Supplement):e681-e2.	7
120	Spencer J. Elf and FIB-4 in non-alcoholic fatty liver disease (NAFLD). <i>Clinical Chemistry and Laboratory Medicine</i> . 2019;57 (8):eA109.	7
121	Srivastava AJ, S.Gola, A.Gailer, R.Morgan, S.Sennett, K.Tanwar, S.Pizzo, E.O'Beirne, J.Tsochatzis, E.Parkes, J.Rosenberg, W. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> . 2019;19 (1) (no pagination)(122).	4
122	Stasi CT, E. A.Hall, A.Rosenberg, W.Milani, S.Dhillon, A. P.Pinzi, M. Comparison and correlation of fibrosis stage assessment by collagen proportionate area (CPA) and the ELF panel in patients with chronic liver disease. <i>Digestive and Liver Disease</i> . 2019;51(7):1001-7.	2
123	Stauber R. Noninvasive Diagnostics in Nonalcoholic Fatty Liver Disease (NAFLD). [German]. <i>Journal fur Gastroenterologische und Hepatologische Erkrankungen</i> . 2019;17(3):75-81.	8
124	Thiele MA, L.Krag, A.Melberg, H. O. Serial testing with the enhanced liver fibrosis test and liver stiffness is cost-effective for detection of advanced alcoholic liver disease in primary care. <i>Journal of Hepatology</i> . 2019;70 (1 Supplement):e345-e6.	7
125	Vilar-Gomez EN, M.Harrison, S. A.Vuppalanchi, R.Allgood, A.Shlevin, H.Chalasani, N. P. Enhanced liver fibrosis (ELF) score significantly predicts 52-week liver decompensation in patients with compensated NASH cirrhosis. <i>Hepatology v70 suppl1</i> 2019. 2019;70 (Supplement 1):728A-9A.	7
126	Williams BC, L.Abouda, G. A nurse-led advice and lifestyle intervention shows high levels of patient-reported satisfaction and motivation in community-based management of NAFLD. <i>Journal of hepatology</i> . 2019;70(1):e579.	7
127	Wong VWSA, Q.Lawitz, E.Akhoury, N.Romero-Gomez, M.Okanoue, T.Trauner, M.Kersey, K.Li, G.Subramanian, M.Myers, R.Djedjos, S.Han, L.Nguyen, T.Kohli, A.Bzowej, N.Younes, Z.Sarin, S.Shiffman, M.Harrison, S.Goodman, Z.Younossi, Z. Routinely available noninvasive tests discriminate advanced fibrosis due to nash in the phase 3 stellar trials of the ASK1 inhibitor selonsertib. <i>Gut</i> . 2019;68 (Supplement 1):A136-A7.	7

연번	서지정보	배제 사유
128	Wong VWST, W. Y.Bee Goh, G. B.Cheng, P. N.Lawitz, E. J.Younossi, Z. M.Vuppalanchi, R.Bzowej, N. H.Younes, Z.Alkhour, N.Wang, Y.Kersey, K.Li, G.Camargo, M.Myers, R. P.Djedjos, C. S.Harrison, S. A.Goodman, Z. D.Trauner, M. H.Romero-Gomez, M.Anstee, Q. M.Sarin, S. K.Nguyen, M. H.Okanoue, T. Race does not affect the performance of routinely available noninvasive tests for the discrimination of advanced fibrosis due to nonalcoholic steatohepatitis (NASH) in the phase 3 stellar trials of selonsertib. <i>Hepatology</i> v70 suppl1 2019. 2019:70 (Supplement 1):1029A-30A.	7
129	Wong VWSY, Z. M.Lawitz, E. J.Alkhour, N.Romero-Gomez, M.Okanoue, T.Trauner, M.Gilead, S. D.Harrison, S. A.Goodman, Z.Anstee, Q. M. Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: Data from the STELLAR clinical trials. <i>Hepatology International</i> . 2019;13 (Supplement 1):S191.	7
130	Xinyun ZH, C.Lisong, S. Association of serum fibrosis-related biomarkers with disease activity in patients with IgG4-related disease. <i>European Journal of Immunology</i> . 2019;49 (Supplement 3):985.	7
131	Anonymous. INASL 2018 Abstracts. <i>Journal of Clinical and Experimental Hepatology Conference: 26th Annual Scientific Meeting of the Indian National Association for Study of the Liver, INASL</i> . 2018;8(Supplement 1).	7
132	Anstee QML, E. J.Alkhour, N.Wong, V. W. S.Romero-Gomez, M.Okanoue, T.Trauner, M. H.Kersey, K.Li, G.Subramanian, M.Myers, R. P.Djedjos, S.Han, L.Li, Y.Nguyen, T.Kohli, A.Bzowej, N. H.Younes, Z. H.Sarin, S. K.Shiffman, M. L.Harrison, S. A.Goodman, Z. D.Younossi, Z. M. Routinely available noninvasive tests discriminate advanced fibrosis due to NASH in the phase 3 stellar trials of the ASK1 inhibitor selonsertib. <i>Hepatology</i> . 2018;68 (Supplement 1):953A.	7
133	Asphaug L. Maximising Diagnoses of Advanced Fibrosis in Primary Care with Non-Invasive Markers of Liver Fibrosis and Minimising Unnecessary Referrals to Secondary Care. <i>Value in Health</i> . 2018;21 (Supplement 2):S73.	7
134	Burke LW, B.Abouda, G.Corless, L. The Community based management of NAFLD Study (COMMANDS): improved diagnosis and referral using a novel integrated care pathway. <i>Journal of hepatology</i> . 2018;68:S562-S3.	7
135	Chen LOB, A.Meng, F.Wu, N.White, T.Venter, J.Francis, H. L.Zhou, T.Kyritsi, K.Gaudio, E.Wu, C.Onori, P.Franchitto, A.Alpini, G.Glaser, S. S. Pinealectomy or prolonged light exposure exacerbates biliary proliferation and senescence and liver fibrosis in bile duct ligated (BDL) rats via decreased biliary melatonin synthesis. <i>Hepatology</i> . 2018;68 (Supplement 1):830A-1A.	7
136	Chen LW, T.Venter, J.Ehrlich, L.O'Brien, A.Nguyen, A. V. V.Wu, N.Kyritsi, K.Han, Y.Huang, Q.Meng, F.Alpini, G.Zhou, T.Glaser, S. Pinealectomy Exacerbates Biliary Proliferation and Senescence and Liver Fibrosis during Rat Cholestatic Liver through Decreased Biliary Melatonin Synthesis. <i>Gastroenterology</i> . 2018;154 (6 Supplement 1):S-1187.	7
137	Corpechot CC, O.Rousseau, A.Le Gruyer, A.Habersetzer, F.Mathurin, P.Goria, O.Potier, P.Minello, A.Silvain, C.Abergel, A.Debette-Gratien, M.Larrey, D.Roux, O.Bronowicki, J. P.Boursier, J.De Ledinghen, V.Heurgue-Berlot, A.Nguyen-Khac, E.Zoulim, F.Ollivier-Hourmand, I.Zarski, J. P.Nkontchou, G.Lemoine, S.Humbert, L.Rainteau, D.Lefevre, G.De Chaisemartin, L.Chollet-Martin, S.Gaouar, F.Admane, F. H.Simon, T.Poupon, R. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. <i>New England Journal of Medicine</i> . 2018;378(23):2171-81.	1
138	Day JWR, W. M. The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis. <i>British journal of hospital medicine (London, England : 2005)</i> . 2018;79(12):694-9.	7

연번	서지정보	배제 사유
139	Eddowes PJM, N.Davies, N.Semple, S. I. K.Kendall, T. J.Hodson, J.Newsoms, P. N.Flintham, R. B.Wesolowski, R.Blake, L.Duarte, R. V.Kelly, C. J.Herlihy, A. H.Kelly, M. D.Oliff, S. P.Hubscher, S. G.Fallowfield, J. A.Hirschfield, G. M. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> . 2018;47(5):631-44.	6
140	Eddowes PJM, N.Davies, N.Semple, S. I. K.Kendall, T. J.Hodson, J.Newsoms, P. N.Flintham, R. B.Wesolowski, R.Blake, L.et al.. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. <i>Alimentary pharmacology & therapeutics</i> . 2018;47(5):631-44.	1
141	Jabor AK, Z.Frankova, S.Senkerikova, R.Franekova, J. Enhanced liver fibrosis (ELF) score: Reference ranges, biological variation in healthy subjects, and analytical considerations. <i>Clinica Chimica Acta</i> . 2018;483:291-5.	1
142	Jekarl DWC, H.Lee, S.Kwon, J. H.Lee, S. W.Yu, H.Kim, M.Kim, Y.Sung, P. S.Yoon, S. K. Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA-M2BP) Among Chronic Hepatitis B Patients. <i>Annals of laboratory medicine</i> . 2018;38(4):348-54.	2
143	Jung JL, D.Haas, U.Sonntag, R.Trautwein, C.Liedtke, C. Caspase-8 is a gender-specific modulator of chronic cholestatic liver disease in female Mdr2 knockout mice. <i>Zeitschrift fur Gastroenterologie Conference</i> . 2018;56(1).	7
144	Kawashiri SYO, T.Umeda, M.Nishino, A.Shimizu, T.Fukui, S.Koga, T.Iwamoto, N.Ichinose, K.Tamai, M.Nakamura, H.Maeda, T.Kawano, M.Yamamoto, M.Izumi, Y.Kawakami, A. Association of serum levels of fibrosis-related biomarkers with disease activity in patients with IgG4-related disease. <i>Arthritis Research and Therapy</i> . 2018;20 (1) (no pagination)(277).	1
145	Kumar M. Efficacy of enhanced liver fibrosis score & transient elastography for assessment of severity of fibrosis in chronic hepatitis C. <i>Hepatology International</i> . 2018;12 (2):S370.	7
146	Kumar MP, A. S.Kumar, A.Sachdeva, S.Srivastava, S.Dalal, A.Dahale, A.Sakhuja, P. Efficacy of enhanced liver fibrosis score & transient elastography for assessment of severity of fibrosis in chronic hepatitis C. <i>Journal of Clinical and Experimental Hepatology</i> . 2018;8 (Supplement 1):S32.	7
147	Kumar MP, A.Kumar, A.Dahale, A.Srivastava, S.Sachdeva, S.Dalal, A.Sakhuja, P. Efficacy of enhanced liver fibrosis score and transient elastography for assessment of significant fibrosis in chronic hepatitis C. <i>Indian Journal of Gastroenterology</i> . 2018;37 (Supplement 1):A68.	7
148	Levy CS, M.Janssen, H.Montano-Loza, A.Caldwell, S.Luketic, V.Ding, D.McColgan, B.Myers, R.Eksteen, B.Chapman, R. W. G.Manns, M. P.Goodman, Z.Bowlus, C.Muir, A.Hirschfield, G. Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis (PSC). <i>Journal of Hepatology</i> . 2018;68 (Supplement 1):S568.	7
149	Loo WMG, G. B.Wang, Y.Yuan, J. M.Ong, L.Dan, Y. Y.Koh, W. P. Enhanced Liver Fibrosis Score as a Predictor of Hepatocellular Carcinoma. <i>Clinical Chemistry</i> . 2018;64(9):1404-5.	6
150	Loo WMG, G. B. B.Wang, Y.Yuan, J. M.Ong, L.Dan, Y. Y.Koh, W. P. Enhanced liver fibrosis score as a predictor of hepatocellular carcinoma. <i>Clinical Chemistry</i> . 2018;64(9):1404-5.	7
151	Mauro EC, G.Montironi, C.Londono, M. C.Diaz, A.Forns, X.Navasa, M. Viral eradication and fibrosis resolution in post-liver transplant cholestatic hepatitis C virus. <i>Liver Transplantation</i> . 2018;24(5):703-7.	7

연번	서지정보	배제 사유
152	McDonald NE, P. J.Hodson, J.Semple, S. I. K.Davies, N. P.Kelly, C. J.Kin, S.Phillips, M.Herlihy, A. H.Kendall, T. J.Brown, R. M.Neil, D. A. H.Hubscher, S. G.Hirschfield, G. M.Fallowfield, J. A. Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study. Scientific reports. 2018;8(1):9189.	1
153	Mocan TR, P.Zaharia, T.Cebotaru, C.Kacso, G.Al Hajjar, N.Sparchez, Z. Contrast enhanced versus conventional ultrasound guided liver biopsy in the diagnosis of hepatocellular carcinoma: a prospective study. Journal of gastrointestinal and liver diseases. 2018;27:39.	7
154	Moon HWP, M.Hur, M.Kim, H.Cho, W. H.Yun, Y. M. Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases. Annals of laboratory medicine. 2018;38(4):331-7.	10
155	Moroni FD, B.Glover, A.Graham, C.McGowan, N.Fraser, A.Campbell, J.Atkinson, A.Mitchell, D.Pass, C.Bailey, L.Turner, M.Hayes, P. C.Fallowfield, J. A.Forbes, S. J. Autologous macrophage therapy for liver cirrhosis (MATCH): A first-in-human, phase 1, single-arm, dose-escalation trial. Hepatology. 2018;68 (Supplement 1):1127A-8A.	7
156	Nah EC, S.Kim, S.Cho, H. Diagnostic performance of enhanced liver fibrosis (ELF) test in predicting liver stiffness. Clinical Chemistry. 2018;64 (Supplement 1):S252.	7
157	Nct. Community Access, Retention in Care, and Engagement for Hepatitis C Treatment. https://clinicaltrials.gov/show/NCT03581383 . 2018.	2
158	Nielsen MJT, D.Leeming, D. J.Hov, J. R.Nygaard, S.Moum, B.Saffioti, F.Gilja, O. H.Boberg, K. M.Mazza, G.Rosjo, H.Pinzani, M.Karlsen, T. H.Karsdal, M. A.Vesterhus, M. Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics. 2018;48(2):179-89.	1
159	Omran DY, A.Darweesh, S. K.Nabeel, M. M.El-Beshlawey, M.Saif, S.Fared, A.Hassany, M.Zayed, R. A. Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment naive chronic HCV patients. Clinical and Experimental Medicine. 2018;18(1):45-50.	10
160	Ooi GJM, S.Eslick, G. D.Burton, P. R.Kemp, W. W.Roberts, S. K.Brown, W. A. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese. Obesity Reviews. 2018;19(2):281-94.	7
161	Pan CI, N.Angus, P.Duseja, A.Nurmukhametova, E.Balabanska, R.Nguyen, T.Yang, J.Lin, L.Gaggar, A.Flaherty, J. F.Subramanian, M.Ryder, S.Chuang, W. L.Marcellin, P. Use of noninvasive biomarkers to assess fibrosis regression in cirrhotic patients during nucleos(t)ide therapy. Journal of Hepatology. 2018;68 (Supplement 1):S501.	7
162	Patel PH, F.Horsfall, L. U.Banh, X.Hayward, K. L.Williams, S.Johnson, T.Bernard, A.Brown, N. N.Lampe, G.Buck, L.Saad, N.Russell, A. W.Valery, P. C.Irvine, K. M.Clouston, A. D.Stuart, K. A.Rosenberg, W.Powell, E. E. A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care. Hepatology Communications. 2018;2(8):897-909.	1

연번	서지정보	배제 사유
163	Patel PJB, X.Horsfall, L. U.Hayward, K. L.Hossain, F.Johnson, T.Stuart, K. A.Brown, N. N.Saad, N.Clouston, A.Irvine, K. M.Russell, A. W.Valery, P. C.Williams, S.Powell, E. E. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. <i>Internal Medicine Journal</i> . 2018;48(2):144-51.	2
164	Peters MK, M.Murphy, R.Matining, R.Rosenberg, W.Wyles, D. No evidence of fibrosis regression in HCV/HIV co-infected and HCV monoinfected participants up to 3 years after achieving SVR with DAA treatment: Interim results for the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). <i>Journal of Hepatology</i> . 2018;68 (Supplement 1):S545.	7
165	Ponsioen CYL, K. D.Mehta, R.Dimick-Santos, L. Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. <i>Hepatology</i> . 2018;68(3):1174-88.	7
166	Qi XB, A.Cardenas, A.Sarin, S. K. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. <i>The Lancet Gastroenterology and Hepatology</i> . 2018;3(10):708-19.	7
167	Ramnath DI, K. M.Lukowski, S. W.Horsfall, L. U.Loh, Z.Clouston, A. D.Patel, P. J.Fagan, K. J.Iyer, A.Lampe, G.Stow, J. L.Schroder, K.Fairlie, D. P.Powell, J. E.Powell, E. E.Sweet, M. J. Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes. <i>JCI insight</i> . 2018;3 (14) (no pagination)(e120274).	6
168	Ramnath DI, K. M.Lukowski, S. W.Horsfall, L. U.Loh, Z.Clouston, A. D.Patel, P. J.Fagan, K. J.Iyer, A.Lampe, G.Stow, J. L.Schroder, K.Fairlie, D. P.Powell, J. E.Powell, E. E.Sweet, M. J. Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes. <i>Jci Insight</i> . 2018;3(14):26.	2
169	Ramnath DI, K.Lukowski, S.Horsfall, L.Loh, K.Clouston, A.Patel, P.Iyer, A.Lampe, G.Stow, J.Schroder, K.Fairlie, D.Powell, J.Powell, E.Sweet, M. RNA-sequencing analysis of biopsies from chronic liver disease patients identifies gene signatures associated with progressive liver disease. <i>Journal of Hepatology</i> . 2018;68 (Supplement 1):S401-S2.	7
170	Rasmussen DT, M.Madsen, B. S.Moller, L.Antonsen, S.Detlevsen, S.Krag, A. Non-invasive markers are superior to histological fibrosis stage for predicting liver-related outcomes in alcoholic liver disease. <i>Hepatology</i> . 2018;68 (Supplement 1):780A.	7
171	Salupere R. Future without hepatitis C: Nonalcoholic fatty liver disease as a rising star. [Estonian]. <i>Eesti Arst</i> . 2018;97(7):357-60.	8
172	Sanyal AC, K.Hartman, M. L.Zhang, S.Bastyr, E. J.Bue-Valleskey, J. M.Chang, A. M.Haupt, A.Jacobber, S. J.Konrad, R. J.Zhang, Q.Hoogwerf, B. J. Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins. <i>Journal of Investigative Medicine</i> . 2018;66(3):661-8.	1
173	Schulze Pellengahr SN, S.Wagner-Golbs, A.Christiansen, N.Schatz, P.Kamlage, B.Stickel, F.Hinrichsen, H.Schafmayer, C.Von Schonfels, W.Montani, M.Rocken, C.Lerch, M. M.Berg, T.Datz, C.Brosch, M.Hampe, J. The combination of an androgen, a bile acid and an eicosanoid is a promising biomarker for liver fibrosis in non-alcoholic fatty liver disease patients. <i>United European Gastroenterology Journal</i> . 2018;6 (8 Supplement):A545.	7

연번	서지정보	배제 사유
174	Selby PJB, R. E.Gregory, W.Hewison, J.Rosenberg, W.Altman, D. G.Deeks, J. J.McCabe, C.Parkes, J.Sturgeon, C.Thompson, D.Twiddy, M.Bestall, J.Bedlington, J.Hale, T.Dinnes, J.Jones, M.Lewington, A.Messenger, M. P.Napp, V.Sitch, A.Tanwar, S.Vasudev, N. S.Baxter, P.Bell, S.Cairns, D. A.Calder, N.Corrigan, N.Del Galdo, F.Heudtlass, P.Hornigold, N.Hulme, C.Hutchinson, M.Lippiatt, C.Livingstone, T.Longo, R.Potton, M.Roberts, S.Sim, S.Trainor, S.Welberry Smith, M.Neuberger, J.Thorburn, D.Richardson, P.Christie, J.Sheerin, N.McKane, W.Gibbs, P.Edwards, A.Soomro, N.Adeyoju, A.Stewart, G. D.Hrouda, D. NIHR Journals Library Programme Grants for Applied Research. 2018;6:6.	7
175	Stauber RES, K.Stift, J.Marculescu, R.Obermayer-Pietsch, B.Trauner, M.Lackner, K. Enhanced liver fibrosis (ELF) score accurately detects advanced fibrosis in nonalcoholic fatty liver disease (NAFLD). Journal of Hepatology. 2018;68 (Supplement 1):S563.	7
176	Stauffer KM, R.Obermayer-Pietsch, B.Stift, J.Lackner, C.Trauner, M.Stauber, R. Enhanced liver fibrosis (ELF) score accurately detects advanced fibrosis in nonalcoholic fatty liver disease (NAFLD). Zeitschrift fur Gastroenterologie. 2018;56 (5):e41.	7
177	Stauffer KM, R.Obermayer-Pietsch, B.Stift, J.Lackner, C.Trauner, M. H.Stauber, R. E. Enhanced liver fibrosis (ELF) score for noninvasive diagnosis of nonalcoholic steatohepatitis (NASH) with advanced fibrosis. United European Gastroenterology Journal. 2018;6 (8 Supplement):A548-A9.	7
178	Stefanantoni KS, I.Vasile, M.Abignano, G.Corinaldesi, C.Antinozzi, C.Crescioli, C.Del Galdo, F.Valesini, G.Ricceri, V. Effect of 6 months therapy with iloprost on enhanced liver fibrosis (ELF) test and its association with disease activity and vascular manifestations in patients with systemic sclerosis (SSc). Journal of Scleroderma and Related Disorders. 2018;3 (Supplement 1):225.	7
179	Taylor AK, J. M.Sheridan, R. M.Singh, R.Lam, S.Dillman, J.Trout, A. T.Serai, S. D.Blaxall, B. C.Fei, L.Miethke, A. G. Morphometric quantification of hepatic collagen content predicts liver fibrosis stage and portal hypertension in pediatric autoimmune liver disease. Hepatology. 2018;68 (Supplement 1):1049A-50A.	7
180	Thiele MN, M. J.Madsen, B. S.Kjaergaard, M.Hansen, J.Antonsen, S.Rasmussen, L. M.Leeming, D.Detlefsen, S.Karsdal, M.Krag, A. The ProC3 marker of type III collagen formation accurately reflects hepatic inflammation and fibrosis stage in asymptomatic alcoholic liver disease patients. Journal of Hepatology. 2018;68 (Supplement 1):S635-S6.	7
181	Trembling PA, S.Gentry-Maharaj, A.Parkes, J.Ryan, A.Tanwar, S.Burnell, M.Harris, S.Menon, U.Rosenberg, W. Enhanced liver fibrosis test predicts liver-related outcomes in postmenopausal women with risk factors in the community. Journal of Hepatology. 2018;68 (Supplement 1):S641.	7
182	Welsh JAS, E.Clough, G. F.Englyst, N. A.Byrne, C. D. Leukocyte extracellular vesicle concentration is inversely associated with liver fibrosis severity in NAFLD. Journal of Leukocyte Biology. 2018;104(3):631-9.	1
183	Wong GL. Non-invasive assessments for liver fibrosis: The crystal ball we long for. Journal of Gastroenterology & Hepatology. 2018;33(5):1009-15.	7
184	Wong GLH. Non-invasive assessments for liver fibrosis: The crystal ball we long for. Journal of Gastroenterology and Hepatology (Australia). 2018;33(5):1009-15.	7
185	Yang LG, J.Zheng, J.Wang, G.Zhu, L.Zhu, Z.Li, F.Zha, S.Li, S.Wang, T.Zhang, B.Ding, Z. Development of imaging and circulating biomarkers for the assessment of hepatic lesions in NHP model of nonalcoholic steatohepatitis. Hepatology. 2018;68 (Supplement 1):1006A-7A.	7

연번	서지정보	배제 사유
186	Younossi ZML, E.Alkhouiri, N.Wong, V. W. S.Romero-Gomez, M.Okanoue, T.Trauner, M. H.Kersey, K.Li, G.Mani Subramanian, G.Myers, R. P.Djedjos, S.Han, L.Chen, G.Nguyen, T.Kohli, A.Bzowej, N. H.Younes, Z.Sarin, S. K.Shiffman, M. L.Harrison, S. A.Goodman, Z. D.Stepanova, M.Afdhal, N. H.Anstee, Q. M. Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to nash: Data from the stellar clinical trials. <i>Hepatology</i> . 2018;68 (1 Supplement 1):1452A-3A.	7
187	Younossi ZML, R.Anstee, Q. M.Rinella, M. E.Bugianesi, E.Marchesini, G.Neuschwander-Tetri, B. A.Serfaty, L.Negro, F.Caldwell, S. H.Ratziu, V.Corey, K. E.Friedman, S. L.Abdelmalek, M. F.Harrison, S. A.Sanyal, A. J.Lavine, J. E.Mathurin, P.Charlton, M. R.Goodman, Z. D.Chalasani, N. P.Kowdley, K. V.George, J.Lindor, K. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. <i>Hepatology</i> . 2018;68(1):349-60.	7
188	Younossi ZMS, M.Anstee, Q. M.Lawitz, E. J.Wong, V. W. S.Romero-Gomez, M.Kersey, K.Li, G.Subramanian, M.Myers, R. P.Djedjos, S.Okanoue, T.Trauner, M. H.Harrison, S. A.Goodman, Z. D. Advanced fibrosis based on noninvasive tests in nonalcoholic steatohepatitis (NASH) is associated with impairment of patient-reported outcomes. <i>Hepatology</i> . 2018;68 (Supplement 1):1134A-5A.	7
189	Abignano GB, J.Bissell, L. A.Dumitru, R. B.Eng, S.Allanore, Y.Avouac, J.Bosello, S.Denton, C.Distler, O.Ferraccioli, G.Jordan, S.Matucci-Cerinic, M.Ong, V.Messenger, M.Hutchinson, M.Buch, M. H.Emery, P.Del Galdo, F. European multicentre study validates ELF test as biomarker of fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> . 2017;76 (Supplement 2):635.	7
190	Anonymous. <i>Gastroenterologie a Hepatologie Conference</i> . 2017;71(Supplement 2).	7
191	Aoyama TK-A, K.Uchiyama, A.Kon, K.Okubo, H.Yamashina, S.Ikejima, K.Kokubu, S.Miyazaki, A.Watanabe, S. Spleen-derived lipocalin-2 in the portal vein regulates Kupffer cells activation and attenuates the development of liver fibrosis in mice. <i>Laboratory Investigation</i> . 2017;97(8):890-902.	5
192	Arzpayma PC, J.Macfarlane, A. Comparison of enhanced liver fibrosis test with procollagen-3 N-terminal peptide (P3NP) as a marker for liver fibrosis. <i>British Journal of Dermatology</i> . 2017;176(6):1439-40.	7
193	Baldo DD, A.Ferraz, M. L.Andrade, L. E. C. Autoantibodies as biomarkers for the identification of pre-clinical stages of autoimmune diseases: Demonstration of inflammatory and fibrotic activity in the liver of asymptomatic and biochemically normal individuals with anti-mitochondria antibodies. <i>Arthritis and Rheumatology Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP</i> . 2017;69(Supplement 10).	7
194	Berti AD-T, E.Gallivanone, F.Canevari, C.Milani, R.Lanzillotta, M.Campochiaro, C.Ramirez, G. A.Bozzalla Cassione, E.Bozzolo, E.Pedica, F.Castiglioni, I.Arcidiacono, P. G.Balzano, G.Falconi, M.Gianolli, L.Dagna, L. Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. <i>Rheumatology</i> . 2017;56(12):2084-92.	6
195	Berti AD-T, E.Gallivanone, F.Canevari, C.Milani, R.Lanzillotta, M.Campochiaro, C.Ramirez, G. A.Cassione, E. B.Bozzolo, E.Pedica, F.Castiglioni, I.Arcidiacono, P. G.Balzano, G.Falconi, M.Gianolli, L.Dagna, L. Quantitative measurement of ¹⁸ F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. <i>Rheumatology (United Kingdom)</i> . 2017;56(12):2084-92.	2

연번	서지정보	배제 사유
196	Bowlus CLP, K.Hirschfield, G.Guha, N.Chapman, R. W.Chazouilleres, O.Ding, D.Jia, C.McColgan, B. J.Natha, M.Myers, R. P.Subramanian, M.McHutchison, J.Muir, A. J.Goodman, Z.Rosenberg, W.Levy, C. Prospective validation of the enhanced liver fibrosis (ELF) test for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis (PSC). <i>Gastroenterology</i> . 2017;152 (5 Supplement 1):S1060.	7
197	Bowlus CLP, K.Hirschfield, G.Guha, N.Chapman, R. W.Chazouilleres, O.Ding, D.Jia, C.McColgan, B. J.Natha, M.et al.,. Prospective validation of the enhanced liver fibrosis (ELF) test for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis (PSC). <i>Gastroenterology</i> . 2017;152(5):S1060.	7
198	Bowlus CP, K.Hirschfield, G.Guha, I.Chapman, R.Chazouilleres, O.Ding, D.Jia, C.McColgan, B.Myers, R.Subramanian, M.McHutchison, J.Muir, A.Goodman, Z.Rosenberg, W.Levy, C. Prospective validation of the Enhanced Liver Fibrosis test for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis. <i>Journal of Hepatology</i> . 2017;66 (1 Supplement 1):S359.	7
199	Bowlus CP, K.Hirschfield, G.Guha, I.Chapman, R.Chazouilleres, O.Ding, D.Jia, C.McColgan, B.Myers, R.et al.,. Prospective validation of the Enhanced Liver Fibrosis test for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis. <i>Journal of hepatology</i> . 2017;66(1):S359.	7
200	Burke LW, B.Mann, V.Wong, L. L.Corless, L.Abouda, G. The COMMANDS study: improving community-based diagnosis and management of non-alcoholic fatty liver disease. <i>Journal of hepatology</i> . 2017;66(1):S419-S20.	7
201	de Vries EMGF, M.Milkiewicz, P.Hov, J. R.Eksteen, B.Thorburn, D.Chazouilleres, O.Pares, A.Nygaard, S.Gilja, O. H.Wunsch, E.Invernizzi, P.Carboni, M.Bernuzzi, F.Boberg, K. M.Rosjo, H.Rosenberg, W.Beuers, U. H.Ponsioen, C. Y.Karlsen, T. H.Vesterhus, M. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. <i>Liver International</i> . 2017;37(10):1554-61.	1
202	Dempster NF, R.Watson, M.Gerogiannis, I.Rickers, L.Fletcher, C.Tan, G.Gillies, R.Sgromo, B.Rosenberg, W.Hodson, L.Tomlinson, J.Ryan, J. Advanced NAFLD is common in patients undergoing bariatric surgery and poorly staged preoperatively by existing noninvasive biomarkers pre-operative management. <i>Obesity Surgery</i> . 2017;27 (1 Supplement 1):138.	7
203	Doyle JSB, A. L.Iser, D. M.Sasadeusz, J.Roney, J.O'Reilly, M.Fairley, C.Gane, E.Hoy, J.Matthews, G. V.et al.,. Suitability of HCV treatment in primary care settings for individuals with HIV/hepatitis C coinfection. <i>Journal of hepatology</i> . 2017;66(1):S524-S5.	7
204	Drasar EF, E.Gardner, K.Awogbade, M.Dhawan, A.Bomford, A.Suddle, A.Thein, S. L. Interim assessment of liver damage in patients with sickle cell disease using new non-invasive techniques. <i>British Journal of Haematology</i> . 2017;176(4):643-50.	1
205	Drks. A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Oral GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline Phosphatase. http://www.whoint/trialsearch/Trial2.aspx?TrialID=DRKS00013664 . 2017.	2
206	Durusoy SY, E. G.Ozdemir, F. T.Ozdogan, O. C. Validation of ELF test score for hepatic fibrosis evaluation in Turkish chronic liver disease patients. <i>Hepatology International</i> . 2017;11 (1 Supplement 1):S908.	7
207	Ebert TL, N.Schaudinn, A.Busse, H.Berger, J.Lichtinghagen, R.Keim, V.Wiegand, J.Karlas, T. Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease. <i>Endocrine</i> . 2017;58(2):246-52.	5

연번	서지정보	배제 사유
208	Euctr BE. A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline Phosphatase. http://www.who.int/trialssearch/Trial2.aspx?TrialID=EUCTR2016-004599-23-BE . 2017.	6
209	Euctr ES. A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline Phosphatase. http://www.who.int/trialssearch/Trial2.aspx?TrialID=EUCTR2016-004599-23-ES . 2017.	2
210	Euctr NL. Effect of LIK066 on reduction of fatty content in livers of obese patients. http://www.who.int/trialssearch/Trial2.aspx?TrialID=EUCTR2017-002046-71-NL . 2017.	2
211	Ferraz MLCGO, E.Perez, R. M.Dellavance, A. L. C. G.Andrade, L. E.Lanzoni, V. P. Non-invasive evaluation of liver fibrosis in autoimmune hepatitis: Still a challenge. <i>Journal of Hepatology</i> . 2017;66 (1 Supplement 1):S548-S9.	7
212	Ghori SSK, H.Alim, M.Quddus, M. A. A cross sectional study to assess liver fibrosis in patients with diabetes and metabolic syndrome. <i>International Journal of Pharmaceutical and Clinical Research</i> . 2017;9(5):358-62.	2
213	Grove JIT, P.Astbury, S.Harris, R.Delahooke, T.Card, T. R.Guha, I. N.Aithal, G. P. Prevalence of combined PNPLA3 and GCKR variant genotype is increased in patients with risk factors for alcoholic or nonalcoholic liver disease who have clinically significant serum procollagen III levels. <i>Journal of Hepatology</i> . 2017;66 (1 Supplement 1):S587.	7
214	Hamed AME-K, O. A.Boctor, S. S.Abd-Elaziz, L. F. Potential involvement of PPAR alpha activation in diminishing the hepatoprotective effect of fenofibrate in NAFLD: Accuracy of non- invasive panel in determining the stage of liver fibrosis in rats. <i>Biomedicine & Pharmacotherapy</i> . 2017;85:68-78.	6
215	Hamed AME-K, O. A.Boctor, S. S. A.Abd-Elaziz, L. F. Potential involvement of PPAR alpha activation in diminishing the hepatoprotective effect of fenofibrate in NAFLD: Accuracy of non- invasive panel in determining the stage of liver fibrosis in rats. <i>Biomedicine and Pharmacotherapy</i> . 2017;85:68-78.	5
216	Harbeson SLM, A. J.Liu, J. F.Aslanian, A. M.Nguyen, S.Bridson, G. W.Brummel, C. L.Wu, L.Tung, R. D.Pilja, L.et al.,. Altering Metabolic Profiles of Drugs by Precision Deuteration 2: discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development. <i>Journal of pharmacology and experimental therapeutics</i> . 2017;362(2):359-67.	1
217	Harrison SAA, M. F.Diehl, A. M.Caldwell, S.Shiffman, M. L.Ghalib, R.Lawitz, E.Rockey, D. C.Aguilar Schall, R. E.Jia, C.McColgan, B. J.Myers, R. P.Subramanian, M.McHutchison, J. G.Muir, A. J.Ratziu, V.Afdhal, N. H.Goodman, Z. D.Bosch, J.Sanyal, A. J. Prospective validation of the Enhanced Liver Fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis. <i>Hepatology</i> . 2017;66 (Supplement 1):1120A-1A.	7
218	Harrison SAA, M. F.Diehl, A. M.Caldwell, S.Shiffman, M. L.Ghalib, R.Lawitz, E.Rockey, D. C.Aguilar Schall, R. E.Jia, C.et al.,. Prospective validation of the Enhanced Liver Fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis. <i>Hepatology (baltimore, md)</i> . 2017;66:1120A-1A.	7
219	Karakoyun IA, F. D.Tatar, B. G.Pala, E.Yildirim, M.Ulasoglu, C.Duman, C.Akar, H.Kose, S.Basok, B. I. Diagnostic efficacy of the elf test in distinguishing significant fibrosis in patients with chronic hepatitis B. <i>Turkish Journal of Biochemistry</i> . 2017;42 (Supplement 2):59.	7

연번	서지정보	배제 사유
220	Kawaguchi TI, T.Amano, K.Kuwahara, R.Arinaga-Hino, T.Miyjima, I.Torimura, T. Changes in fibrotic markers in chronic hepatitis C patients treated with direct antiviral agents and the enhanced liver fibrosis score as a predictor of hepatocellular carcinoma. <i>Hepatology</i> . 2017;66 (Supplement 1):554A-5A.	7
221	Kumar MP, A. S.Kumar, A.Sachdeva, S.Srivastava, S.Dalal, A.Dahale, A.Sakhuja, P.Mantri, A. Efficacy of enhanced liver fibrosis score and transient elastography for assessment of severity of fibrosis in chronic hepatitis C. <i>Indian Journal of Gastroenterology</i> . 2017;36 (1 Supplement 1):A53.	7
222	Lee JHK, M. H.Kim, H. H.Cho, S.Shim, Y. R.Seo, W.Choi, W. M.Kim, S. Y.Jeong, W. I. CD40L enrichment of hepatic exosomes augment IL-17A production of gamma delta T cells by regulating hepatic stellate cells and Kupffer cells in alcoholic liver disease. <i>Hepatology</i> . 2017;66 (Supplement 1):62A-3A.	7
223	Lutterkort GLW, A.Yurdaydin, C.Budde, E.Westphal, M.Lichtinghagen, R.Stift, J.Bremer, B.Hardtke, S.Keskin, O.Idilman, R.Koch, A.Manns, M. P.Dienes, H. P.Wedemeyer, H.Heidrich, B. Non-invasive fibrosis score for hepatitis delta. <i>Liver International</i> . 2017;37(2):196-204.	2
224	Majumdar AC, C.Thorburn, D.Srivastava, A.Rosenberg, W.Pinzani, M.Longworth, L.Tsochatzis, E. A. Referral pathways for patients with non-alcoholic fatty liver disease based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis of a two-tier approach. <i>Journal of Hepatology</i> . 2017;66 (1 Supplement 1):S51.	7
225	Markova MJ, W.Rodiger, M.Tacke, C.Murahovschi, V.Kessler, K.Lichtinghagen, R.Sticht, C.Gretz, N.Hornemann, S.Pfeiffer, A.Pivovarova, O.Ouwens, M.Schurmann, A.Rudovich, N. Up-regulation of novel proinflammatory adipokine Wnt1 inducible signalling pathway protein 1 (WISP1) in liver fibrosis. <i>Diabetologia</i> . 2017;60 (1 Supplement 1):S291-S2.	7
226	Maybury C. Abdominal obesity and insulin resistance are significant risk factors for liver fibrosis in a cohort of patients with severe psoriasis; results from a prospective, observational cohort study. <i>Gut</i> . 2017;66 (Supplement 2):A93.	7
227	Maybury CP, H.Lewis, C.Kloczko, E.Duckworth, M.Dew, T.Crook, M.Natas, S.Miquel, R.Wong, T.Smith, C.Barker, J. Abdominal obesity and insulin resistance are significant risk factors for liver fibrosis in a cohort of patients with severe psoriasis: Results from a prospective, observational cohort study. <i>British Journal of Dermatology</i> . 2017;177 (Supplement 1):10-1.	7
228	Morell-Garcia DB, J. M.Bonet, M. L.Escarda, A.Latorre, R.Barcelo, B.Barcelo, A. Usefulness of direct serum biomarkers for liver fibrosis (ELF score) in patients with Hepatitis C. <i>Clinical Chemistry and Laboratory Medicine</i> . 2017;55 (Supplement 1):S661.	7
229	Muir AJT, M.Hassanzadeh, E.Sahni, V. A.Sainani, N.Shiffman, M. L.Ding, D.Jia, C.McColgan, B. J.Myers, R. P.Subramanian, M.McHutchison, J. G.Goodman, Z. D.Eksteen, B.Manns, M. P.Levy, C.Bowlus, C. L.Chapman, R. W.Tempany-Afdhal, C. Radiologic progression in primary sclerosing cholangitis (PSC) by two-dimensional magnetic resonance cholangiopancreatography (MRCP): Prospective data from a randomized controlled trial. <i>Hepatology</i> . 2017;66 (Supplement 1):156A.	7
230	Nct. Financial Incentives, Randomization With Stepped Treatment Trial. https://clinicaltrials.gov/show/NCT03089320 . 2017.	1
231	Olveda DUI, M.Olveda, R. M.Vinluan, M. L.Ng, S. K.Weerakoon, K.McManus, D. P.Ramm, G. A.Harn, D. A.Li, Y.Lam, A. K.Guevarra, J. R.Ross, A. G. Diagnosing schistosomiasis-induced liver morbidity: implications for global control. <i>International Journal of Infectious Diseases</i> . 2017;54:138-44.	1

연번	서지정보	배제 사유
232	Omran DY, A.Darweesh, S. K.Nabeel, M. M.Beshlawey, M. E.Saif, S.Farred, A.Hassany, M.Zayed, R. A. Enhanced liver fibrosis test accurately discriminates advanced stage of fibrosis in HCV patients. <i>Gastroenterologie a Hepatologie</i> . 2017;71 (Supplement 2):2S19.	7
233	Parikh PR, J. D.Tsochatzis, E. A. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. <i>Annals of Translational Medicine</i> . 2017;5 (3) (no pagination)(40).	2
234	Patel PJS, K. A.Horsfall, L. U.Hayward, K. L.Hossain, F.Williams, S.Johnson, T.Brown, N.Lampe, G.Buck, L.Saad, N.Clouston, A.Irvine, K. M.Russell, A.Valery, P. C.Powell, E. E. Enhanced Liver Fibrosis test and liver stiffness measurements identify high prevalence of advanced fibrosis in people with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> . 2017;32 (Supplement 2):103.	7
235	Pencheva BM, R.Ruseva, A.Mitova, R.Petrov, K.Taneva, G.Genov, J. Reference Values of Certain Serum Indicators of Liver Fibrosis. <i>Clinical Laboratory</i> . 2017;63(11):1793-800.	6
236	Pencheva BM, R.Ruseva, A.Mitova, R.Pavlov, K.Taneva, G.Genov, J. Reference values of certain serum indicators of liver fibrosis. <i>Clinical Laboratory</i> . 2017;63(11-12):1793-800.	1
237	Ragazzo TGP-V, D.Lima, F. R.de Campos Mazo, D. F.Pessoa, M. G.Oliveira, C. P.Alves, V. A. F.Carrilho, F. J. Accuracy of transient elastography-FibroScan R, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C. <i>Clinics (Sao Paulo, Brazil)</i> . 2017;72(9):516-25.	6
238	Ramachandran JH, M.Hrycek, C.Tse, E.Muller, K. R.Woodman, R. W.Wigg, A. J. Fewer liver-related emergency admissions and improved survival in cirrhotic patients within a chronic liver failure program. <i>Journal of gastroenterology and hepatology (australia)</i> . 2017;32:105-6.	7
239	Rockstroh JKP, F.Bansal, M.Fatkenheuer, G.Small, C. B.Asmuth, D. M.Pialoux, G.Zhang-Roper, R.Wang, R.Pineda, J. A.Heera, J. Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial. <i>Antiviral Therapy</i> . 2017;22(3):263-9.	6
240	Rockstroh JKP, F.Bansal, M.Fätkenheuer, G.Small, C. B.Asmuth, D. M.Pialoux, G.Zhang-Roper, R.Wang, R.Pineda, J. A.et al., Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial. <i>Antiviral therapy</i> . 2017;22(3):263-9.	3
241	Shiha GI, A.Helmy, A.Sarin, S. K.Omata, M.Kumar, A.Bernstien, D.Maruyama, H.Saraswat, V.Chawla, Y.Hamid, S.Abbas, Z.Bedossa, P.Sakhuja, P.Elmahatab, M.Lim, S. G.Lesmana, L.Sollano, J.Jia, J. D.Abbas, B.Omar, A.Sharma, B.Payawal, D.Abdallah, A.Serwah, A.Hamed, A.Elsayed, A.AbdelMaqsood, A.Hassanein, T.Ihab, A.G. Haziuan HZein, N.Kumar, M. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. <i>Hepatology International</i> . 2017;11(1).	7
242	Spreafico MM, F. F.Berzuini, A.Raffaele, L.Colli, A.Prati, D. Identification of the healthy ranges for enhanced liver fibrosis score. <i>Journal of Hepatology</i> . 2017;66 (1 Supplement 1):S412.	7
243	Srivastava AG, R.Demma, S.Warner, A.Suri, D.Morgan, S.Sennett, K.Thorburn, D.Parkes, J.Tsochatzis, E.Rosenberg, W. Primary care sequential use of FIB-4 and the enhanced liver fibrosis test to stratify patients with non-alcoholic fatty liver disease increases cirrhosis detection and reduces referrals of patients with mild disease - 2 year study analysis. <i>Journal of Hepatology</i> . 2017;66 (1 Supplement 1):S68.	7

연번	서지정보	배제 사유
244	Srivastava AP, E. Benefits of using the enhanced liver fibrosis test (ELF) test TM * in non-alcoholic fatty liver disease (NAFLD) in primary care. <i>Clinical Chemistry and Laboratory Medicine</i> . 2017;55 (Supplement 1):S184.	7
245	Swierkot JF, M.Skoczynska, M.Starba, A.Gomulkiewicz, M. S.Wojtala, P.Bujak, M. The role of enhanced liver fibrosis (ELF) score in patients with rheumatoid arthritis treated with methotrexate. <i>Annals of the Rheumatic Diseases</i> . 2017;76 (Supplement 2):276.	7
246	Tanwar ST, P. M.Hogan, B. J.Srivastava, A.Parkes, J.Harris, S.Grant, P.Nastouli, E.Ocker, M.Wehr, K.et al.,. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy. <i>European journal of gastroenterology & hepatology</i> . 2017;29(3):289-96.	6
247	Thiele MM, B. S.Hansen, J. F.Detlefsen, S.Antonsen, S.Krag, A. The enhanced liver fibrosis test predicts advanced fibrosis in alcoholic liver disease: A Biopsy-controlled study in 289 patients. <i>Journal of Hepatology</i> . 2017;66 (1 Supplement 1):S66.	7
248	van der Voort EAMW, M.Veldt-Kok, P.Darwish Murad, S.Nijsten, T. Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP). <i>British Journal of Dermatology</i> . 2017;176(6):1599-606.	1
249	Vesterhus MH, A.Hov, J. R.Nygaard, S.Schrumpf, E.Melum, E.Thorbjornsen, L. W.Paulsen, V.Lundin, K.Dale, I.Gilja, O. H.Zweers, SjlbVatn, M.Schaap, F. G.Jansen, P. L. M.Ueland, T.Rosjo, H.Moum, B.Ponsioen, C. Y.Boberg, K. M.Farkkila, M.Karlsen, T. H.Lund-Johansen, F. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. <i>Journal of Hepatology</i> . 2017;66(6):1214-22.	6
250	Vesterhus MH, A.Hov, J. R.Nygaard, S.Schrumpf, E.Melum, E.Thorbjornsen, L. W.Paulsen, V.Lundin, K.Dale, I.Gilja, O. H.Zweers, S. J. L. B.Vatn, M.Schaap, F. G.Jansen, P. L. M.Ueland, T.Rosjo, H.Moum, B.Ponsioen, C. Y.Boberg, K. M.Farkkila, M.Karlsen, T. H.Lund-Johansen, F. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. <i>Journal of Hepatology</i> . 2017;66(6):1214-22.	1
251	Younossi ZMS, M.Sanyal, A. J.Harrison, S. A.Ratziu, V.McColgan, B. J.Myers, R. P.Subramanian, M.McHutchison, J. G.Afdhal, N. H.Abdelmalek, M. F.Bosch, J.Goodman, Z. D. Predictors of fibrosis progression and regression by histology and morphometrically quantified collagen in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis. <i>Hepatology</i> . 2017;66 (Supplement 1):1171A.	7
252	Abdel-Hameed ER, S. D.Sherman, K. E. Assessment of hepatic antifibrotic effect of cenicriviroc in patients with HIV. <i>Topics in antiviral medicine</i> . 2016;24(E-1):219-20.	7
253	Aibe YT, T.Sasaki, R.Nishimura, T.Matsuda, T.Matsumoto, T.Fujisawa, K.Yamamoto, N.Tani, K.Sakaida, I. The efficacy and safety of liver regeneration therapy by hepatic arterial infusion of cultured autologous bone marrow mesenchymal stem cells in our established canine cirrhotic model. <i>Hepatology Conference: 67th annual meeting of the american association for the study of liver diseases: the liver meeting 2016 United states Conference start: 20161111 Conference end: 20161115</i> . 2016;63(1 Supplement 1):212A-3A.	7
254	Babaei ZP, H. Hyaluronic acid algorithm-based models for assessment of liver fibrosis: Translation from basic science to clinical application. <i>Hepatobiliary and Pancreatic Diseases International</i> . 2016;15(2):131-40.	7

연번	서지정보	배제 사유
255	Bernuth SY, E.Schuppan, D.Sprinzi, M. F.Zimmermann, A.Schad, A.Kittner, J. M.Weyer, V.Knapstein, J.Schattenberg, J. M.Worns, M. A.Galle, P. R.Zimmermann, T. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. <i>Digestive and Liver Disease</i> . 2016;48(3):291-7.	10
256	Byrne CDT, G. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate? <i>Diabetologia</i> . 2016;59(6):1141-4.	7
257	Crespo GG, M.Millan, O.Casals, G.Ruiz, P.Londono, M. C.Mira, A.Forns, X.Brunet, M.Jimenez, W.Navasa, M. Early non-invasive selection of patients at high risk of severe hepatitis C recurrence after liver transplantation. <i>Transplant Infectious Disease</i> . 2016;18(3):471-9.	1
258	D'Ambrosio RD, E.Aghemo, A.Fraquelli, M.Lampertico, P.Rumi, M. G.Facchetti, F.Grassi, E.Casazza, G.Rosenberg, W.Bedossa, P.Colombo, M. Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon. <i>PLoS ONE</i> . 2016;11 (6) (no pagination)(e0155967).	2
259	Day CG, J.Floros, L.Pryke, R. Authors' reply to Tavabie. <i>BMJ (Online)</i> . 2016;355 (no pagination)(i5436).	7
260	de Alwis NMA, Q. M.Day, C. P. How to Diagnose Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases</i> . 2016;34 Suppl 1:19-26.	6
261	De Alwis NMWA, Q. M.Day, C. P. How to Diagnose Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases</i> . 2016;34(1 Supplement 1):19-26.	7
262	De Vries EMF, M. A.Milkiewicz, P.Hov, J. R.Eksteen, B.Thorburn, D.Chazouilleres, O.Pares, A.Gilja, O. H.Wunsch, E.Invernizzi, P.Carboni, M.Bernuzzi, F.Boberg, K. M.Rosjo, H.Rosenberg, W. M.Ponsioen, C. Y.Karlsen, T. H.Vesterhus, M. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-center study. <i>Hepatology</i> . 2016;64 (1 Supplement 1):185A-6A.	7
263	De Vries EMF, M. A.Milkiewicz, P.Hov, J. R.Eksteen, B.Thorburn, D.Chazouilleres, O.Pares, A.Gilja, O. H.Wunsch, E.et al.,. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-center study. <i>Hepatology Conference: 67th annual meeting of the american association for the study of liver diseases: the liver meeting 2016 United states Conference start: 20161111 Conference end: 20161115</i> . 2016;63(1 Supplement 1):185A-6A.	7
264	Della-Torre EF, E.Deshpande, V.Mattoo, H.Mahajan, V.Kulikova, M.Wallace, Z. S.Carruthers, M.Chung, R. T.Pillai, S.Stone, J. H. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> . 2016;74(12):2236-43.	1
265	Dellavance AF, F.Shimabokuro, N.Latini, F.Baldo, D.Barreto, J. A.Marvulle, V.Andrade, L. E.Ferraz, M. L. Enhanced liver fibrosis (ELF) score: Analytical performance and distribution range in a large cohort of blood donors. <i>Clinica Chimica Acta</i> . 2016;461:151-5.	1
266	Dyvorne HAJ, G. H.Bane, O.Fiel, M. I.Chou, H.Schiano, T. D.Dieterich, D.Babb, J. S.Friedman, S. L.Taouli, B. Prospective comparison of magnetic resonance imaging to transient elastography and serum markers for liver fibrosis detection. <i>Liver International</i> . 2016;36(5):659-66.	4

연번	서지정보	배제 사유
267	Eddowes PJM, N.Davies, N. P.Semple, S. I.Hubscher, S. G.Kendall, T. J.Hodson, J.Newsoms, P. N.Kelly, C.Herlihy, A. H.Kelly, M. D.Fallowfield, J.Hirschfield, G. M. Exclusion of clinically significant non-alcoholic fatty liver disease with multi-parametric magnetic resonance imaging: A prospective evaluation. <i>Hepatology</i> . 2016;64 (1 Supplement 1):572A-3A.	7
268	Eddowes PT, P.Corrigan, M.Ferguson, J.Hirschfield, G. Correlation of non-invasive markers of liver fibrosis in patients with primary sclerosing cholangitis: A validation cohort. <i>Journal of Hepatology</i> . 2016;1):S640.	7
269	Euctr SK. A 2 part clinical study that will evaluate the safety and effectiveness of LJN452A to treat patients with fatty liver disease for a period of 12 weeks. The first part will be used for LJN452 dose selection for the second part of the study. http://www.who.int/trialssearch/Trial2.aspx?TrialID=EUCTR2015-005215-33-SK . 2016.	2
270	Floros LD, C.Wonderling, D.Glen, J.Harker, M. Cost-effectiveness of diagnostic tests for people at risk of non-alcoholic fatty liver disease (NAFLD) in the UK. <i>Value in Health</i> . 2016;19 (7):A699.	7
271	Fonvig CEK, J. T.Chabanova, E.Johansen, M.Berre, I.Thomsen, H. S.Holm, J. C. The ELF score is associated with 1H-MRS measured liver fat content in Danish children with overweight and obesity. <i>Obesity Facts</i> . 2016;1):18.	7
272	French ALH, A.Young, M.Nowicki, M.Augenbraun, M.Anastos, K.Seaberg, E.Rosenberg, W.Peters, M. G. Isolated Hepatitis B Core Antibody Status Is Not Associated with Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection. <i>Journal of Acquired Immune Deficiency Syndromes</i> . 2016;72(3):274-80.	3
273	Gathercole LLH, J. M.Armstrong, M. J.Crowley, R.Boocock, S.O'Reilly, M. W.Round, M.Brown, R.Bolton, S.Cramb, R.Newsoms, P. N.Semple, R. K.Paisey, R.Tomlinson, J. W.Geberhiwot, T. Advanced non-alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alstrom syndrome. <i>Liver International</i> . 2016;36(11):1704-12.	3
274	Ge XM, F.Arriazu, E.Chen, Y.Dela Cruz, R. D.Theise, N. D.Nieto, N. High mobility group box-1 participates in the pathogenesis of liver fibrosis. <i>Hepatology</i> . 2016;64 (1 Supplement 1):828A.	7
275	Grgurevic IC, D.Bokun, T.Mustapic, S.Lukic, A.Banic, M.Brkljadic, B.Curic, J.Kujundzic, M. Liver and spleen stiffness assessed by transient elastography and real-time 2D shear wave elastography and ELFTM test have very good performance for non-invasive detection and estimating severity of portal hypertension. <i>United European Gastroenterology Journal</i> . 2016;4 (5 Supplement 1):A361.	7
276	Gungoren MS. ELF test in the evaluation of hepatic fibrosis. <i>Turkish Journal of Biochemistry</i> . 2016;41 (Supplement 3):53-4.	7
277	Habuchi HU, T.Habuchi, O. Mice deficient in N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase exhibit enhanced liver fibrosis and delayed recovery from fibrosis in carbon tetrachloride-treated mice. <i>Heliyon</i> . 2016;2(8):e00138.	5
278	Hametner SF, A.Ferlitsch, M.Etschmaier, A.Schofl, R.Ziachehabi, A.Maieron, A. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a new marker for clinically significant portal hypertension in comparison to other non-invasive parameters of fibrosis including ELF test. <i>PLoS ONE</i> . 2016;11(2).	2
279	Henson JBL, C.Goodman, Z.Ding, D.Aguilar, R.Myers, R. P.Muir, A. Sex-specific differences in patients with primary sclerosing cholangitis. <i>Gastroenterology</i> . 2016;1):S1070.	7

연번	서지정보	배제 사유
280	Heo JYK, B. K.Park, J. Y.Kim, D. Y.Ahn, S. H.Kim, H. S.Park, Y. N.Han, K. H.Kim, S. U. Validation of a diagnostic strategy combining the transient elastography liver stiffness value and enhanced liver fibrosis test to assess the fibrotic burden in patients with chronic hepatitis B. <i>Hepatology</i> . 2016;64 (1 Supplement 1):905A.	7
281	Hirschfield GMG, M. E.Strauss, R.Mayo, M. J.Levy, C.Zou, B.Johanns, J.Nhane, I. P.Dasgupta, B.Li, K.Selmi, C.Marschall, H. U.Jones, D.Lindor, K.Purifi Study Group. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. <i>Hepatology</i> . 2016;64(1):189-99.	6
282	Hirschfield GMG, M. E.Strauss, R.Mayo, M. J.Levy, C.Zou, B.Johanns, J.Nhane, I. P.Dasgupta, B.Li, K.Selmi, C.Marschall, H. U.Jones, D.Lindor, K. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. <i>Hepatology</i> . 2016;64(1):189-99.	1
283	Horvath AL, B.Schmerboeck, B.Tawdrous, M.Zettel, G.Hartl, A.Madl, T.Stryeck, S.Fuchs, D.Lemsch, S.et al.. A multispecies probiotic enhances antimicrobial activity in cirrhosis: a randomized, double blind placebo-controlled study. <i>Zeitschrift fur gastroenterologie</i> . 2016;54(5).	7
284	Irvine KMW, L. F.Shanker, M.Fagan, K. J.Horsfall, L. U.Fletcher, L. M.Ungerer, J. P. J.Pretorius, C. J.Miller, G. C.Clouston, A. D.Lampe, G.Powell, E. E. The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. <i>Liver International</i> . 2016;36(3):370-7.	6
285	Irvine KMW, L. F.Hoffmann, I.Horsfall, L. U.Fagan, K. J.Bijin, V.Lee, B.Clouston, A. D.Lampe, G.Connolly, J. E.Powell, E. E. Multiplex serum protein analysis identifies novel biomarkers of advanced fibrosis in patients with chronic liver disease with the potential to improve diagnostic accuracy of established biomarkers. <i>PLoS ONE</i> . 2016;11 (11) (no pagination)(167001).	4
286	Jeftic IJ, N.Pantic, J.Arsenijevic, N.Lukic, M. L.Pejnovic, N. Galectin-3 deficiency exacerbates liver steatosis but protects from steatohepatitis and IL-33/IL-13 dependent fibrosis in HFD-induced obesity mouse model. <i>Journal of Hepatology</i> . 2016;1):S679.	7
287	Karanjia RNC, M. M. E.Cox, I. J.Fye, H. K. S.Njie, R.Goldin, R. D.Taylor-Robinson, S. D. Hepatic steatosis and fibrosis: Non-invasive assessment. <i>World Journal of Gastroenterology</i> . 2016;22(45):9880-97.	7
288	Keane MGH, C.Pereira, S. P. Improving the identification and monitoring of cirrhosis. <i>The Practitioner</i> . 2016;260(1798):25-9.	7
289	Leeming DJD, G.Nielsen, M. J.Karsdal, M. A.Patel, K.Irving, W.Guha, I. N. True collagen type III formation (PRO-C3) is predictive of outcome in HCV patients with advanced liver fibrosis within the trent study. <i>Journal of Hepatology</i> . 2016;1):S719-S20.	7
290	Leiting SS, S.Martinez-Palacian, A.Muhl, L.Kanse, S. M. Transforming growth factor-beta (TGF-beta) inhibits the expression of factor VII-activating protease (FSAP) in hepatocytes. <i>Journal of Biological Chemistry</i> . 2016;291(40):21020-8.	5
291	Nct. Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy. https://clinicaltrials.gov/show/NCT02948998 . 2016.	7
292	Nct. Metabolic Effects of Furosemide +HSS in Refractory Ascites. https://clinicaltrials.gov/show/NCT02821377 . 2016.	2
293	Nielsen MJT, D.Leeming, D. J.Hov, J. R.Moum, B.Saffioti, F.Gilja, O. H.Boberg, K. M.Mazza, G.Pinzani, M.Karlsen, T. H.Karsdal, M. A.Vesterhus, M. Serological biomarkers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis patients. <i>Journal of Hepatology</i> . 2016;1):S199.	7

연번	서지정보	배제 사유
294	Palaniyappan NC, E.Bradley, C.Scott, R.Austin, A.O'Neill, R.Ramjas, G.Travis, S.White, H.Singh, R.Thurley, P.Guha, I. N.Francis, S.Aithal, G. P. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging. <i>Journal of Hepatology</i> . 2016;65(6):1131-9.	1
295	Patel PJS, K. A.Horsfall, L. U.Hossain, F.Williams, S.Johnson, T.Brown, N.Lampe, G.Buck, L.Clouston, A.Irvine, K. M.Russell, A.Powell, E. E. Non-invasive markers indicate a high prevalence of advanced fibrosis in adults with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> . 2016;31 (Supplement 2):114-5.	7
296	Peters MGB, P.Boylan, R.French, A. L.Tien, P. C.Plankey, M. W.Glesby, M. J.Augenbraun, M.Golub, E. T.Karim, R.Parkes, J.Rosenberg, W. Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV. <i>Aids</i> . 2016;30(5):723-9.	6
297	Peters MGB, P.Boylan, R.French, A. L.Tien, P. C.Plankey, M. W.Glesby, M. J.Augenbraun, M.Golub, E. T.Karim, R.et al... Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV. <i>AIDS (london, england)</i> . 2016;30(5):723-9.	10
298	Puigvehi MB, T.Garcia-Retortillo, M.Hernandez, J. J.Fernandez, R.Canete, N.Coll, S.Cabrero, B.Gimeno, J.Gimenez, M. D.Bory, F.Sola, R.Carrion, J. A. Enhanced liver fibrosis (ELF) test quantification in HBeAg-negative patients with nucleos(T)IDE analogues 1, 3, 5 and 8 years after liver biopsy. <i>Journal of Hepatology</i> . 2016;1):S730.	7
299	Puigvehi MH, J.Broquetas, T.Coll, S.Garcia-Retortillo, M.Canete, N.Gimenez, M. D.Garcia, M.Bory, F.Salvado, M.Sola, R.Carrion, J. A. Diagnostic Accuracy of the Enhanced Liver Fibrosis (ELF R) Score Using HCV-Infected Serum Samples Cryopreserved for up to 25 Years. <i>PLoS ONE [Electronic Resource]</i> . 2016;11(12):e0164883.	6
300	Saffioti FR, D.Vesterhus, M.Hov, J. R.Rosenberg, W.Pinanzi, M.Karlsen, T. H.Pereira, S. P.Boberg, K. M.Thorburn, D. Biliary tract cancer with or without primary sclerosing cholangitis is associated with a raised enhanced liver fibrosis test result compared with PSC alone. <i>Journal of Hepatology</i> . 2016;1):S722-S3.	7
301	Sandahl TDM, R.Moller, H. J.Reverter, E.Moller, S.Turon, F.Hernandez-Gea, V.Bendtsen, F.Vilstrup, H.Garcia-Pagan, J. C.Gronbaek, H. The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> . 2016;43(11):1222-31.	3
302	Srivastava AG, R.Demma, S.Warner, A.Suri, D.Morgan, S.Tanwar, S.Sennett, K.Thorburn, D.Parkes, J.Tsochatzis, E.Rosenberg, W. Primary care sequential use of FIB-4 and the enhanced liver fibrosis test to stratify patients with nonalcoholic fatty liver acide doubles cirrhosis detection and reduces referrals of patients with mild disease. <i>Journal of Hepatology</i> . 2016;1):S474-S5.	7
303	Sung PSJ, D. W.Jang, J. W.Bae, S. H.Choi, J. Y.Kim, Y.Yoon, S. K. Serum wisteria floribunda agglutinin-positive MAC-2-binding protein level as a predictor of hepatic fibrosis in chronic HBV infection. <i>Hepatology</i> . 2016;64 (1 Supplement 1):214A.	7
304	Swanson SM, Y.Scherzer, R.Huhn, G.French, A. L.Plankey, M. W.Grunfeld, C.Rosenberg, W. M.Peters, M. G.Tien, P. C. Association of HIV, hepatitis C virus, and liver fibrosis severity with the enhanced liver fibrosis score. <i>Journal of Infectious Diseases</i> . 2016;213(7):1079-86.	3

연번	서지정보	배제 사유
305	Tavabie OD. Ruling out fibrosis in non-alcoholic fatty liver disease. <i>BMJ (Online)</i> . 2016;355 (no pagination)(i5433).	7
306	Van Der Voort EW, M.Nijsten, T. Enhanced liver fibrosis test (ELF) in psoriasis, psoriatic arthritis and rheumatoid arthritis patients: A daily practice comparison with procollagen-3 N-terminal peptide (P3NP). <i>Journal of the European Academy of Dermatology and Venereology</i> . 2016;30 (Supplement 6):8.	7
307	Vosoghinia HE, A.Ganji, A.Hosseini, Sm- R.Jamehdar, S. A.Salehi, M.Bahari, A.Ghanaei, O.Sahebari, M.Rajabzadeh, F.et al., Vitamin D in standard HCV regimen (PEG-interferon plus ribavirin), its effect on the early virologic response rate: a clinical trial. <i>Razavi international journal of medicine</i> . 2016;4(2).	2
308	Wan YM, K.Wu, N.Lorenzo, S. R.Zhou, T.Venter, J.Francis, H. L.Glaser, S. S.Alpini, G.Meng, F. Knockout of alpha-calcitonin gene-related peptide (α-CGRP) reduces liver fibrosis in cholestatic bile duct ligated (BDL) mice. <i>Hepatology</i> . 2016;64 (1 Supplement 1):260A.	7
309	Wan YZ, T.Wu, N.Invernizzi, P.Standeford, H. A.McDaniel, K.Bernuzzi, F.Venter, J.Onori, P.Gaudio, E.Franchitto, A.Sato, K.Francis, H. L.Meng, F.Alpini, G.Glaser, S. S. Inhibition of the substance P/neurokinin-1 receptor (NK-1R) axis decreases liver fibrosis in the Mdr2-/-mouse model of primary sclerosing cholangitis (PSC) through changes in senescence in cholangiocytes and hepatic stellate cells. <i>Hepatology</i> . 2016;64 (1 Supplement 1):824A-5A.	7
310	Wang HZ, H.Zhang, Z.Huang, B.Cheng, X.Wang, D.la Gahu, Z.Xue, Z.Da, Y.Li, D.Yao, Z.Gao, F.Xu, A.Zhang, R. Adiponectin-derived active peptide ADP355 exerts anti-inflammatory and anti-fibrotic activities in thioacetamide-induced liver injury. <i>Scientific reports</i> . 2016;6:19445.	5
311	Anavi SE-B, M.Hahn-Obercyger, M.Genin, O.Pines, M.Tirosh, O. The role of iNOS in cholesterol-induced liver fibrosis. <i>Laboratory Investigation</i> . 2015;95(8):914-24.	5
312	Asano H. Possibility of Using ELF Score as Index for Hepatic Fibrosis Evaluation. [Japanese]. <i>Rinsho byori</i> . 2015;The Japanese journal of clinical pathology. 63(1):78-83.	8
313	Asano H. [Possibility of Using ELF Score as Index for Hepatic Fibrosis Evaluation]. <i>Rinsho Byori - Japanese Journal of Clinical Pathology</i> . 2015;63(1):78-83.	8
314	Baldry EA, G. P.Kaye, P.Idris, I.Leeder, P.Bennett, A.Macdonald, I. Effects of short term very low energy diets prior to bariatric surgery on liver histology and circulating biomarkers: Results of a randomised controlled trial (RCT). <i>Journal of Hepatology</i> . 2015;2):S716.	7
315	Bandula SP, S.Rosenberg, W. M.Jalan, R.Hall, A. R.Dhillon, A.Moon, J. C.Taylor, S. A. Equilibrium contrast-enhanced CT imaging to evaluate hepatic fibrosis: Initial validation by comparison with histopathologic analysis. <i>Radiology</i> . 2015;275(1):136-43.	6
316	Bandula SP, S.Rosenberg, W. M.Jalan, R.Hall, A. R.Dhillon, A.Moon, J. C.Taylor, S. A. Equilibrium contrast-enhanced CT imaging to evaluate hepatic fibrosis: initial validation by comparison with histopathologic sampling. <i>Radiology</i> . 2015;275(1):136-43.	3
317	Buzzetti EL, R.De Luca, L.Tsochatzis, E. A. Noninvasive assessment of fibrosis in patients with nonalcoholic fatty liver disease. <i>International Journal of Endocrinology</i> . 2015;2015 (no pagination)(343828).	7
318	D'Ambrosio RD, E.Fraquelli, M.Riccardo, P.Aghemo, A.Lampertico, P.Bedossa, P.Rosenberg, W.Colombo, M. Enhanced liver fibrosis (ELF) test does not predict residual cirrhosis after a sustained virological response to hepatitis C treatment. <i>Journal of Hepatology</i> . 2015;2):S610.	7

연번	서지정보	배제 사유
319	Della-Torre EF, E.Deshpande, V.Mattoo, H.Mahajan, V.Kulikova, M.Wallace, Z. S.Carruthers, M.Chung, R. T.Pillai, S.Stone, J. H. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> . 2015;74(12):2236-43.	1
320	Drasar EF, E.Gardner, K.Awogbade, M.Dhawan, A.Bomford, A.Suddle, A.Thein, S. L. Noninvasive assessment of liver fibrosis in patients with sickle cell disease. <i>Blood</i> . 2015;126 (23):3406.	7
321	Dufour JF. Hepatology highlights. <i>Hepatology</i> . 2015;62(1):1-3.	7
322	Euctr GB. A clinical trial to test a novel treatment using a product manufactured from blood cells collected from a patient and administered back to the same patient for the treatment of liver disease. http://www.who.int/trialssearch/Trial2.aspx?TrialID=EUCTR2015-000963-15-GB . 2015.	2
323	Fagan KJP, C. J.Horsfall, L. U.Irvine, K. M.Wilgen, U.Choi, K.Fletcher, L. M.Tate, J.Melino, M.Nusrat, S.Miller, G. C.Clouston, A. D.Ballard, E.O'Rourke, P.Lampe, G.Ungerer, J. P. J.Powell, E. E. ELF score >=9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity. <i>Liver International</i> . 2015;35(6):1673-81.	6
324	Fernandes FFdMP, R.Ferraz, M. L. Determining cut-off points for enhanced liver fibrosis panel. <i>Journal of clinical gastroenterology</i> . 2015;49(1):91-2.	7
325	Goldschmidt IDN, A.Streckenbach, C.Schnell, K.Danne, T.Baumann, U. Improvement of BMI after lifestyle intervention is associated with normalisation of elevated elf score and liver stiffness in obese children. <i>BioMed Research International</i> . 2015;2015 (no pagination)(457473).	1
326	Guechot J. Non-invasive evaluation of liver fibrosis: More well-validated tests available for patient management. <i>Liver International</i> . 2015;35(6):1643-5.	7
327	Hoad CLP, N.Kaye, P.Chernova, Y.James, M. W.Costigan, C.Austin, A.Marciani, L.Gowland, P. A.Guha, I. N.Francis, S. T.Aithal, G. P. A study of T1 relaxation time as a measure of liver fibrosis and the influence of confounding histological factors. <i>NMR in Biomedicine</i> . 2015;28(6):706-14.	6
328	Hoad CLP, N.Kaye, P.Chernova, Y.James, M. W.Costigan, C.Austin, A.Marciani, L.Gowland, P. A.Guha, I. N.Francis, S. T.Aithal, G. P. A study of T ₁ relaxation time as a measure of liver fibrosis and the influence of confounding histological factors. <i>NMR in Biomedicine</i> . 2015;28(6):706-14.	3
329	Hogan BJOB, J.Patch, D. W.Yu, D.Parisi, I.Dhillon, A. P.Hall, A. R.Srivastava, A.Trembling, P. M.Tanwar, S.Parkes, J.Rosenberg, W. M. ELFTM predicts clinical outcomes in liver disease. <i>Hepatology</i> . 2015;1):604A-5A.	7
330	Hogan BJP, I.Patch, D. W.Yu, D.Dhillon, A. P.Hall, A. R.Srivastava, A.Trembling, P. M.Tanwar, S.Parkes, J.Meyer, T.Rosenberg, W. M.O'Beirne, J. ELFTM and Angiopietins accurately predict clinically significant portal hypertension. <i>Hepatology</i> . 2015;1):956A.	7
331	Irvine KMW, L. F.Shanker, M.Fagan, K. J.Horsfall, L. U.Fletcher, L. M.Ungerer, J.Pretorius, C. J.Miller, G. C.Clouston, A. D.Lampe, G.Powell, E. E. Predicting clinical outcomes in chronic liver disease: The ELF test is superior to histology and simple scores. <i>Journal of Gastroenterology and Hepatology (Australia)</i> . 2015;3):104-5.	7
332	Irvine KW, L. F.Shanker, M.Fagan, K.Horsfall, L.Fletcher, L.Ungerer, J.Pretorius, C. J.Miller, G.Clouston, A. D.Lampe, G.Powell, E. E. Predicting clinical outcomes in chronic liver disease: The ELF test is superior to histology and simple scores. <i>Hepatology</i> . 2015;1):600A.	7

연번	서지정보	배제 사유
333	Isrctn. BUTEO: a clinical trial of BTT1023 in patients with primary sclerosing cholangitis (PSC). http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN11233255 . 2015.	2
334	Jeftic IJ, N.Pantic, J.Arsenijevic, N.Lukic, M. L.Pejnovic, N. Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis. <i>Molecular Medicine</i> . 2015;21:453-65.	5
335	Karlas TD, A.Peter, V.Wittekind, C.Lichtinghagen, R.Garnov, N.Linder, N.Schaudinn, A.Busse, H.Prettin, C.Keim, V.Troltzsch, M.Schutz, T.Wiegand, J. Evaluation of transient elastography, Acoustic Radiation Force Impulse Imaging (ARFI), and Enhanced Liver Function (ELF) score for detection of fibrosis in morbidly obese patients. <i>PLoS ONE</i> . 2015;10 (11) (no pagination)(e0141649).	1
336	Loo WMO, L. Z.Dan, Y. Y.Koh, W. P. Enhanced liver fibrosis score predicts hepatocellular carcinoma in Singapore Chinese. <i>Journal of Gastroenterology and Hepatology (Australia)</i> . 2015;4):344-5.	7
337	Mansoor SC, E.Alkhour, N. A Comprehensive Review of Noninvasive Liver Fibrosis Tests in Pediatric Nonalcoholic Fatty Liver Disease. <i>Current Gastroenterology Reports</i> . 2015;17 (6) (no pagination)(23).	7
338	Miele LDM, T.Isgro, M. A.Marrone, G.Cefalo, C.Biolato, M.Rapaccini, G. L.Gasbarrini, A.Zuppi, C.Grieco, A. ELF test is a reliable non invasive test for fibrosis in NAFLD subjects. <i>Journal of Hepatology</i> . 2015;2):S736.	7
339	Mijuskovic ZP, J.Ratic, V.Perisic, N.Kostic, Z. Comparison of elf with fibrotest as the the non-invasive laboratory markers of liver fibrosis. <i>Clinical Chemistry and Laboratory Medicine</i> . 2015;1):S1232.	7
340	Morling JF, J.Williamson, R.Robertson, C.Glancey, S.Guha, I.Strachan, M.Price, J. Gamma-glutamyl transferase but not markers of hepatic fibrosis is associated with cardiovascular disease in older people with type 2 diabetes mellitus: The Edinburgh type 2 diabetes study. <i>Gut</i> . 2015;1):A258.	7
341	Morling JRF, J. A.Williamson, R. M.Strachan, M. W.Price, J.Guha, I. N. How common is chronic liver disease in a community type 2 diabetes population? The Edinburgh Type 2 Diabetes Study. <i>Hepatology</i> . 2015;1):1264A-5A.	7
342	Nieto Sanchez CVA, J. A.Vera Mendez, F.Albaladejo Oton, M. D.Martinez Gascon, L. E.Moreno Fuentes, A. M.Castaneda San Cirilo, M. Effectiveness evaluation of ELF test for assessment of liver fibrosis, in a population of patients with chronic hepatitis by HCV background. <i>Clinical Chemistry and Laboratory Medicine</i> . 2015;1):S196.	7
343	Powell EEI, K. M.Fagan, K. J.Ballard, E.O'Rourke, P. Response to ELF cut-off points: Aetiology is also a relevant factor. <i>Liver International</i> . 2015;35(7):1921-.	7
344	Puigvehí MH, J.Canete, N.Broquetas, T.García-Retortillo, M.Coll, S.Cabrero, B.García, M.Gimenez, D.Bory, F.Salvado, M.Sola, R.Carrion, J. A. Biological stability and diagnostic accuracy of ELF (enhanced liver fibrosis test) to identify liver fibrosis in patients with chronic hepatitis C using cryopreserved serum samples during 25 years. <i>Journal of Hepatology</i> . 2015;2):S508.	7
345	Rockstroh JKS, V.Plonski, F.Bansal, M.Fatkenheuer, G.Small, C. B.Asmuth, D. M.Pialoux, G.Mukwaya, G.Jagannatha, S.Heera, J.Pineda, J. A. Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: A randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. <i>HIV Clinical Trials</i> . 2015;16(2):72-80.	2

연번	서지정보	배제 사유
346	Saffiotti FV, M.Telese, A.Mazza, G.Roccarina, D.Rosselli, M.Jonasson, W.Pares, A.Karlsen, T. H.Rosenberg, W.Pinzani, M.Marshall, A.Thorburn, D. Non-invasive assessment of disease severity in primary sclerosing cholangitis (PSC): Clinical scores, transient elastography (TE) and the enhanced liver fibrosis (ELF) test. Gut. 2015;1):A254.	7
347	Samokhodskaja LMS, E. E.Yarovaya, E. B.Krasnova, T. N.Mukhin, N. A.Tkachuk, V. A.Sadovnichy, V. A. Mathematic Model for Prediction of Liver Fibrosis Progression Rate in Patients with Chronic Hepatitis C Based on Combination of Genomic Markers. [Russian]. Vestnik Rossiiskoi akademii meditsinskikh nauk / Rossiiskaia akademiia meditsinskikh nauk. 2015(6):651-61.	8
348	Samokhodskaja LMS, E. E.Yarovaya, E. B.Krasnova, T. N.Mukhin, N. A.Tkachuk, V. A.Sadovnichy, V. A. [Mathematic Model for Prediction of Liver Fibrosis Progression Rate in Patients with Chronic Hepatitis C Based on Combination of Genomic Markers]. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 2015(6):651-61.	8
349	Sands CJG, I. N.Kyriakides, M.Wright, M.Beckonert, O.Holmes, E.Rosenberg, W. M.Coen, M. Metabolic phenotyping for enhanced mechanistic stratification of chronic hepatitis C-induced liver fibrosis. American Journal of Gastroenterology. 2015;110(1):159-69.	3
350	Sertoglu EK, H.Uyanik, M. Detailed evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests in assessing hepatic fibrosis. Journal of Clinical Gastroenterology. 2015;49(2):170.	7
351	Sertoglu EK, H.Uyanik, M. Important issues in determining the cut-offs for liver fibrosis index. Journal of Clinical Gastroenterology. 2015;49(1):90-1.	7
352	Srivastava AG, R.Gulati, S.Warner, A.Morgan, S.Sennett, K.Suri, D.Thorburn, D.Tsochatzis, E.Rosenberg, W. Analysis of new patient attendances for NAFLD at three London hospitals highlights the need to develop clinical risk stratification pathways. Gut. 2015;1):A249.	7
353	Srivastava AG, R.Tanwar, S.Trembling, P.Warner, A.Morgan, S.Sennett, K.Thorburn, D.Tsochatzis, E.Rosenberg, W. A one year retrospective review of new patient attendances at a tertiary hepatology centre highlighting the increasing challenge of NAFLD and the need to develop clinical pathways. Journal of Hepatology. 2015;2):S740.	7
354	Szybowska PW, M.Starzyk, J. B.Sztefko, K. Enhanced liver fibrosis (ELF) test in obese children with ultrasound-proven liver steatosis. Neuroendocrinology Letters. 2015;36(7):700-5.	3
355	Takashima TI, H.Nishiguchi, S. Diagnosis of liver fibrosis in patients with chronic hepatitis using serum enhanced liver fibrosis (ELF). [Japanese]. Nihon rinsho. 2015;Japanese journal of clinical medicine. 73(Supplement 9):145-9.	8
356	Takashima TI, H.Nishiguchi, S. [Diagnosis of liver fibrosis in patients with chronic hepatitis using serum enhanced liver fibrosis (ELF)]. Nippon Rinsho - Japanese Journal of Clinical Medicine. 2015;73 Suppl 9:145-9.	8
357	Takashima TI, H.Aoki, T.Nakano, C.Aizawa, N.Kishino, K.Shimono, Y.Hasegawa, K.Takata, R.Yo, K.Ishii, A.Sakai, Y.Nishimura, T.Nishikawa, H.Iwata, Y.Ikeda, N.Enomoto, H.Hirota, S.Fujimoto, J.Yano, H.Nakashima, O.Kage, M.Nishiguchi, S. Usefulness of liver fibrosis markers elf in chronic hepatitis. [Japanese]. Acta Hepatologica Japonica. 2015;56(10):543-5.	8
358	Trocme CT, B.Guergour, D.Bosson, J.Zarski, J.Faure, P. Evaluation of the ELFTM score for the diagnosis of liver fibrosis in a population of hepatitis C patients. Clinical Chemistry and Laboratory Medicine. 2015;1):S1270.	7

연번	서지정보	배제 사유
359	Vesterhus MH, J. R.Holm, A.Schrumpf, E.Nygaard, S.Godang, K.Andersen, I. M.Naess, S.Thorburn, D.Saffioti, F.Vatn, M.Gilja, O. H.Lund-Johansen, F.Syversveen, T.Brabrand, K.Pares, A.Ponsioen, C. Y.Pinzani, M.Farkkila, M.Moum, B.Ueland, T.Rosjo, H.Rosenberg, W.Boberg, K. M.Karlsen, T. H. Enhanced Liver Fibrosis Score Predicts Transplant-Free Survival in Primary Sclerosing Cholangitis. <i>Hepatology</i> . 2015;62(1):188-97.	1
360	Abignano GC, G.Buch, M. H.Rosenberg, W. M.Valentini, G.Emery, P.Del Galdo, F. The enhanced liver fibrosis test: A clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> . 2014;73(2):420-7.	1
361	Baldo DCD, A.Latini, F.Barreto, J. A.N. R. FrancaAndrade, L. E. C. Enhanced Liver Fibrosis (ELF) Score indicates progressive fibrosis in preclinical stages of primary biliary cirrhosis. <i>Clinical Chemistry</i> . 2014;1):S30.	7
362	Bansal RF, L.Brenndorfer, E.Prakash, J.Sallberg, M. Hepatitis c nonstructural protein 3/4a dampens inflammation and contributes to slow fibrosis progression during chronic liver injury in mice. <i>United European Gastroenterology Journal</i> . 2014;1):A130.	7
363	Bansal RF, L.Brenndorfer, E. D.Storm, G.Prakash, J.Sallberg, M. Hepatitis C nonstructural protein 3/4a dampens inflammation and contributes to slow fibrosis progression during chronic liver injury in mice. <i>Journal of Hepatology</i> . 2014;1):S138.	7
364	Dolman GEZ, A.Irving, W. L.Guha, N. I. Enhanced liver fibrosis (ELF) test performs better than histological parameters in predicting clinical outcomes in patients with advanced fibrosis due to chronic hepatitis c infection. <i>Gut</i> . 2014;1):A245.	7
365	Dolman GEZ, A. M.Irving, W. L.Guha, I. N. Enhanced liver fibrosis (ELF) test performs better than histological parameters in predicting clinical outcomes in patients with advanced fibrosis due to chronic hepatitis C infection. <i>Journal of Hepatology</i> . 2014;1):S412.	7
366	Dvorak KS, J.Petryl, J.Vitek, L.Sroubkova, R.Lenicek, M.Smid, V.Haluzik, M.Bruha, R. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice - An exploratory case-control study. <i>PLoS ONE</i> . 2014;9 (10) (no pagination)(e111551).	3
367	Fagan KH, L.Irvine, K.Fletcher, L.Tate, J.Choi, K.Nusrat, S.Melino, M.Clouston, A.Ballard, E.O'Rourke, P.Lampe, G.Ungerer, J.Powell, E. An ELF score of ≥ 9.8 can identify advanced fibrosis in Australian patients with chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> . 2014;2):77-8.	7
368	Fernandes FFD, A.Andrade, L. E. C.Campos, F. F.Chindamo, M. C.Araujo-Neto, J. M.Villela-Nogueira, C.Coelho, H. S. M.Terra, C.Pereira, G.Pereira, J. L.Figueiredo, F. A.Perez, R. M.Ferraz, M. L. New cut-off points of enhanced liver fibrosis (ELF) panel for chronic hepatitis C patients. <i>Hepatology</i> . 2014;1):924A-5A.	7
369	Fernandes FFF, M. L.Perazzo, H.Andrade, L. E. C.Dellavance, A.Terra, C.Pereira, G.Pereira, J. L.Campos, F. F.Figueiredo, F. A.Perez, R. M. Is the diagnostic accuracy of non-invasive methods better than liver biopsy ? A Latent Class Analysis on assessment of liver fibrosis in chronic hepatitis C. <i>Hepatology</i> . 2014;1):911A.	7
370	Flores-Contreras LS-R, A. S.Mena-Enriquez, M. G.Lucano-Landeros, S.Arellano-Olivera, I.Alvarez-Alvarez, A.Sanchez-Parada, M. G.Armendariz-Borunda, J. Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. <i>BMC gastroenterology</i> . 2014;14(1).	2
371	French ALH, A.Young, M.Nowicki, M.Augenbraun, M.Anastos, K.Peters, M. Isolated Hepatitis B Core Antibody and Hepatic Fibrosis in HIV/HCV-Coinfected Women. <i>Topics in Antiviral Medicine</i> . 2014;22 (e-1):350.	7

연번	서지정보	배제 사유
372	Gungoren MSE, S. C.Kav, T.Akbiyik, F. Comparison of diagnostic value of enhanced liver fibrosis test with liver biopsy in patients with autoimmune hepatitis. <i>Journal of Hepatology</i> . 2014;1):S415.	7
373	Gungoren MSE, C.Kav, T.Akbiyik, F. Comparison of enhanced liver fibrosis test and acoustic radiation force impulse elastography with liver biopsy in patients with autoimmune hepatitis: Preliminary results. <i>Clinical Chemistry and Laboratory Medicine</i> . 2014;1):S1205.	7
374	Harkisoen SB, G. J.van den Hoek, J. A.van Erpecum, K. J.Hoepelman, A. I.Arends, J. E. ELF-test less accurately identifies liver cirrhosis diagnosed by liver stiffness measurement in non-Asian women with chronic hepatitis B. <i>Journal of Clinical Virology</i> . 2014;61(4):503-8.	6
375	Harkisoen SB, G. J.van den Hoek, J. A. R.van Erpecum, K. J.Hoepelman, A. I. M.Arends, J. E. ELF-test less accurately identifies liver cirrhosis diagnosed by liver stiffness measurement in non-Asian women with chronic hepatitis B. <i>Journal of Clinical Virology</i> . 2014;61(4):503-8.	10
376	Harrison SAC, N. P.Lawitz, E.Marri, S.Noureddin, M.Sanyal, A. J.Schiano, T. D.Siddiqui, M. S.Neuschwander-Tetri, B. A.Traber, P. G. Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis. <i>Hepatology</i> . 2014;60:225A-6A.	7
377	Hassan SS, S.Kehar, S. I. Review of diagnostic techniques of hepatic fibrosis. <i>Journal of the Pakistan Medical Association</i> . 2014;64(8):941-5.	7
378	Isgro MAM, L.Caldarella, C.Cefalo, C.Giannace, A.Morlacchi, C.Rapaccini, G. L.Gasbarrini, A.Grieco, A.Zuppi, C.De Michele, T. Elf test as a new diagnostic tool for non-invasive diagnosis of liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Biochimica Clinica</i> . 2014;38 (5):538.	7
379	Isgro MAM, L.Cefalo, C.Giannace, A.Morlacchi, C.Rapaccini, G. L.Gasbarrini, A.Grieco, A.Zuppi, C.De Michele, T. ELF test as a new non invasive diagnostic tool for staging liver fibrosis: Validation in a cohort of patients with nonalcoholic fatty liver disease. <i>Clinical Chemistry and Laboratory Medicine</i> . 2014;1):S1195.	7
380	Kim BKK, H. S.Yoo, E. J.Oh, E. J.Park, J. Y.Kim do, Y.Ahn, S. H.Han, K. H.Kim, S. U.Park, Y. N. Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. <i>Hepatology (Baltimore, Md)</i> . 2014;60(6):1911-9.	6
381	Knudsen CSH, L.Nexo, E. Measurement of amino terminal propeptide of type III procollagen (PIIINP) employing the ADVIA Centaur platform. Validation, reference interval and comparison to UniQ RIA. <i>Clinical Chemistry and Laboratory Medicine</i> . 2014;52(2):237-41.	2
382	Krystyna SP, S.Malgorzata, W.Jerzy, S. Enhanced liver fibrosis test in obese children with ultrasound-proven steatosis. <i>Clinical Biochemistry</i> . 2014;47 (9):774-5.	7
383	Manen LDP, D. F.Bunschoten, E. M.Erpecum, K.Boland, G. The Enhanced Liver Fibrosis (ELF) test compared to transient elastography in hemophilia patients with chronic hepatitis C. <i>Haemophilia</i> . 2014;3):38.	7
384	Martyn-Simmons CLR, W. M.Cross, R.Wong, T.Smith, C. H.Barker, J. N. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study. <i>British Journal of Dermatology</i> . 2014;171(2):267-73.	6
385	Martyn-Simmons CLR, W. M. C.Cross, R.Wong, T.Smith, C. H.Barker, J. N. W. N. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: A retrospective cohort study. <i>British Journal of Dermatology</i> . 2014;171(2):267-73.	1

연번	서지정보	배제 사유
386	Medeiros TBD, A. L. C.Lopes, E. P.Dellavance, A.Andrade, L. E. C.Ferraz, M. L. Enhanced liver fibrosis (ELF) score for the evaluation of liver fibrosis in shistosomiasis mansoni. <i>Clinical Chemistry</i> . 2014;1):S34.	7
387	Mijuskovic ZP, J.Duvnjak, V.Andjelic, T.Perisic, N.Nozić, D. Noninvasive laboratory test for assessment the severity of liver fibrosis. <i>Clinical Chemistry and Laboratory Medicine</i> . 2014;1):S1369.	7
388	Morling JRF, J. A.Williamson, R. M.Robertson, C. M.Nee, L. D.Glancy, S.Guha, I. N.Strachan, M. W. J.Price, J. F. Cardiovascular disease and biomarkers of liver injury in Type 2 diabetes: The Edinburgh Type 2 Diabetes Study (ET2DS). <i>Diabetic Medicine</i> . 2014;1):76.	6
389	Morling JRF, J. A.Williamson, R. M.Nee, L. D.Jackson, A. P.Glancy, S.Reynolds, R. M.Hayes, P. C.Guha, I. N.Strachan, M. W.Price, J. F. Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study. <i>Liver International</i> . 2014;34(8):1267-77.	1
390	Morling JRF, J. A.Williamson, R. M.Nee, L. D.Jackson, A. P.Glancy, S.Reynolds, R. M.Hayes, P. C.Guha, I. N.Strachan, M. W. J.Price, J. F. Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: The Edinburgh type 2 diabetes study. <i>Liver International</i> . 2014;34(8):1267-77.	7
391	Oliveira EP, R. M.Oliveira, P. M.Dellavance, A.Andrade, L. E. C.Ferraz, M. L. Enhanced liver fibrosis (ELF) score for the evaluation of liver fibrosis in autoimmune hepatitis. <i>Clinical Chemistry</i> . 2014;1):S33.	7
392	Paisey RBG, T.Watson, M.Cramb, R.Steeds, R.Williams, K.White, A.Hardy, C. Modification of severe insulin resistant diabetes in response to lifestyle changes in Alstrom syndrome. <i>European Journal of Medical Genetics</i> . 2014;57(2-3):71-5.	4
393	Pasricha SRS, E.Chong, C. P.Shochet, L.Cheong, J.Ong, S. Y.Hodge, A.Cheng, K.Dev, A. Hepatic fibrosis and cirrhosis in patients with thalassaemia major is associated with present and historical iron overload, age, and active hepatitis c infection. <i>Haematologica</i> . 2014;1):185-6.	7
394	Rajanayagam JKL, A. W.McKiernan, P. J. Serial enhanced liver fibrosis test (ELF) to monitor disease progression in pediatric non-alcoholic fatty liver disease. <i>Hepatology</i> . 2014;1):528A.	7
395	Sztefko KS, P.Wojcik, M.Starzyk, J. B. Enhanced liver fibrosis test in obese children with ultrasound-proven steatosis. <i>Hormone Research in Paediatrics</i> . 2014;1):228.	7
396	Vesterhus MH, J. R.Holm, A.Schrumpf, E.Godang, K.Andersen, I. M.Naess, S.Rosjo, H.Vatn, M.Gilja, O. H.Lund-Johansen, F.Ponsioen, C. Y.Farkkila, M.Moum, B.Ueland, T.Boberg, K. M.Karlsen, T. H. Enhanced liver fibrosis score predicts transplant-free survival in PSC independently of the mayo risk score. <i>Journal of Hepatology</i> . 2014;1):S188.	7
397	Wong GLHC, H. L. Y.Choi, P. C. L.Chan, A. W. H.Yu, Z.Lai, J. W. Y.Chan, H. Y.Wong, V. W. S. Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> . 2014;39(2):197-208.	6
398	Xie QZ, X.Huang, P.Wei, J.Wang, W.Zheng, S. The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: A meta-analysis. <i>PLoS ONE</i> . 2014;9(4) (no pagination)(e92772).	7
399	Yoshida YK, T.Furuta, K.Ogura, S.Egawa, M.Chatani, N.Kamada, Y.Kiso, S.Takehara, T. Grb2-associated binder 1 protects against liver fibrosis via suppression of CCL5 production from hepatocytes. <i>Hepatology</i> . 2014;1):567A.	7

연번	서지정보	배제 사유
400	Abignano GC, G.Buch, M.Rosenberg, W. M.Valentini, G.Emery, P.Del Galdo, F. Sub-analysis of ELF score biomarkers components indicates a specific correlation with different organ involvement in systemic sclerosis. Annals of the Rheumatic Diseases Conference: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR. 2013;72(SUPPL. 3).	7
401	Bansal RF, L.Sallberg, M. Hepatitis C virus non-structural 3/4 a protein expression promotes hepatic fibrogenesis in mice after administration with carbon tetrachloride. Hepatology International. 2013;1):S327-S8.	7
402	Bansal RF, L.Sallberg, M. Hepatitis C virus non-structural 3/4A protein expression promotes hepatic fibrogenesis in mice after administration of carbon tetrachloride. Journal of Hepatology. 2013;1):S451.	7
403	Boland GV, L. M.Mauser-Bunschoten, E.Fransen-Van De Putte, D.Van Erpecum, K. J. Comparison of the enhanced liver fibrosis (ELF) score and transient elastography in haemophilia patients with chronic hepatitis C. Hepatology. 2013;1):924A-5A.	7
404	Borkham-Kamphorst EZ, H. W.Gassler, N.Bissels, U.Bosio, A.Tacke, F.Weiskirchen, R.Kanse, S. M. Factor VII activating protease (FSAP) exerts anti-inflammatory and anti-fibrotic effects in liver fibrosis in mice and men. Journal of Hepatology. 2013;58(1):104-11.	2
405	Catanzaro RM, M.Arona, S.Sapienza, C.Vasta, D.Arcoria, D.Marotta, F. Diagnostic accuracy of enhanced liver fibrosis test to assess liver fibrosis in patients with chronic hepatitis C. Hepatobiliary and Pancreatic Diseases International. 2013;12(5):500-7.	9
406	Catanzaro RM, M.Arona, S.Italia, A.Cannavo, M.Bellavia, N.Vasta, D.Arcoria, D. Enhanced liver fibrosis (ELF) test: A prospective study of non-invasive diagnostic method of liver fibrosis. Digestive and Liver Disease. 2013;2):S217.	7
407	Chavez-Tapia NCR, E.de Mattos, A. A.Bessone, F.Daruich, J.Sanchez-Avila, J. F.Cheinquer, H.Zapata, R.Uribe, M.Bosques-Padilla, F.Gadano, A.Soza, A.Davalos-Moscol, M.Marroni, C.Munoz-Espinoza, L.Castro-Narro, G.Parana, R.Mendez-Sanchez, N. An update on the management of hepatitis C: Guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. Annals of Hepatology. 2013;12(SUPPL.2):s3-s35.	7
408	Dellavance AF, F. F.Baldo, D. C.Netto, E. L.Oliveira, E.Camargo, J. M.Borzacov, L.Perez, R. M.Andrade, L. E. C.Ferraz, M. L. C. G. Enhanced Liver Fibrosis (ELF) panel in the evaluation of several chronic liver diseases. Clinical Chemistry. 2013;1):A125-A6.	7
409	Fernandes FD, A.Andrade, L. E.Campos, F.Pereira, G. H.Terra, C.Pereira, J.Figueiredo, F.Perez, R.Ferraz, M. L. Enhanced liver fibrosis (ELF) panel as a predictor of liver fibrosis in chronic Hepatitis C Patients. Clinical Chemistry. 2013;1):A122.	7
410	Fernandes FFD, A.Andrade, L. E. C.Campos, F. F.Pereira, G.Terra, C.Pereira, J. L.Figueiredo, F. A.Perez, R. M.Ferraz, M. L. G. Enhanced liver fibrosis (ELF) panel as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology. 2013;1):923A.	7
411	Fuchs BCW, H.Yang, Y.Wei, L.Polasek, M.Schuhle, D. T.Lauwers, G. Y.Parkar, A.Sinsky, A. J.Tanabe, K. K.Caravan, P. Molecular MRI of collagen to diagnose and stage liver fibrosis. Journal of Hepatology. 2013;59(5):992-8.	2
412	Guha INB, S.Ahmad, Z.Sheron, N.Cope, R.Marshall, C.Veldtman, G. Structural and functional uncoupling of liver performance in the Fontan circulation. International Journal of Cardiology. 2013;164(1):77-81.	3
413	Gumusay OO, S.Atak, A.Sonmez, C.Ozkan, S.Tuncel, A. F.Yilmaz, G.Akyol, G. Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B. Hepatology Research. 2013;43(3):228-37.	9

연번	서지정보	배제 사유
414	Ingegnoli FG, R.Schioppo, T.Orenti, A.Boracchi, P.Lubatti, C.Murgo, A.Zeni, S.Mastaglio, C.Galbiati, V.Monti, G.Grossi, C.Borghi, O.Rosenberg, W.Meroni, P. L. How early starts increased collagen synthesis in systemic sclerosis? Annals of the Rheumatic Diseases Conference: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR. 2013;72(SUPPL. 3).	7
415	Lichtinghagen RB, H.Brand, K.Bahr, M. J. The enhanced liver fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values. Biochimica Clinica. 2013;1):S668.	7
416	Lichtinghagen RP, D.Bantel, H.Manns, M. P.Brand, K.Bahr, M. J. The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values. Journal of Hepatology. 2013;59(2):236-42.	7
417	Lichtinghagen RP, D.Bantel, H.Manns, M. P.Brand, K.Bahr, M. J. Erratum: The enhanced liver fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values (J Hepatol (2013) 59 (236-242)). Journal of Hepatology. 2013;59(6):1365.	9
418	Nct. Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis. https://clinicaltrials.gov/show/NCT01769040 . 2013.	2
419	Paisey RBG, T.Watson, M.Costelloe, M.Bunce, S.Cramb, R.Parkinson, K. Progression and remission of Type 2 diabetes and all aspects of the metabolic syndrome in a sibling pair with Alstrom syndrome. Diabetic Medicine. 2013;1):95.	7
420	Rosenberg W. Non-invasive technologies and biomarkers for assessment of severity of liver fibrosis. Biochimica Clinica. 2013;1):S61.	7
421	Sitch AD, J.Parkes, J.Gregory, W.Hewison, J.Altman, D.Deeks, J. Simulation modelling to identify optimal monitoring strategies: The use of the ELF biomarker in liver disease monitoring. Trials. 2013;1):109DUMMY.	7
422	Stauber RES, W.Putz-Bankuti, C.Pock, H.Stojakovic, T.Obermayer-Pietsch, B. Enhanced liver fibrosis (ELF) score is related to liver dysfunction and predicts mortality in cirrhosis. Journal of Hepatology. 2013;1):S297.	7
423	Stauber RES, W.Putz-Bankuti, C.Pock, H.Stojakovic, T.Obermayer-Pietsch, B. Enhanced Liver Fibrosis (ELF) score predicts mortality in cirrhosis. Hepatology International. 2013;1):S492-S3.	7
424	Takemura TY, Y.Kiso, S.Kizu, T.Furuta, K.Ezaki, H.Hamano, M.Egawa, M.Chatani, N.Kamada, Y.Imai, Y.Higashiyama, S.Iwamoto, R.Mekada, E.Takehara, T. Conditional loss of heparin-binding EGF-like growth factor results in enhanced liver fibrosis after bile duct ligation in mice. Biochemical and Biophysical Research Communications. 2013;437(2):185-91.	5
425	Ue MI, N.Munekage, K.Ochi, T.Hirose, A.Kataoka, H.Fujimoto, S.Kikuchi, K.Okuhara, Y.Ono, M.Saibara, T. Hepatocyte destruction with enhanced collagen synthesis: Characteristic feature of chronic hepatitis C patients on haemodialysis. Journal of Viral Hepatitis. 2013;20(5):350-7.	2
426	Wawrzynowicz-Syczewska ML, L.Jurczyk, K.Lachtara, M.Kornak, D. Fibrosis assessment in alcoholic liver disease using the siemens enhanced liver fibrosis (ELF) test. Alcohol and Alcoholism. 2013;1):i50.	7
427	Wong GLHW, V. W.Chan, H. L. Y. Development of a combined algorithm of fibroscan and enhanced liver fibrosis (ELF) to detect liver fibrosis in chronic hepatitis B. Hepatology. 2013;1):602A.	7

연번	서지정보	배제 사유
428	Yoo EJK, B. K.Kim, S. U.Park, J. Y.Kim, D. Y.Ahn, S. H.Han, K. H.Chon, C. Y.Kim, H. S. Normal enhanced liver fibrosis (ELF) values in apparently healthy subjects undergoing a health check-up and in living liver donors in South Korea. <i>Liver International</i> . 2013;33(5):706-13.	1
429	Yoo EJK, B. K.Kim, S. U.Kim, H. S.Park, J. Y.Kim, D. Y.Ahn, S. H.Han, K. H.Chon, C. Y. Normal enhanced liver fibrosis values in apparently healthy subjects in South Korea. <i>Hepatology International</i> . 2013;1):S496.	7
430	Abignano GC, G.Buch, M.Rosenberg, W. M.Valentini, G.Emery, P.Del Galdo, F. ELF score: A validated serum test strongly predictive of fibrosis in SSc. <i>Rheumatology</i> . 2012;2):ii14.	7
431	Abignano GC, G.Buch, M. H.Rosenberg, W. M.Valentini, G.Emery, P.Del Galdo, F. ELF score: A validated serum test strongly predictive of fibrosis in systemic sclerosis. <i>Rheumatology (United Kingdom)</i> . 2012;3):iii84.	7
432	Abignano GC, G.Buch, M. H.Rosenberg, W. M.Valentini, G.Emery, P.Del Galdo, F. Sub-analysis of ELF score biomarkers components indicates a specific correlation with different organ involvement in systemic sclerosis. <i>Arthritis and Rheumatism</i> . 2012;10):S632-S3.	7
433	Bangen JML, D.Huss, S.Barbacid, M.Trautwein, C.Liedtke, C. Loss of CDK2 in hepatocytes leads to increased hepatic fibrogenesis after CCL4-treatment in mice. <i>Journal of Hepatology</i> . 2012;2):S145-S6.	7
434	Chapman WS, V.Seetharam, A.Steward, N.Crippin, J.Shenoy, S.Mohanakumar, T. Programmed death receptor (pd-1) in modulation of hepatitis c virus specific ifn-gamma and il-17 and fibrosis after human liver transplantation. <i>Hpb</i> . 2012;2):499.	7
435	Chouteau PD, N.Florimond, A.Calderaro, J.Higgs, M.Gaudin, A.Merour, E.Dhumeaux, D.Lerat, H.Pawlotsky, J. M. Hepatitis C virus (HCV) protein expression enhances hepatic fibrosis in HCV transgenic mice exposed to a fibrogenic agent. <i>Journal of Hepatology</i> . 2012;57(3):499-507.	5
436	Dillon PP, B.Saxton, E.Cheek, J.Li, Y. Distribution of EL F (enhanced liver fibrosis) test (and component assay) results from blood donor samples on the AD VIA centaur immunoassay system. <i>Clinical Chemistry</i> . 2012;1):A78.	7
437	eudract_number. DSC-MRP in cognitive decline. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-001583-29 . 2012.	2
438	Everson GTS, M. L.Hoefs, J. C.Morgan, T. R.Sterling, R. K.Wagner, D. A.Lauriski, S.Curto, T. M.Stoddard, A.Wright, E. C. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. <i>Hepatology (Baltimore, Md)</i> . 2012;55(4):1019-29.	2
439	Gaetani EP, D.Straface, G.Campanale, C.Pecere, S.Scaldaferri, F.Rapaccini, G. L.Gasbarrini, A.Pola, R. Functional role and therapeutic potentials of Sonic hedgehog in an experimental model of biliary obstruction. <i>Digestive and Liver Disease</i> . 2012;1):S28.	7
440	Gaetani EP, D.Scaldaferri, F.Campanale, M.Pecere, S.Forte, F.Rapaccini, G. L.Gasbarrini, A.Pola, R. The sonic hedgehog (SHH) signaling pathway: A novel player and potential therapeutic target for biliary obstruction. <i>Gastroenterology</i> . 2012;1):S930.	7
441	Gaetani EP, D.Straface, G.Scaldaferri, F.Rapaccini, G. L.Gasbarrini, A.Pola, R. Sonic hedgehog gene therapy for cholestatic liver diseases: Results from an experimental model of biliary obstruction. <i>Digestive and Liver Disease</i> . 2012;2):S67-S8.	7

연번	서지정보	배제 사유
442	Gangadharan BB, M.Rossa, J.Antrobus, R.Chittenden, D.Kampa, B.Barnes, E.Klenerman, P.Dwek, R. A.Zitzmann, N. Discovery of novel biomarker candidates for liver Fibrosis in Hepatitis C patients: A preliminary study. PLoS ONE. 2012;7 (6) (no pagination)(e39603).	3
443	Guechot JT, C.Renversez, J. C.Sturm, N.Zarski, J. P. Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clinical Chemistry and Laboratory Medicine. 2012;50(4):693-9.	6
444	Guillot AH, N.Bizy, A.Zoltani, K.Deveaux, V.Zafrani, E. S.Mallat, A.Lotersztajn, S.Lafdil, F. Inhibition of the pro-fibrogenic TH17 immune response by cannabinoid receptor 2 agonist decreases liver fibrosis. Hepatology. 2012;1):764A.	7
445	Hou XY, F.Man, S.Huang, D.Zhang, Y.Liu, M.Ren, C.Shen, J. Negative regulation of Schistosoma japonicum egg-induced liver fibrosis by natural killer cells. PLoS Neglected Tropical Diseases. 2012;6 (1) (no pagination)(e1456).	2
446	Ingegnoli FG, R.Schioppo, T.Orenti, A.Boracchi, P.Lubatti, C.Rizzini, S. L.Murgo, A.Zeni, S.Mastaglio, C.Galbiati, V.Grossi, C.Borghi, M.Rosenberg, W. M.Meroni, P. L. Enhanced liver fibrosis test: A further step toward depiction of fibrotic process in very early diagnosis of systemic sclerosis. Arthritis and Rheumatism. 2012;10):S632.	7
447	Lafdil FG, A.Bizy, A.Zoltani, K.Deveaux, V.Zafrani, S.Mallat, A.Lotersztajn, S. Inhibition of the pro-fibrogenic TH17 immune response by cannabinoid receptor 2 agonist decreases liver fibrosis. Journal of Hepatology. 2012;2):S152.	7
448	Lichtinghagen RP, D.Brand, K.Bahr, M. Interpretation of results from the enhanced liver fibrosis (ELF) test as a multiparametric tool for the assessment of liver fibrosis. Clinical Chemistry and Laboratory Medicine. 2012;50 (9):A257.	7
449	Morgan MYS, M. D.Lloyd Jones, M. The clinical utility and cost-effectiveness of non-invasive tests for detecting fibrosis in patients with suspected alcohol-related liver disease. Gut. 2012;2):A203.	7
450	Morling JRS, M. W.Williamson, R. M.Price, J. F.Fallowfield, J. A.Guha, I. N. Hepatic fibrosis in people with type 2 diabetes mellitus: The Edinburgh type 2 diabetes study. Gut. 2012;2):A28.	7
451	Nct. L-ornithine L-aspartate in Overt Hepatic Encephalopathy. https://clinicaltrials.gov/show/NCT01722578 . 2012.	7
452	Roh YC, A.Park, S.Lim, C. W.Seki, E.Kim, B. Toll-like receptor 7-mediated production of type I IFN prevents cholestasis-and hepatotoxin-induced liver fibrosis. Hepatology. 2012;1):1116A-7A.	7
453	Ruth NDR, W. M.Sharif, K.McKiernan, P. J. The predictive value of ELF test in patients with biliary atresia. Hepatology. 2012;1):725A-6A.	7
454	Sethi SS, D. A.Abdelmoneim, S. S.Campion, M. B.Kaloiani, I.Clayton, A. C.Kremers, W. K.Halling, K. C.Kamath, P. S.Talwalkar, J.Shah, V. H. Comparison of circulating endothelial cell/platelet count ratio to aspartate transaminase/platelet ratio index for identifying patients with cirrhosis. Journal of Clinical & Experimental Hepatology. 2012;2(1):19-26.	2
455	Stevenson ML-J, M.Morgan, M. Y.Wong, R. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: A systematic review and economic evaluation. Health Technology Assessment. 2012;16(4).	4

연번	서지정보	배제 사유
456	Takashima TI, H.Aizawa, N.Ishii, A.Sakai, Y.Iwata, K.Ikeda, N.Tanaka, H.Iwata, Y.Enomoto, H.Saito, M.Imanishi, H.Nakashima, O.Yano, H.Nishiguchi, S. Diagnosis of liver fibrosis in patients with chronic hepatitis and nonalcoholic steatohepatitis using serum enhanced liver fibrosis (ELF) score and ultrasound elastography. <i>Hepatology</i> . 2012;1):812A-3A.	7
457	Trembling PMC, M.Tanwar, S.Rosenberg, W. M. Concordance of non-invasive markers of liver fibrosis in a mixed population of liver diseases. <i>Gut</i> . 2012;2):A408.	7
458	Trembling PMP, J.Tanwar, S.Burt, A. D.Rosenberg, W. M. Enhanced liver fibrosis test accurately identifies liver fibrosis and predicts clinical outcomes in alcoholic liver disease. <i>Journal of Hepatology</i> . 2012;2):S424.	7
459	Application of transient elastography in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology(대한간학회지)</i> . 2020;26(2):128-41.	2
460	이호규. Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal (DMJ)</i> . 2020;44(2):267-76.	10
461	Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years. <i>Clinical and Molecular Hepatology(대한간학회지)</i> . 2020;26(3):318-27.	2
462	Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection. <i>Clinical and Molecular Hepatology(대한간학회지)</i> . 2020;26(1):33-44.	2
463	Alsayed MAL, Shymaa MohsenEl-Desoky, Manal M.Elziny, Shereen MagdyMegahed, Ahmed. Polymorphism in Macrophage Migratio Inhibitory Factor -173GC in Pediatric Patients with Autoimmune Hepatitis. <i>Pediatric gastroenterology, hepatology & nutrition</i> . 2020;23(1):63-71.	2
464	Cho I, Bon-NyeoKam, Eun HeeLee, Su KyoungOh, HanseulKim, So Yeon. Bile duct ligation of C57BL/6 mice as a model of hepatic encephalopathy. <i>Anesth Pain Med</i> . 2020;15(1):19-27.	8
465	Cho YS, Woo Kyoung Kim, Yongsoo. Ultrasonographic morphological diagnosis of chronic liver disease: 2-dimensional shear wave elastography as an add-on test. <i>Ultrasonography</i> . 2020;39(3):272-80.	10
466	Eda K. Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> . 2020;14(4):486-91.	10
467	Eda K, Bakir Haluk Tarik, Kani Coskun Ozer, Demirtas Caglayan, Keklikkiran Yusuf, Yilmaz. Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> . 2020;14(4):486-91.	10
468	Kaya E, Alev Kani, Haluk Tarik Demirtas, Coskun Ozer Keklikkiran, Caglayan Yilmaz, Yusuf. Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. <i>Gut Liver</i> . 2020;14(4):486-91.	2
469	Kim HS, Seung Up Kim, Beom Kyung Park, Jun Yong Kim, Do Young Ahn, Sang Hoon Han, Kwang-Hyub Park, Young Nyun Han, Dai Hoon Kim, Kyung Sik Choi, Jin Sub Choi, Gi Hong Kim, Hyon-Suk. Serum (i>Wisteria floribunda</i> agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection. <i>Clin Mol Hepatol</i> . 2020;26(1):33-44.	2
470	Lee H, Gyuri Choi, Young Ju Huh, Byung Wook Lee, Byung-Wan Kang, Eun Seok Cha, Bong-Soo Lee, Eun Jig Lee, Yong-ho Huh, Kap Bum. Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus. <i>Diabetes Metab J</i> . 2020;44(2):267-76.	2

연번	서지정보	배제 사유
471	Mona Abdel Latif AM, ElbeahManal, M. El-DesokyShereen Magdy, ElzinyAhmed, Megahed. Polymorphism in Macrophage Migration Inhibitory Factor -173GC in Pediatric Patients with Autoimmune Hepatitis. Pediatric gastroenterology, hepatology & nutrition. 2020;23(1):63-71.	2
472	Rostom Dina M. The Therapeutic Potential of Extracellular Vesicles Versus Mesenchymal Stem Cells in Liver Damage. 조직공학과 재생의학. 2020;17(4):537-52.	10
473	Rostom Dina MA, NohaKhalifa Hoda, M.Abou Nazel Maha, W.El Sabaawy Eshrak, A. The Therapeutic Potential of Extracellular Vesicles Versus Mesenchymal Stem Cells in Liver Damage. 조직공학과 재생의학. 2020;17(4):537-52.	2
474	Xinrong Z. Application of transient elastography in nonalcoholic fatty liver disease. Clinical and Molecular Hepatology. 2020;26(2):128-41.	2
475	Xinrong ZL-H, Wong Vincent Wai-Sun, Wong. Application of transient elastography in nonalcoholic fatty liver disease. Clinical and Molecular Hepatology(대한간학회지). 2020;26(2):128-41.	10
476	Yoo J, Jeong MinJoo, IjinYoon, Jeong Hee. Assessment of liver fibrosis using 2-dimensional shear wave elastography: a prospective study of intra- and inter-observer repeatability and comparison with point shear wave elastography. Ultrasonography. 2020;39(1):52-9.	2
477	Young C. Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years. Clinical and Molecular Hepatology. 2020;26(3):318-27.	2
478	Young CI, Kim Bora, Lee Sang Gyune, Kim Min Jung, Jung Young Seok, Kim Soung Won, Jeong Jae Young, Jang Jeong-Ju, Yoo. Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years. Clinical and Molecular Hepatology(대한간학회지). 2020;26(3):318-27.	10
479	강성호, 유선경, 이정은, 안치영, 초음파 B-모드 영상에서 FCN(fully convolutional network) 모델을 이용한 간 섬유화 단계 분류 알고리즘. 의공학회지. 2020;41(1):48-54.	2
480	박상봉, 최희정, 두송희, 정동, 심예나, 오한진, 비알코올성 지방간질환이 있는 성인 남녀에서 비알코올성지방간질환 섬유화 점수와 저밀도 지질단백콜레스테롤과의 연관성. Korean Journal of Family Practice. 2020;10(2):110-5.	2
481	심병학. Quantitative Evaluation of Liver Fibrosis on T1 Relaxometry in Comparison with Fibroscan. 대한영상의학회지. 2020;81(2):365-78.	10
482	심병학, 허숙희, 신상수, 조성범, 정용연. Quantitative Evaluation of Liver Fibrosis on T1 Relaxometry in Comparison with Fibroscan. 대한영상의학회지. 2020;81(2):365-78.	2
483	양정훈. Hepatic dysfunction in critically ill patients. Acute and Critical Care. 2020;35(1):44-5.	2
484	유대열. Relevance of reactive oxygen species in liver disease observed in transgenic mice expressing the hepatitis B virus X protein. Laboratory Animal Research. 2020;36(1):10-8.	2
485	유정인. Assessment of liver fibrosis using 2-dimensional shear wave elastography : a prospective study of intra- and interobserver repeatability and comparison with point shear wave elastography. ULTRASONOGRAPHY. 2020;39(1):52-9.	10
486	유정인, 주이진, 윤정희, Assessment of liver fibrosis using 2-dimensional shear wave elastography: a prospective study of ntra- and interobserver repeatability and comparison with point shear wave elastography. ULTRASONOGRAPHY. 2020;39(1):52-9.	2
487	유인영, 이경훈 조재원, 김종만, 박금연, 신동현, 하상윤, 강은숙, 박형두, 만성 B형간염에 의한 간세포암 환자에서 간경변 진단을 위한 M2BPGi, Fibroscan 및 기타 간섬유화 표지자 비교. Laboratory Medicine Online. 2020;10(2):109-15.	2
488	이상민. Comparison of point and 2-dimensional shear wave elastography for the evaluation of liver fibrosis. ULTRASONOGRAPHY. 2020;39(3):288-97.	10
489	이상민, 윤정희, 홍원주, 하홍일, 이관섭, 최지영, 이정우, 윤삼열, 한준희, Comparison of point and 2-dimensional shear wave elastography for the evaluation of liver fibrosis. ULTRASONOGRAPHY. 2020;39(3):288-97.	2

연번	서지정보	배제 사유
490	이호규. Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal. 2020;44(2):267-76.	2
491	이호규, 최영주, 허병욱, 이병완, 강은석, 차봉수, 이은직, 이용호, 허갑범, Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal. 2020;44(2):267-76.	10
492	전태주. 만성 췌장염에서 통증, 외분비 및 내분비 기능장애의 치료. 대한췌담도학회지. 2020;25(1):5-10.	1
493	조영서. Ultrasonographic morphological diagnosis of chronic liver disease: 2-dimensional shear wave elastography as an add-on test. ULTRASONOGRAPHY. 2020;39(3):272-80.	10
494	조영서, 정우경, 김용수, Ultrasonographic morphological diagnosis of chronic liver disease : 2-dimensional shear wave elastography as an add-on test. ULTRASONOGRAPHY. 2020;39(3):272-80.	2
495	조인자, 감은희, 이수경, 오한솔, 김소연. Bile duct ligation of C57BL/6 mice as a model of hepatic encephalopathy. Anesthesia and pain medicine. 2020;15(1):19-27.	8
496	한소정, 박준용. 경구 항바이러스제 치료로 완치받은 C형간염 환자에서 간세포암종 발생의 장기 위험. 대한소화기학회지. 2020;75(5):308-10.	2
497	Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. Gut and Liver. 2019;13(2):197-205.	2
498	R. Luca. New emerging pharmacological treatment for IPF. 대한결핵 및 호흡기학회 추계학술대회 초록집. 2019;127(-):89-.	1
499	K. B. Sung Min, Kim Hoo Min, Choi Jae Won, Kang Byung In, Ro Han Kyoung, Cho. P105 : A case of linear scleroderma. 대한피부과학회 학술발표대회집. 2019;71(1):400-1.	1
500	PE173 : Visfatin induces CCL20 production in macrophages via p38 and JNK signaling pathways and contributes to hepatic stellate cell activation. International Congress of Diabetes and Metabolism. 2019;2019(0):82-.	2
501	Recent research trends and updates on nonalcoholic fatty liver disease. Clinical and Molecular Hepatology(대한간학회지). 2019;25(1):1-11.	2
502	Atsushi T. IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis. Gut and Liver. 2019;13(3):300-7.	1
503	Bong Eun LH, Kim Geun Am, Song Jong Hun, SeoHye Kyung, Jeon Dong Hoon, Baek Dong Uk, Kim. Continuous Infusion versus Intermittent Dosing with Pantoprazole for Gastric Endoscopic Submucosal Dissection. Gut and Liver. 2019;13(1):40-7.	1
504	Dae Ho L. RG1-2 : Noninvasive evaluation of NAFLD and its progression. International Congress of Diabetes and Metabolism. 2019;2019(0):21-.	2
505	Ding Q, Xiao-LiWang, Miao-MiaoYin, JieTian, Jin-MeiJiang, Xiao-YuZhang, DiHan, JingBai, YunCui, Zi-JinJiang, Hui-Qing. The role of the apoptosis-related protein BCL-B in the regulation of mitophagy in hepatic stellate cells during the regression of liver fibrosis. Experimental & molecular medicine : EMM. 2019;51(1):6.	2
506	Haesung Y. Quantitative Imaging in Pediatric Hepatobiliary Disease. Korean Journal of Radiology. 2019;20(9):1342-57.	10
507	Haesung YJ, Shin김명준,이미정. Quantitative Imaging in Pediatric Hepatobiliary Disease. Korean Journal of Radiology. 2019;20(9):1342-57.	2
508	Hitoshi M, Kato. Advances in ultrasound diagnosis in chronic liver diseases. Clinical and Molecular Hepatology(대한간학회지). 2019;25(2):160-7.	2
509	Jae Young C. Benign Recurrent Intrahepatic Cholestasis Type 2 in Siblings with Novel ABCB11 Mutations. Pediatric gastroenterology, hepatology & nutrition. 2019;22(2):201-6.	1
510	Jang SI, SeokLee, Don HaengNa, KunYang, SugeunLee, Dong Ki. Safety Evaluation of Paclitaxel-Eluting Biliary Metal Stent with Sodium Caprate in Porcine Biliary Tract. Gut Liver. 2019;13(4):471-8.	1

연번	서지정보	배제 사유
511	Jeong-Ju Y, Moon Young, Kim김상균,Jong Eun, Yeon이진우,조용균,Sang Hoon, ParkJoo Hyun, SohnKasl, Knsng. Recent research trends and updates on nonalcoholic fatty liver disease. Clinical and Molecular Hepatology(대한간학회지). 2019;25(1):1-11.	2
512	Kim MN, Seong GyuKim, Beom KyungPark, Jun YongKim, Do YoungHan, Kwang HyubKim, Seung UpAhn, Sang Hoon. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. Gut Liver. 2019;13(2):197-205.	2
513	Kim MN, Seong GyuKim, Beom KyungPark, Jun YongKim, Do YoungHan, Kwang-HyubKim, Seung UpAhn, Sang Hoon. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. Gut and liver. 2019;13(2):197-205.	2
514	Luca R. New emerging pharmacological treatment for IPF. 대한결핵및호흡기학회 추계학술발표초록집. 2019;127(0):89-.	1
515	Maruyama H, Naoya. Advances in ultrasound diagnosis in chronic liver diseases. Clin Mol Hepatol. 2019;25(2):160-7.	2
516	Nyam B, DamdinsurenNyamaa, Bayarmaa. PE106 : NAFLD SCREENING AMONG NEWLY DIAGNOSED DIABETICS IN DORNOD PROVINCE, MONGOLIA. International Congress of Diabetes and Metabolism. 2019;2019(0):69-.	2
517	Park JH, Ok Hee Kim, Kee Hwan Hong, Ha Eun Seo, Hae yeon Choi, Ho Joong Ahn, Joseph Lee, Tae Yun Kim, Say June. Isolation of Secretome with Enhanced Antifibrotic Properties from miR-214-Transfected Adipose-Derived Stem Cells. J Korean Med Sci. 2019;34(45):e273-.	1
518	Qian D. The role of the apoptosis-related protein BCL-B in the regulation of mitophagy in hepatic stellate cells during the regression of liver fibrosis. Experimental and olecular Medicine. 2019;51(0):1-13.	10
519	Qian D-L, XieMiao-Miao, WangJie, YinJin-Mei, TianXiao-Yu, JiangDi, ZhangJing, HanYun, BaiZi-Jin, CuiHui-Qing, Jiang. The role of the apoptosis-related protein BCL-B in the regulation of mitophagy in hepatic stellate cells during the regression of liver fibrosis. Experimental and molecular medicine. 2019;51(-):1-13.	2
520	Schlossberger V, MathiasKihm, ChristinaMontani, MatteoDatz, ChristianHampe, JochenStickel, Felix. Plasma Levels of K18 Fragments Do Not Correlate with Alcoholic Liver Fibrosis. Gut and liver. 2019;13(1):77-82.	2
521	Size W. Patchy echogenicity of the liver in patients with chronic hepatitis B does not indicate poorer elasticity. ULTRASONOGRAPHY. 2019;38(4):327-35.	10
522	Size W, TuXian, Liang. Patchy echogenicity of the liver in patients with chronic hepatitis B does not indicate poorer elasticity. ULTRASONOGRAPHY. 2019;38(4):327-35.	2
523	Sohn MJ, Min Hyung Seong, Moon Woo Park, Sung SupKang, Gyeong Hoon Moon, Jin Soo Ko, Jae Sung. Benign Recurrent Intrahepatic Cholestasis Type 2 in Siblings with Novel ABCB11 Mutations. Pediatr Gastroenterol Hepatol Nutr. 2019;22(2):201-6.	10
524	Sohn MJ, Min HyungSeong, Moon-WooPark, Sung SupKang, Gyeong HoonMoon, Jin SooKo, Jae Sung. Benign Recurrent Intrahepatic Cholestasis Type 2 in Siblings with Novel ABCB11 Mutations. Pediatric gastroenterology, hepatology & nutrition. 2019;22(2):201-6.	2
525	Sung III J. Safety Evaluation of Paclitaxel-Eluting Biliary Metal Stent with Sodium Caprate in Porcine Biliary Tract. Gut and Liver. 2019;13(4):471-8.	1
526	Sung III J, JeongDon Haeng, LeeKun, NaSugeun, YangDong Ki, Lee. Safety Evaluation of Paclitaxel-Eluting Biliary Metal Stent with Sodium Caprate in Porcine Biliary Tract. Gut and Liver. 2019;13(4):471-8.	1
527	Sung Min KB, KimHoo Min, ChoiJae Won, KangByung In, RoHan Kyoung, Cho. P105 : A case of linear scleroderma. 프로그램북(구 초록집). 2019;71(1):400-1.	1
528	Tanaka A. IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis. Gut and liver. 2019;13(3):300-7.	2

연번	서지정보	배제 사유
529	Viola S, WorniChristina, KihmMatteo, MontaniChristian, DatzJochen, HampeFelix, Stickel. Plasma Levels of K18 Fragments Do Not Correlate with Alcoholic Liver Fibrosis. Gut and Liver. 2019;13(1):77-82.	2
530	Wang Z, HansuBae, Eun Ju. Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study. The Korean Journal of Physiology & Pharmacology. 2019;23(6):459-66.	10
531	Yoon H, Hyun JooKim, Myung JoonLee, Mi Jung. Quantitative Imaging in Pediatric Hepatobiliary Disease. Korean J Radiol. 2019;20(9):1342-57.	2
532	Yu Nh, So YoungHa, Yun SokKim, Hyun TaeLih, EugeneKim, Dae HwanKim, JeongshikChung, Jae WookSong, Phil HyunYoo, Eun SangChung, Sung KwangHan, Dong KeunKim, Bum SooKwon, Tae Gyun. In Vivo Safety and Regeneration of Long-Term Transported Amniotic Fluid Stem Cells for Renal Regeneration. Tissue Eng Regen Med. 2019;16(1):81-92.	8
533	Zheng W, Park Eun Ju, Bae. Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study. The Korean Journal of Physiology & Pharmacology. 2019;23(6):459-66.	10
534	Zheng W, 백은주,. Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study. The Korean Journal of Physiology & Pharmacology. 2019;23(6):459-66.	8
535	강효정 홍, 오석희,김경모,유한옥,김구환,유은실,. Progressive Familial Intrahepatic Cholestasis in Korea: A Clinicopathological Study of Five Patients. Journal of Pathology and Translational Medicine. 2019;53(4):253-60.	2
536	김원. Genetic predisposition or acquired lifestyle in NAFLD. 대한당뇨병학회 학술발표논문집. 2019;2019(0):113-.	2
537	김익림, 권정아, 홍석일, 조한익,. IMM-03 : AFP 경도 증가의 임상적 의의. 임상면역검사학회 초록집. 2019;2019(1):156-.	2
538	김진수, 박운규. 섬유화 진행 간경변 조직 모델에서 Thymosin β 4 와 C-myc mRNA 융합 발현 연구. 한국융합학회논문지. 2019;10(6):65-71	10
539	박운규, 김진수. 섬유화 진행 간경변 조직 모델에서 Thymosin β 4와 C-myc mRNA 융합 발현 연구. 한국융합학회논문지. 2019;10(6):65-71.	2
540	남지희, 김정훈. 간질환 종류에 따른 비침습적 간섬유화 평가법의 유용성 분석: C형 간염 보균자 중심으로. 방사선기술과학. 2019;42(5):345-50.	2
541	남지희, 김정훈. 만성 C형간염 환자에서 간섬유화 등급별 혈청표지자들의 Cut-off값에 대한 고찰. 한국방사선학회논문지. 2019;13(4):539-46.	2
542	박정현. Isolation of Secretome with Enhanced Antifibrotic Properties from miR-214-Transfected Adipose-Derived Stem Cells. Journal of Korean Medical Science. 2019;34(45):1-15.	10
543	박정현 김옥희, 김기환, 홍하은, 서해연, 최호중, Joseph Ahn, 이태윤, 김세준. Isolation of Secretome with Enhanced Antifibrotic Properties from miR-214-Transfected Adipose-Derived Stem Cells. Journal of Korean medical science. 2019;34(45):1-15.	8
544	신솔, 박재형, 이정미, 허로운,. 2P-246 : Therapeutics based on exosomes from human mesenchymal stem cell for the treatment of liver fibrosis. 한국공업화학학회 연구논문 초록집. 2019;2019(1):347-.	2
545	안현, 이효정, 임인철. 초음파검사를 통한 간 섬유화 병기단계 평가 : 조직검사결과 기준으로. 한국방사선학회논문지. 2019;13(4):547-55.	2
546	안현, 지태정, 이효영, 임인철. 복부 초음파검사서 영상 점수 시스템 분류에 따른 간 섬유화 평가의 유용성. 방사선기술과학 = Journal of radiological science and technology. 2019;42(3):187-94.	2
547	유나희, Yun-Sok, HaHyun Tae, KimEugene, LihDae-Hwan, Kim, 김정식,정재욱,Phil Hyun, SongEun Sang, YooSung Kwang, 한동근, Bum Soo, KimTae Gyun, Kwon. In Vivo Safety and Regeneration of Long-Term Transported Amniotic Fluid Stem Cells for Renal Regeneration. 조직공학과 재생의학. 2019;16(1):81-92.	8

연번	서지정보	배제 사유
548	유정주. HVPG as a Predictor of Mortality in Non-Critically-Ill Cirrhotic Patients. Journal of Korean Medical Science. 2019;34(33):1-2.	10
549	유정주 김상균. HVPG as a Predictor of Mortality in Non-Critically-Ill Cirrhotic Patients. Journal of Korean medical science. 2019;34(33):1-2.	2
550	이종한. 만성 B형 및 C형 간염 환자의 간섬유화 진단을 위한 비침습적 혈액 표지자 평가. Laboratory Medicine Online. 2019;9(3):153-60.	10
551	이종한, 조주영, 김주원, 어영, 윤갑준,. 만성 B형 및 C형 간염 환자의 간섬유화 진단을 위한 비침습적 혈액 표지자 평가. Laboratory Medicine Online. 2019;9(3):153-60.	2
552	Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B. Gut and Liver. 2018;12(2):190-200.	10
553	Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. Clinical and Molecular Hepatology(대한간학회지). 2018;24(2):108-13.	2
554	O-028 : Non-Invasive Evaluation of Liver Fibrosis, Steatosis, and Nonalcoholic Steatohepatitis in Biopsy-Proven NAFLD Patients. 춘·추계 학술대회 (KASL). 2018;2018(1):24-5.	2
555	O-029 : Growth Differentiation Factor 15 Predicts Advanced Fi -brosis in Biopsy-Proven Non-Alcoholic Fatty Liver Disease. 춘·추계 학술대회 (KASL). 2018;2018(1):25-.	2
556	O-120 : Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-Cause Mortality. 춘·추계 학술대회 (KASL). 2018;2018(1):72-3.	2
557	PE-025 : Role of Fibroscan and APRI Score in Detection of Liver Fibrosis in Patients with Hepatitis B. 춘·추계 학술대회 (KASL). 2018;2018(1):139-40.	2
558	PE-089 : HCC Screening Program in Mongolia Single Center Data. 춘·추계 학술대회 (KASL). 2018;2018(1):172-.	2
559	PE-173 : Comparative Study of Cirrhosis Stage in Patients with HBV Infection and HBV/HDV Co-Infection in Mongolia. 춘·추계 학술대회 (KASL). 2018;2018(1):213-4.	2
560	PE-208 : Differential DNA Methylation as a Potential Biomarker for Stratification of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. 춘·추계 학술대회 (KASL). 2018;2018(1):229-30.	2
561	R. P. Sanjib Mani, Lamichhane. PE-245 : Assessment of Methotrexate Hepatotoxicity in Psoriasis Patients from Nepal. 춘·추계 학술대회 (KASL). 2018;2018(1):244-.	1
562	PE-252 : Liver Stiffness Decrease Post Ledipasvir/Sofosbuvir Com bination Treatment in Mongolian Patients with Chronic Hepatitis C. 춘·추계 학술대회 (KASL). 2018;2018(1):247-.	2
563	PE-264 : Value of Blood Culture for the Ascetic Fluid in the Diagnosis of Spontaneous Bacterial Peritonitis. 춘·추계 학술대회 (KASL). 2018;2018(1):253-.	1
564	PO-013 : Efficacy and Safety of Tenofovir with and without Ursodeoxycholic Acid in Chronic Hepatitis B Patients with Elevated ALT: Interim Analysis of Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study. 춘·추계 학술대회 (KASL). 2018;2018(1):84-5.	2
565	PO-040 : Comparison of Liver Volume of Chronic Liver Disease between Viral and Non-Viral Etiology by Using Computed Tomography Volumetry. 춘·추계 학술대회 (KASL). 2018;2018(1):97-8.	2
566	PO-058 : FIB-4 at Sustained Virological Response Independently Predicts Hepatocellular Carcinoma Development among Chronic Hepatitis C Patients Treated with Interferon-Based Regimen. 춘·추계 학술대회 (KASL). 2018;2018(1):105-6.	2
567	PO-061 : Efficacy and Safety of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Patients. 춘·추계 학술대회 (KASL). 2018;2018(1):107-.	2
568	PO-093 : The Diagnostic Efficacy of M2BPGi for Liver Fibrosis in HCC and NAFLD Patients. 춘·추계 학술대회 (KASL). 2018;2018(1):123-4.	2

연번	서지정보	배제 사유
569	Upcoming Direct-Acting Antivirals for Prior Treatment Failure. 춘·추계 학술대회 (KASL). 2018;2018(1):299-.	2
570	Alessio A. Upcoming Direct-Acting Antivirals for Prior Treatment Failure. 춘·추계 학술대회 (KASL). 2018;2018(1):299-.	2
571	Allison RS, V. LinAnna, RutherfordWalter, W. ChanMarvin, Ryou. A Prospective Blinded Study of Endoscopic Ultrasound Elastography in Liver Disease: Towards a Virtual Biopsy. Clinical Endoscopy. 2018;51(2):181-5.	2
572	Jekari DW, 이승욱, 권정현, 이성원, 유혜인, 김명신, 김용구, 성필수, 윤승규. Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFAM2BP) Among Chronic Hepatitis B Patients. Annals of Laboratory Medicine. 2018;38(4):348-54.	2
573	Hee Yeon KW, KimJi Young, KimSeung Up, KimBeom Kyung, KimJung Hyun, KwonSoon Woo, NamJoo Ho, LeeSeong Gyu, HwangHana, ParkHyung Jum, YimYoung Kul, JungJae Youn, CheongSoon Sun, Kim. PO-013 : Efficacy and Safety of Tenofovir with and without Ur sodeoxycholic Acid in Chronic Hepatitis B Patients with Elevated ALT: Interim Analysis of Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study. 춘·추계 학술대회 (KASL). 2018;2018(1):84-5.	2
574	허자윤, 박준용, 김도영, 안상훈, 김현숙, 김도영, 박준영, 한광협, 송기준, 김승업. Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B. Gut and Liver. 2018;12(2):190-200.	10
575	Heo JY, Beom KyungPark, Jun YongKim, Do YoungAhn, Sang HoonKim, Hyon SukPark, Young NyunHan, Kwang HyubSong, KijunKim, Seung Up. Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B. Gut Liver. 2018;12(2):190-200.	10
576	Heo JY, Beom KyungPark, Jun YongKim, Do YoungAhn, Sang HoonKim, Hyon-SukPark, Young NyunHan, Kwang-HyubSong, KijunKim, Seung Up. Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B. Gut and liver. 2018;12(2):190-200.	10
577	Hye Sung HM, Kim Kui Young, Park Seong Jun, Seo Chang Kwun, Hong. P150: Systemic sclerosis in a patient with primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. 프로그램북(구 초록집). 2018;70(1):366-7.	1
578	허자윤, 박준용, 김도영, 안상훈, 김현숙, 김도영, 박준영, 한광협, 송기준, 김승업. Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B. Gut and Liver. 2018;12(2):190-200.	10
579	Jekarl DW, HyunyuLee, SeungokKwon, Jung HyunLee, Sung WonYu, HeinKim, MyungshinKim, YonggooSung, Pil SooYoon, Seung Kew. Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA-M2BP) Among Chronic Hepatitis B Patients. Annals of laboratory medicine. 2018;38(4):348-54.	2
580	Lee HS, JinhyeokSon, TaekwonWee, Hee-JunBae, Sung-JinSeo, Ji HaePark, Ji HyunRyu, Soo HyungLee, DanbiJang, Myoung KukYu, EunsilChung, Young-HwaKim, Kyu-Won. Altered AKAP12 expression in portal fibroblasts and liver sinusoids mediates transition from hepatic fibrogenesis to fibrosis resolution. Experimental & molecular medicine : EMM. 2018;50:48.	2
581	Moon H-W, Mikyoung Hur, Mina Kim, Hanah Choe, Won Hyeok Yun, Yeo-Min. Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases. Annals of laboratory medicine. 2018;38(4):331-7.	10
582	Moon HW, MikyoungHur, MinaKim, HanahChoe, Won HyeokYun, Yeo Min. Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases. Ann Lab Med. 2018;38(4):331-7.	10
583	Park SJ, Ah RanChoe, Won HyeokKim, Jeong HanYoo, Byung ChulKwon, So Young. The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study. Korean J Gastroenterol. 2018;72(4):197-204.	2

연번	서지정보	배제 사유
584	Roh YS, Ara Cha, Youn-Soo Oh, Suk-Heung Lim, Chae Woong Kim, Bumseok. Lactobacillus Aggravate Bile Duct Ligation-Induced Liver Inflammation and Fibrosis in Mice. Toxicological Research. 2018;34(3):241-7.	10
585	Sanjib Mani RP, Lamichhane. PE-245 : Assessment of Methotrexate Hepatotoxicity in Psoriasis Patients from Nepal. 춘·추계 학술대회 (KASL). 2018;2018(1):244-.	1
586	Seong Jun PH, ChoeJeong Han, KimByung Chul, YooAh Ran, KimSo Young, Kwon. PO-061 : Efficacy and Safety of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Patients. 춘·추계 학술대회 (KASL). 2018;2018(1):107-.	2
587	Ying-Jie N, Zhou Zheng-Wen, Nie Kyung-Tae, Shin Yong-Han, Kim Xiang-Shun, Cui. Melatonin enhances mitochondrial biogenesis and function in porcine preimplantation embryos. 한국수정란이식학회 학술대회. 2018;2018(11):135-.	1
588	Yin-Hua Z-P, DingDe-Qiang, MaJuan, LiLin-Li, ChenKang-Jian, AoYou-You, Tian. S100A4 Gene is Crucial for Methionine-Choline-Deficient Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. Yonsei medical journal. 2018;59(9):1064-71.	10
589	Yoon Seok R, ChoYoun-Soo, ChaSuk-Heung, OhChae Woong, LimBumseok, Kim. Lactobacillus Aggravate Bile Duct Ligation-Induced Liver Inflammation and Fibrosis in Mice. Toxicological Research. 2018;34(3):241-7.	8
590	Yu Rim L, LeeSe Young, JangWon Young, TakYoung Oh, KweonBina, JungGyouun Eun, KangSang Kyung, SeoJung Gil, ParkHye Won, LeeYoung Seok, HanJae Min, ChunSoo Young, ParkKeun, Hur. PE-208 : Differential DNA Methylation as a Potential Biomarker for Stratification of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. 춘·추계 학술대회 (KASL). 2018;2018(1):229-30.	2
591	Zhang Y-H, De-QiangDing, De-PingLi, JuanChen, Lin-LiAo, Kang-JianTian, You-You. S100A4 Gene is Crucial for Methionine-Choline-Deficient Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. Yonsei medical journal. 2018;59(9):1064-71.	10
592	Zhang YH, De QiangDing, De PingLi, JuanChen, Lin LiAo, Kang JianTian, You You. S100A4 Gene is Crucial for Methionine-Choline-Deficient Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. Yonsei Med J. 2018;59(9):1064-71.	8
593	권정현. 혈청 HBV RNA와 간조직 내 바이러스, 조직학적 활동도와의 관련성. 대한소화기학회지. 2018;71(5):297-9.	2
594	박미경, 문희원, 허미나, 김한아, 최원혁, 윤여민, Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases. Annals of Laboratory Medicine. 2018;38(4):331-7.	10
595	박성준. The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study. 대한소화기학회지. 2018;72(4):197-204.	10
596	박성준, 김아란, 최원혁, 김정한, 유병철, 권소영. 만성 C형 간염 환자를 대상으로 한 Direct Acting Antiviral 병합 요법의 효과와 안정성: 단일기관 연구. 대한소화기학회지. 2018;72(4):197-204.	2
597	유정주, 김상균. 비알코올성 지방간염의 진단. Korean Journal of Medicine(구 대한내과학회지). 2018;93(1):33-7.	2
598	이민영, 이호규, 배재현, 김다함, 고은애, 이병완, 안철우, 차봉수, 허갑범, 이용호. P20 : Hepatic steatosis and fibrosis are independent predictive markers for LV diastolic dysfunction in patients with T2DM. 대한당뇨병학회 학술발표논문집. 2018;2018(0):139-.	1
599	이숙영, 김종백, 최후민, 김성민, 고은정, 노병인, 조한경. 표재확산모세혈관성혈관종 1예. 대한피부과학회지. 2018;56(6):396-7.	1
600	이혜신. Altered AKAP12 expression in portal fibroblasts and liver sinusoids mediates transition from hepatic fibrogenesis to fibrosis resolution. Experimental and Molecular Medicine. 2018;50(0):1-13.	10
601	이혜신, 손태권, 이희준, 배성진, 서지혜, 박지현, 류수형, 이단비, 장명국, 유은실, 정영화, 김규원, Altered AKAP12 expression in portal fibroblasts and liver sinusoids mediates transition from hepatic fibrogenesis to fibrosis resolution. Experimental and molecular medicine. 2018;50(-):1-13.	2

연번	서지정보	배제 사유
602	이혜원. Hepatocellular Carcinoma Prediction Models for Patients with Chronic Hepatitis B Virus Infection in the Era of Potent Antiviral Therapy. Journal of Liver Cancer. 2018;18(2):87-93.	10
603	이혜원, 김범경. 강력한 항바이러스 치료가 보편적으로 가능한 시대에서 만성 B형간염 환자의 간암 발생 예측 모델. 대한간암학회지. 2018;18(2):87-93.	2
604	제갈동욱, 최현유, 이승욱, 권정현, 이성원, 유혜인, 김명신, 김용구, 성필수, 윤승규. Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA-M2BP) Among Chronic Hepatitis B Patients. Annals of Laboratory Medicine. 2018;38(4):348-54.	2
605	조선영 허미나. Mac-2 Binding Protein Glycosylation Isomer: Emerging Non-Invasive Serum Marker for Liver Fibrosis. Annals of Laboratory Medicine. 2018;38(4):289-90.	2
606	Diagnostic Accuracy of Hepatic Vein Arrival Time Performed with Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis. Gut and Liver. 2017;11(1):93-101.	2
607	Microbiome in Liver Cirrhosis. 춘·추계 학술대회 (KASL). 2017;2017(1):256-7.	2
608	Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease. Gut and Liver. 2017;11(5):674-83.	2
609	O-029 : Comparison of Risk Factors for NASH and Advanced Fibrosis between Patients with Obese and Non-Obese Nonalcoholic Fatty Liver Disease. 춘·추계 학술대회 (KASL). 2017;2017(1):29-30.	2
610	O-100 : The Real-Life Data of Daclatasvir and Asunaprevir Treatment in Korean Patients with Hepatitis C Genotype 1b Infection. 춘·추계 학술대회 (KASL). 2017;2017(1):63-.	2
611	O-122 : Changes in Markers of Liver Function in HCV 1b Patients with Compensated Cirrhosis Treated with Ombitasvir/Paritaprevir/ Ritonavir plus Dasabuvir with Ribavirin. 춘·추계 학술대회 (KASL). 2017;2017(1):74-.	2
612	OP10-3 : Metformin ameliorates the activation of Hepatic Stellate cells and hepatic fibrosis by succinate and GPR91 inhibition. International Congress of Diabetes and Metabolism. 2017;2017(0):140-.	2
613	PE-018 : Risk Assessment of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Using Noninvasive Serum Fibrosis Markers. 춘·추계 학술대회 (KASL). 2017;2017(1):143-.	2
614	PE-096 : Quantitative Assessment of Liver Fibrosis Using Shore Durometer. 춘·추계 학술대회 (KASL). 2017;2017(1):179-.	2
615	PE-147 : Profiling of Secretory Proteins from Human Bone Marrow- Derived Mesenchymal Stem Cells in Liver Repair by cDNA Microarray. 춘·추계 학술대회 (KASL). 2017;2017(1):199-.	2
616	PE-194 : Mycoplasma Pneumonia-Associated Hepatitis: Severe Acute Hepatitis with Bicytopenia in Immunocompetent Adult. 춘·추계 학술대회 (KASL). 2017;2017(1):218-9.	1
617	PE-258 : Discrepancy between Liver Stiffness Measured by Shear-Wave Elastography and Ultrasonographic Echo-Texture: A Study of Four Case Examples. 춘·추계 학술대회 (KASL). 2017;2017(1):244-.	2
618	PO-095 : Performance of Fibrosis Markers for Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients under Antiviral Therapy. 춘·추계 학술대회 (KASL). 2017;2017(1):127-.	2
619	PS 1-7 : Exosomal miRNA Regulates Liver Fibrosis during Progression of Nonalcoholic Fatty Liver Disease. 춘·추계 학술대회 (KASL). 2017;2017(1):5-6.	2
620	PS 2-3 : Safety and Efficacy of Besifovir in Treatment-Naive Chronic Hepatitis B Virus Infection: A Randomized, Double-Blind, Double Dummy, Phase 3 Study. 춘·추계 학술대회 (KASL). 2017;2017(1):10-.	2
621	Ahn K, JuwonKim, YoonjungUh, YoungYoon, Kap Jun. FIB-4 Score as a Useful Screening Test for Diagnosing Liver Fibrosis. J Lab Med Qual Assur. 2017;39(1):16-22.	2

연번	서지정보	배제 사유
622	Chang Hyeong LS, KimJung Eun, SongHan Taek, JungJae Young, Oh. PE-194 : Mycoplasma Pneumonia-Associated Hepatitis: Severe Acute Hepatitis with Bicytopenia in Immunocompetent Adult. 춘·추계 학술대회 (KASL). 2017;2017(1):218-9.	2
623	Gaeun KY, ShimSoon Koo, Baik. Diagnostic Accuracy of Hepatic Vein Arrival Time Performed with Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis. Gut and Liver. 2017;11(1):93-101.	10
624	Hayashi T, SatoshiFukuzawa, KeiTsuji, YoshinoriTakahashi, JunjiKawamura, YusukeAkuta, NorioKobayashi, MasahiroIkeda, KenjiFujii, TakeshiMiyati, TosiakiKumada, Hiromitsu. Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease. Gut and liver. 2017;11(5):674-83.	2
625	Heesun HY, KimMeegun, HongDong Joon, KimKi Tae, Suk. PE-147 : Profiling of Secretory Proteins from Human Bone Marrow- Derived Mesenchymal Stem Cells in Liver Repair by cDNA Microarray. 춘·추계 학술대회 (KASL). 2017;2017(1):199-.	2
626	Kim G, Kwang YongBaik, Soon Koo. Diagnostic Accuracy of Hepatic Vein Arrival Time Performed with Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis. Gut and liver. 2017;11(1):93-101.	2
627	Kim KY, Ju Whi Lee, Kyung Jae Park, Eunhyang Kang, Gyeong Hoon Choi, Young, Hun Kim, Woo Sun Ko, Jung Min Moon, Jin Soo Ko, Jae Sung. A Novel Homozygous LIPA Mutation in a Korean Child with Lysosomal Acid Lipase Deficiency. Pediatric gastroenterology, hepatology & nutrition. 2017;20(4):263-7.	1
628	Lee GM, Youe ReeRyu, Jong HyunKim, Tae HoonCho, Eun YoungLee, Young HwanYoon, Kwon Ha. Quantitative Measurement of Hepatic Fibrosis with Gadoteric Acid-Enhanced Magnetic Resonance Imaging in Patients with Chronic Hepatitis B Infection: A Comparative Study on Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index. Korean J Radiol. 2017;18(3):444-51.	10
629	Lee GM, Youe ReeRyu, Jong HyunKim, Tae-HoonCho, Eun YoungLee, Young HwanYoon, Kwon-Ha. Quantitative Measurement of Hepatic Fibrosis with Gadoteric Acid-Enhanced Magnetic Resonance Imaging in Patients with Chronic Hepatitis B Infection: A Comparative Study on Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index. Korean journal of radiology : official journal of the Korean Radiological Society. 2017;18(3):444-51.	2
630	Marco TM, Vela VizcainoLenin, Pliego Reyes. Primary Sclerosing Cholangitis in an Elderly Patient: A Diagnostic Challenge. Ann Geriatr Med Res. 2017;21(3):138-41.	10
631	Massimo F. Microbiome and metabolic health: clinical implications and perspectives. International Congress of Diabetes and Metabolism. 2017;2017(0):77-.	1
632	Mi Na KS, RimHana, ParkJu Ho, LeeYun Bin, LeeYoung Eun, ChonYeonjung, HaSeong Gyu, Hwang. PE-018 : Risk Assessment of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Using Noninvasive Serum Fibrosis Markers. 춘·추계 학술대회 (KASL). 2017;2017(1):143-.	2
633	Moon Young K. Microbiome in Liver Cirrhosis. 춘·추계 학술대회 (KASL). 2017;2017(1):256-7.	2
634	Park SM, Eun HyeKim, Jae KwangJegal, Kyung HwanPark, Chung A.Cho, Il JeKim, Sang Chan. 20S-Protopanaxadiol, an aglycosylated ginsenoside metabolite, induces hepatic stellate cell apoptosis through liver kinase B1-AMP-activated protein kinase activation. Journal of Ginseng Research. 2017;41(3):392-402.	10
635	Sae Kyung J, KimWon, Kim. O-029 : Comparison of Risk Factors for NASH and Advanced Fibrosis between Patients with Obese and Non-Obese Nonalcoholic Fatty Liver Disease. 춘·추계 학술대회 (KASL). 2017;2017(1):29-30.	2
636	Sang Mi PH, JungJae Kwang, KimKyung Hwan, JegalChung, A. ParkII Je, ChoSang Chan, Kim. 20S-Protopanaxadiol, an aglycosylated ginsenoside metabolite, induces hepatic stellate cell apoptosis through liver kinase B1-AMP-activated protein kinase activation. Journal of Ginseng Research. 2017;41(3):392-402.	2

연번	서지정보	배제 사유
637	Tatsuya H, SaitohKei, FukuzawaYoshinori, TsujiJunji, TakahashiYusuke, KawamuraNorio, AkutaMasahiro, KobayashiKenji, IkedaTakeshi, FujiiTosiaki, MiyatiHiromitsu, Kumada. Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease. Gut and Liver. 2017;11(5):674-83.	2
638	Tobar M. Primary Sclerosing Cholangitis in an Elderly Patient: A Diagnostic Challenge. Annals of geriatric medicine and research. 2017;21(3):138-41.	10
639	Tobar M-V, HiramPliego-Reyes, Lenin. Primary Sclerosing Cholangitis in an Elderly Patient: A Diagnostic Challenge. Annals of geriatric medicine and research. 2017;21(3):138-41.	1
640	Vincent W. Genetic Susceptibility and Disease Severity. 춘·추계 학술대회 (KASL). 2017;2017(1):327-.	2
641	Yoo H, Jeong MinYoon, Jeong HeeKang, Hyo-JinLee, Sang MinYang, Hyun KyungHan, Joon Koo. T2 * Mapping from Multi-Echo Dixon Sequence on Gadoteric Acid-Enhanced Magnetic Resonance Imaging for the Hepatic Fat Quantification: Can It Be Used for Hepatic Function Assessment? Korean journal of radiology : official journal of the Korean Radiological Society. 2017;18(4):682-90.	10
642	Yoo H, Jeong MinYoon, Jeong HeeKang, Hyo JinLee, Sang MinYang, Hyun KyungHan, Joon Koo. Ta.,* Mapping from Multi-Echo Dixon Sequence on Gadoteric Acid-Enhanced Magnetic Resonance Imaging for the Hepatic Fat Quantification: Can It Be Used for Hepatic Function Assessment? Korean J Radiol. 2017;18(4):682-90.	2
643	Yoon YC, Jun SuhPark, Sang UkKwon, Jung HyunHong, Tae HoKim, Dong Goo. Quantitative assessment of liver fibrosis using shore durometer. Annals of surgical treatment and research : ASTR. 2017;93(6):300-4.	10
644	Young Chul YS, LeeJung Hyun, KwonTae Ho, HongDong Goo, Kim. PE-096 : Quantitative Assessment of Liver Fibrosis Using Shore Durometer. 춘·추계 학술대회 (KASL). 2017;2017(1):179-.	2
645	Young Chul YS, LeeSang Uk, ParkJung Hyun, KwonTae Ho, HongDong Goo, Kim. Quantitative assessment of liver fibrosis using shore durometer. Annals of Surgical Treatment and Research. 2017;93(6):300-4.	2
646	Young Min PJ, YooSang Jong, Park. PE-258 : Discrepancy between Liver Stiffness Measured by Shear-Wave Elastography and Ultrasonographic Echo-Texture: A Study of Four Case Examples. 춘·추계 학술대회 (KASL). 2017;2017(1):244-.	2
647	김가은, 심광용, 백순구, Diagnostic Accuracy of Hepatic Vein Arrival Time Performed with Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis. Gut and Liver. 2017;11(1):93-101.	2
648	김광연, 이경재, 박은향, 강경훈, 최영훈, 김우선, 고정민, 문진수, 고재성, A Novel Homozygous LIPA Mutation in a Korean Child with Lysosomal Acid Lipase Deficiency. Pediatric gastroenterology, hepatology & nutrition. 2017;20(4):263-7.	1
649	김민정, 한만석, 장재욱. 초음파를 이용한 간 섬유화 스캔 검사의 융합 탄성도 측정 평가. 한국융합학회논문지. 2017;8(5):79-85.	2
650	김석현, 임지애, 김소영, 이경민, 최원정, M2BPGi 간 섬유화 검사 [화학발광효소면역측정법]. 신의료 기술평가 보고서. 2017;1(14):1-99.	2
651	김소현, 임용, 박주빈, 곽재환, 김극준, 김정희, 송현근, 조준용, 황대연, 김길수, 정영석,. Comparative study of fatty liver induced by methionine and choline-deficiency in C57BL/6N mice originating from three different sources. Laboratory Animal Research. 2017;33(2):157-64.	8
652	김진수. 섬유화된 간조직에서 알파토코페롤에 따른 조직학적 변화 연구. 한국융합학회논문지. 2017;8(4):123-9.	2
653	노윤석. 담즙정체성 간섬유증에서 헬리코박터 파일로리균 감염의 병리효과. 약 학 회 지. 2017;61(1):18-23.	10
654	노윤석 임채웅, 김법석,. 담즙정체성 간섬유증에서 헬리코박터 파일로리균 감염의 병리효과. 약학회지. 2017;61(1):18-23.	2

연번	서지정보	배제 사유
655	박상미, 정은혜, 김재관, 제갈경환, 박정아, 조일제, 김상찬,. 20S-Protopanaxadiol, an aglycosylated ginsenoside metabolite, induces hepatic stellate cell apoptosis through liver kinase B1eAMP-activated protein kinase activation. Journal of Ginseng Research. 2017;41(3):392-402.	2
656	박새미, 한형진, 유동수, 김진우, 이영복, 음경귀등을 침범한 다발성 소아황색육아종 1예. 대한피부과 학회지. 2017;55(2):138-9.	1
657	서연석. 간경변의 진단. 대한의사협회지. 2017;60(7):561-7.	2
658	서정완, 김태훈, 최승환, 송기훈, 김기호. Methotrexate로 치료한 예스너 피부림프침윤 1예. 대한피부과학회지. 2017;55(2):143-5.	1
659	윤희영, 이석현, 하세진, 류진숙, 김동순, 송진우, P-135 The Value of 18F-FDG PET/CT in evaluating disease severity in idiopathic pulmonary fibrosis. 대한결핵및호흡기학회 추계학술발표초록집. 2017;124(0):227-.	1
660	이규목, 류종현, 김태훈, 조은영, 이영환, 윤권하,. Quantitative Measurement of Hepatic Fibrosis with Gadoteric Acid-Enhanced Magnetic Resonance Imaging in Patients with Chronic Hepatitis B Infection: A Comparative Study on Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index. Korean Journal of Radiology. 2017;18(3):444-51.	2
661	이대호 최, 박이병, 김병준, 이기영, 이시훈, 엄영실, 유승희, 김연수, 권오상, 최철수, 김광원, 건강한 젊은 성인남성에서 지방간질환 변수 측정을 위한 MRI검사 방법과 FibroScan 검사법의 비교연구. 대한당뇨병학회 학술발표논문집. 2017;2017(0):127-.	2
662	이세환. Evaluation of liver fibrosis. Single Topic Symposium (STS). 2017;2017(2):3-12.	2
663	이호규, 김규리, 권혜진, 신유진, 최영주, 이병완, 강은석, 차병수, 이은직, 허갑범, 이용호,. Hepatic steatosis and fibrosis are associated with left ventricular diastolic dysfunction in type 2 diabetic patients with insulin resistance. 대한당뇨병학회 학술발표논문집. 2017;2017(0):118-.	1
664	임지애 김소영, 최원정, 김석현,. M2BPGi 간 섬유화 검사 : 체계적 문헌고찰. 근거와 가치. 2017;3(2):131-7.	2
665	전대원. Definition and diagnostic criteria of NAFLD. 대한당뇨병학회 학술발표논문집. 2017;2017(0):11-.	2
666	정진웅, 이준범, 권준일, 류영욱, 김성애, 치료에 반응하지 않는 과증식성 반흔 병변에서 발견된 Skin Staple. 대한피부과학회지. 2017;55(7):466-7.	1
667	최예용. 가슴기살균제 참사의 진행과 교훈(Q&A). 한국환경보건학회지. 2017;43(1):1-22.	1
668	추진우, 문성훈. 만성 췌장염의 임상상, 자연경과 및 합병증. 대한체담도학회지. 2017;22(2):63-71.	1
669	O-004: Combined Use of AST to Platelet Ratio Index and Fibrosis-4 Score Can Risk Stratify Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients with Low Level Viremia. 춘·추계 학술대회 (KASL). 2016;2016(1):20-.	7
670	O-022: The Accuracy of Transient Elastography and Comparison of Non-invasive Markers for Assessing Fibrosis in Korean Patients with Nonalcoholic Fatty Liver Disease. 춘·추계 학술대회 (KASL). 2016;2016(1):29-.	7
671	O-025: Computer-aided Relative Scoring of Fatty Liver Intensity in High Frequency 9 MHz Ultrasound Image: A Feasibility Study. 춘·추계 학술대회 (KASL). 2016;2016(1):30-1.	7
672	O-050: Transplantation with Autologous Bone Marrow-derived Mesenchymal Stem Cells for Alcoholic Cirrhosis: Phase 2 Trial. 춘·추계 학술대회 (KASL). 2016;2016(1):42-3.	7
673	O-080: Serum Wisteria Floribunda Agglutinin-positive Mac-2-binding Protein Level as a Predictor of Hepatic Fibrosis in Chronic HBV Infection. 춘·추계 학술대회 (KASL). 2016;2016(1):57-8.	7
674	O-091: Exosome Derived from Palmitic Acid-treated Hepatocytes Activates Hepatic Stellate Cells. 춘·추계 학술대회 (KASL). 2016;2016(1):62-3.	7

연번	서지정보	배제 사유
675	O-110: Risk Assessment of Developing Hepatocellular Carcinoma Using Wisteria Floribunda Agglutinin-positive Human Mac-2 Binding Protein in Chronic Hepatitis B Patients. 춘·추계 학술대회 (KASL). 2016;2016(1):71-.	7
676	O-114: A Novel Biomarker-based Model for the Prediction of Response to Sorafenib and Overall Survival for Advanced Hepatocellular Carcinoma: A Prospective Cohort Study. 춘·추계 학술대회 (KASL). 2016;2016(1):73-4.	7
677	Original Article : Magnetization-tagged MRI is a simple method for predicting liver fibrosis. Clinical and Molecular Hepatology(대한간학회지). 2016;22(1):140-5.	10
678	PE-097: Comparisons of Non Invasive Parameters on Fibrosis Regression in Chronic Hepatitis B Patients on Entecavir Therapy. 춘·추계 학술대회 (KASL). 2016;2016(1):168-.	7
679	PE-169: Validation of a Diagnostic Strategy of Combining Liver Stiffness Value by Transient Elastography and Enhanced Liver Fibrosis to Assess Fibrotic Burden in Patients with Chronic Hepatitis B. 춘·추계 학술대회 (KASL). 2016;2016(1):199-.	7
680	PE-170: Body Mass Index as a Predictor of Severity of Fibrosis from a Tertiary Liver Center in the Philippines. 춘·추계 학술대회 (KASL). 2016;2016(1):199-200.	7
681	PO-028: Prevalence of Vitamin D Deficiency in Chronic Liver Disease at the Outpatient Clinics of the University of the Philippines- Philippine General Hospital. 춘·추계 학술대회 (KASL). 2016;2016(1):93-.	7
682	PO-038: Role of FIB-4 Predicting Clinical Outcomes after HBsAg Seroclearance in Patients with Chronic Hepatitis B. 춘·추계 학술대회 (KASL). 2016;2016(1):97-8.	7
683	S-361 유미홍과 유미성 복수가 동반된 재발성 IgG4 연관 폐질환 1예. 대한내과학회 추계학술발표논문집. 2016;2016(1):230-.	7
684	Angelo L, Teh. PE-170: Body Mass Index as a Predictor of Severity of Fibrosis from a Tertiary Liver Center in the Philippines. 춘·추계 학술대회 (KASL). 2016;2016(1):199-200.	7
685	Arafat SY, MohammadJahan, SharfiatKarim, ZarifaReza, Hasan MahmudHossain, Md HemayetShohel, MohammadAlam, Md Ashraful. Ellagic acid rich Momordica charantia fruit pulp supplementation prevented oxidative stress, fibrosis and inflammation in liver of alloxan induced diabetic rats. Oriental pharmacy and experimental medicine. 2016;16(4):267-78.	10
686	Aubrey QTD, S. VelascoMara Teresa, T. PanlilioMaria Joanne, M. RubioMargaret Elaine, J. VillamayorJanus, P. OngMa. Lourdes, O. Daez. PO-028: Prevalence of Vitamin D Deficiency in Chronic Liver Disease at the Outpatient Clinics of the University of the Philippines- Philippine General Hospital. 춘·추계 학술대회 (KASL). 2016;2016(1):93-.	7
687	Dong Wook JS, SungBo Hyun, JangKwang Il, SeoJeong Won, JangSi Hyun, BaeJong Young, ChoiYonggoo, KimSeung Kew, Yoon. O-080: Serum Wisteria Floribunda Agglutinin-positive Mac-2-binding Protein Level as a Predictor of Hepatic Fibrosis in Chronic HBV Infection. 춘·추계 학술대회 (KASL). 2016;2016(1):57-8.	7
688	Gabriel WW, LeeBeom Kyung, KimSeung Up, KimDo Young, KimSang Hoon, AhnKwang Hyub, HanJun Yong, Park. PE-097: Comparisons of Non Invasive Parameters on Fibrosis Regression in Chronic Hepatitis B Patients on Entecavir Therapy. 춘·추계 학술대회 (KASL). 2016;2016(1):168-.	7
689	Jianxue L, JiHong, AiBo, NingJunzhi, ZhaoYaoren, ZhangGuoliang, Dun. Liver Shear-Wave Velocity and Serum Fibrosis Markers to Diagnose Hepatic Fibrosis in Patients with Chronic Viral Hepatitis B. Korean Journal of Radiology. 2016;17(3):396-404.	2
690	Kim K-E, Mi-SukChung, SohaeAn, ChansikAxel, LeonErgashovna, Rakhmonova Gulbahor. Magnetization-tagged MRI is a simple method for predicting liver fibrosis. Clinical and molecular hepatology. 2016;22(1):140-5.	10
691	Kyung Eun KS, ParkSohae, ChungChansik, AnLeon, AxelRakhmonova Gulbahor, Ergashovna. Original Article : Magnetization-tagged MRI is a simple method for predicting liver fibrosis. Clinical and Molecular Hepatology(대한간학회지). 2016;22(1):140-5.	2

연번	서지정보	배제 사유
692	Liu J, YonghaoAi, HongNing, BoZhao, JunzhiZhang, YaorenDun, Guoliang. Liver Shear-Wave Velocity and Serum Fibrosis Markers to Diagnose Hepatic Fibrosis in Patients with Chronic Viral Hepatitis B. Korean journal of radiology : official journal of the Korean Radiological Society. 2016;17(3):396-404.	10
693	Seung Kak SH, KimOh Sang, KwonDuck Joo, ChoiYun Soo, Kim. PO-038: Role of FIB-4 Predicting Clinical Outcomes after HBsAg Seroclearance in Patients with Chronic Hepatitis B. 춘·추계 학술대회 (KASL). 2016;2016(1):97-8.	7
694	Shin JW, Neung Hwa. Clinical Application of Non-invasive Diagnostic Tests for Liver Fibrosis. 대한소화기학회지 = The Korean journal of gastroenterology. 2016;68(1):4-9.	7
695	Syed Yeasin A. Ellagic acid rich Momordica charantia fruit pulp supplementation prevented oxidative stress, fibrosis and inflammation in liver of alloxan induced diabetic rats. Oriental Pharmacy and Experimental Medicine. 2016;31(4):267-78.	10
696	Syed Yeasin A, AlamMohammad, NayeemSharfiat, JahanZarifa, KarimHasan Mahmud, RezaHemayet, HossainMohammad, Shohel. Ellagic acid rich Momordica charantia fruit pulp supplementation prevented oxidative stress, fibrosis and inflammation in liver of alloxan induced diabetic rats. Oriental Pharmacy and Experimental Medicine. 2016;31(4):267-78.	8
697	Vahedi L-B, Morteza Ghojazadeh, Morteza Vahedi, Amir Rafeey, Mandana. Gender Differences in Clinical Presentations of Cystic Fibrosis Patients in Azeri Turkish Population. Tuberculosis and respiratory diseases : TRD = 결핵 및 호흡기 질환. 2016;79(4):267-73.	1
698	Yoo H, Jeong MinYoon, Jeong HeeLee, Dong HoChang, WonHan, Joon Koo. Prospective Comparison of Liver Stiffness Measurements between Two Point Shear Wave Elastography Methods: Virtual Touch Quantification and Elastography Point Quantification. Korean journal of radiology : official journal of the Korean Radiological Society. 2016;17(5):750-7.	2
699	Young Min P, SonSun Hong, YooSang Jong, Park. O-025: Computer-aided Relative Scoring of Fatty Liver Intensity in High Frequency 9 MHz Ultrasound Image: A Feasibility Study. 춘·추계 학술대회 (KASL). 2016;2016(1):30-1.	2
700	곽금연. Pre-, pro-, synbiotics in nonalcoholic fatty liver diseases. Single Topic Symposium (STS). 2016;2016(2):64-8.	2
701	김범희. 흰쥐의 만성 알콜성 근위축에 시호소간산(柴胡疎肝散)이 미치는 효과. 大韓韓醫學方劑學會誌. 2016;24(4):311-21.	8
702	김영석. Treatment Target: Would prioritizing treatment be necessary in DAA era? Single Topic Symposium (STS). 2016;2016(1):28-41.	2
703	박호준, 이반석, 서안나, 배한익. 경화성 장간막염과 감별이 어려웠던 총담관암 림프절전이 1예. 대한 췌담도학회지. 2016;21(4):216-21.	2
704	신방섭, 최진호, 김정, 이상협, 김용태, 류지곤. S-175 항암치료를 통해 병리학적 완전 관해가 확인된 절제가 불가능한 진행성 간내담관암 1예. 대한내과학회 추계학술발표논문집. 2016;2016(1):137-.	2
705	신정우, 박능화. 비침습적 간섬유화 검사의 종류와 의의. 대한소화기학회지. 2016;68(1):4-9.	2
706	임창범. S-461 리팜핀 유발성 ANCA 음성 반월상 사구체신염. 대한내과학회 추계학술발표논문집. 2016;2016(1):280-.	1
707	OP9-1 : Waist-to-calf circumference ratio is associated with hepatic steatosis and fibrosis independently of insulin resistance in type 2 diabetes. International Congress of Diabetes and Metabolism. 2015;2015(0):143-.	7
708	PG2. Fatty Liver Disease (ASH & NASH) : Comorbidities and Long-term Outcomes of Nonalcoholic Fatty Liver Disease. Postgraduate Courses (PG). 2015;2015(1):43-7.	10
709	Review : Personalized management of cirrhosis by non-invasive tests of liver fibrosis. Clinical and Molecular Hepatology(대한간학회지). 2015;21(3):20-31.	7
710	S-95 : The GPR is an independent predictor of the development of HBV-related HCC. 대한내과학회 추계학술대회. 2015;2015(1):85-.	10

연번	서지정보	배제 사유
711	S-96 : The effect and safety of Cordyceps militaris in Korean adults who have mild liver dysfunction. 대한내과학회 추계학술대회. 2015;2015(1):85-.	10
712	S-443 : Septic portal vein thrombophlebitis as a rare complication of diverticulitis. 대한내과학회 추계학술발표논문집. 2015;2015(1):259-.	7
713	Chang EJ, Dae YongYang, Hye Ran. Vitamin D Status and Bone Mineral Density in Obese Children with Nonalcoholic Fatty Liver Disease. Journal of Korean medical science : JKMS. 2015;30(12):1821-7.	10
714	Cheng W, LiuPeng, ZhaoDan, TangDingkang, YaoLiang, ZhuZhiqiang, Wang. ORiginal Article : Potential Serum Markers for Monitoring the Progression of Hepatitis B Virus-Associated Chronic Hepatic Lesions to Liver Cirrhosis. Gut and Liver. 2015;9(5):665-71.	10
715	Cheng WJ, LiuPeng, ZhaoDan, TangDing Kang, YaoLiang, ZhuZhi Qiang, Wang. ORiginal Article : Potential Serum Markers for Monitoring the Progression of Hepatitis B Virus-Associated Chronic Hepatic Lesions to Liver Cirrhosis. Gut and Liver. 2015;9(5):665-71.	2
716	Jeong Hoon L. PG2. Fatty Liver Disease (ASH & NASH) : Comorbidities and Long-term Outcomes of Nonalcoholic Fatty Liver Disease. Postgraduate Courses (PG). 2015;2015(1):43-7.	7
717	Jin Young HW, BaikHyuk Jung, Kim. S-96 : The effect and safety of Cordyceps militaris in Korean adults who have mild liver dysfunction. 대한내과학회 추계학술발표논문집. 2015;2015(1):85-.	7
718	Kim KE, HwajinHeo, Rok WonShin, Hyun JooYi, Chin OkLee, Dong HoonKim, Hyun JoonKang, Sang SooCho, Gyeong JaeChoi, Wan SungRoh, Gu Seob. Myeloid-specific SIRT1 Deletion Aggravates Hepatic Inflammation and Steatosis in High-fat Diet-fed Mice. Korean J Physiol Pharmacol. 2015;19(5):451-60.	10
719	Kim KE, HwajinHeo, Rok WonShi, Hyun JooYi, Chin-okLee, Dong HoonKim, Hyun JoonKang, Sang SooCho, Gyeong JaeChoi, Wan SungRoh, Gu Seob. Myeloid-specific SIRT1 Deletion Aggravates Hepatic Inflammation and Steatosis in High-fat Diet-fed Mice. The Korean Journal of Physiology & Pharmacology. 2015;19(5):451-60.	10
720	Kwon OH, Jae Woon. Hepatic Actinomycosis Mimicking a Malignant Tumor: Three Case Reports. J Korean Soc Radiol. 2015;72(5):352-7.	8
721	Kyung Eun K, KimRok Won, HeoHyun Joo, ShinChin-ok, YiDong Hoon, LeeHyun Joon, KimSang Soo, KangGyeong Jae, ChoWan Sung, ChoiGu Seob, Roh. Myeloid-specific SIRT1 Deletion Aggravates Hepatic Inflammation and Steatosis in High-fat Diet-fed Mice. The Korean Journal of Physiology & Pharmacology. 2015;19(5):451-60.	8
722	Wong GL-H, Wendell ZaragozaWong, Vicnent Wai-Sun. Personalized management of cirrhosis by non-invasive tests of liver fibrosis. Clinical and molecular hepatology. 2015;21(3):200-11.	7
723	Wu C, LijieZhao, PengTang, DanYao, DingkangZhu, LiangWang, Zhiqiang. Potential Serum Markers for Monitoring the Progression of Hepatitis B Virus-Associated Chronic Hepatic Lesions to Liver Cirrhosis. Gut and liver. 2015;9(5):665-71.	10
724	Yong Eun PU, KimBeom Kyung, KimJun Yong, Park. S-95 : The GPR is an independent predictor of the development of HBV-related HCC. 대한내과학회 추계학술발표논문집. 2015;2015(1):85-.	7
725	구소미, 김양기, 김기업, 어수택, 김도진, 김용훈, 박춘식. F-7 : 교원성 혈관질환과 동반된 간질성 폐렴 환자에서 위식도 역류가 폐기능과 영상 소견에 미치는 영향. 대한결핵및호흡기학회 추계학술발표 초록집. 2015;120(0):99-.	7
726	김경은, 김화진, 허록원, 신현주, 이친옥, 이동훈, 김현준, 강상수, 조경제, 최완성, 노구섭. Myeloid-specific SIRT1 Deletion Aggravates Hepatic Inflammation and Steatosis in High-fat Diet-fed Mice. The Korean Journal of Physiology & Pharmacology. 2015;19(5):451-60.	8
727	김영, 강성욱, 심승철, 유인설, 유수진, 이정찬, 박찬걸. S-519 : 혼합결합조직병과 동반된 MPO-ANCA 연관 혈관염 환자에서 발생한 다발성 수부 궤양 1례. 대한내과학회 추계학술발표논문집. 2015;2015(1):297-.	7

연번	서지정보	배제 사유
728	백진이, 황주환, 이유림, 이종성, 최병순. 무기분진 노출 이직 근로자들의 림프구 아형분석. 임상면역 검사학회 초록집. 2015;2015(1):67-.	7
729	윤소영, 정주양, 김현아,서창희,. S-506 : 전신성경화증에서 iloprost에 의한 폐동맥고혈압의 호전 사례. 대한내과학회 추계학술발표논문집. 2015;2015(1):290-.	7
730	이성곤, 장재영, 김정욱, 장영운,. S-68 : 단기간에 급속 성장한 거대 염증성섬유양용종 1예. 대한내과학회 추계학술발표논문집. 2015;2015(1):71-.	7
731	이은송, 권상훈, 김나리, 은정수, 배기범, 남언정, 강영모. S-501 : 유방 지방종염 및 비결석 담낭염을 동반한 남성 전신홍반루푸스 1예. 대한내과학회 추계학술발표논문집. 2015;2015(1):288-.	7
732	이정현, 김동현, 김창수. Fibroscan에서의 혈액검사를 이용한 간질환의 영상분석. 한국콘텐츠학회논문지. 2015;15(8):389-96.	2
733	이종현, 최재필, 김지은,. S-426 : MERS-CoV 폐렴환자에서 발생한 Bickerstaff 뇌간뇌증 1예. 대한내과학회 추계학술발표논문집. 2015;2015(1):250-.	7
734	이호진, 이원홍,서대건. 간 섬유화와 혈액생화학적 인자들의 연관성 분석. 대한초음파의료영상학회지. 2015;6(1):87-97.	2
735	장은재, 양혜란, 이대영. Vitamin D Status and Bone Mineral Density in Obese Children with Nonalcoholic Fatty Liver Disease. Journal of Korean medical science. 2015;30(12):1821-7.	5
736	정소희, 방기태, 신종호, 정진욱,. S-277 : 초병 음독 후 폐 섬유화가 진행된 약물 중독 1례. 대한내과학회 추계학술발표논문집. 2015;2015(1):176-.	7
737	천신욱, 손현욱, 이숙영, 노병인, 최한규, 조한경, Danazol로 호전된 경화성 지방종염. 대한피부과학회지. 2015;53(1):84-5.	1
738	최대희. Single Topic Symposium : Debate in NAFLD (Key note Lecture and panel discussion) ; Role of non-invasive diagnosis: Cons. Single Topic Symposium (STS). 2015;2015(2):61-9.	7
739	최창원, 강창돈, 이성준, 최대희, 박성철, 이승구, 이상혁, 남승주, 이상훈,. S-118 : Ig G4 related disease with retroperitoneal fibrosis. 대한내과학회 추계학술발표논문집. 2015;2015(1):96-.	7
740	Articles : Inhibitory Effect of Rutaecarpine on Thioacetamide (TAA)-induced Hepatic Fibrosis. Natural Product Sciences. 2014;20(4):262-8.	10
741	Mest Attenuates CCl4-Induced Liver Fibrosis in Rats by Inhibiting the Wnt/ β -Catenin Signaling Pathway. Gut and Liver. 2014;8(3):282-91.	10
742	OP1-3 : Sarcopenia is associated with non-alcoholic fatty liver disease regardless of obesity and metabolic syndrome: nationwide surveys (KNHANES 2008-2011). International Congress of Diabetes and Metabolism. 2014;2014(0):127-.	7
743	PE-82 : SIRT3-SDH-GPR91 signaling in hepatic stellate cell activation. International Congress of Diabetes and Metabolism. 2014;2014(0):163-.	7
744	Poster Session : PS 1242 ; Pulmonology : A Case of Hemophagocytic Lymphohistiocytosis after Lung Transplantation. 대한내과학회 추계학술대회. 2014;2014(1):311-.	10
745	Review : Prediction of fibrosis progression in chronic viral hepatitis. Clinical and Molecular Hepatology(대한간학회지). 2014;20(3):228-36.	7
746	Ahn H, Sung-JinNam, Kung-WooMar, Woongchon. Inhibitory Effect of Rutaecarpine on Thioacetamide (TAA)-induced Hepatic Fibrosis. Natural Product Sciences. 2014;20(4):262-8.	10
747	El-Mahdi MMM, Wafaa A.Hammam, OlfatMehana, Noha A.Hussein, Taghreed M. Ameliorative Effect of Bone Marrow-Derived Stem Cells on Injured Liver of Mice Infected with Schistosoma mansoni. The Korean Journal of Parasitology. 2014;52(2):151-62.	8
748	El-Zahar KMAE-Z, Ahmed M.Ramadan, Mohamed Fawzy. Levels of Biogenic Amines in Cheeses and Their Impact on Biochemical and Histological Parameters in Rats. Applied Biological Chemistry. 2014;57(1):73-81.	8

연번	서지정보	배제 사유
749	Grace Lai Hung W. Review : Prediction of fibrosis progression in chronic viral hepatitis. Clinical and Molecular Hepatology(대한간학회지). 2014;20(3):228-36.	7
750	Guan Y-S. Comments to Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score. Gut and liver. 2014;8(2):228-.	10
751	Guan YS. Comments to Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score. Gut Liver. 2014;8(2):228-.	7
752	Hyun Jin AJ, LeeKung Woo, NamWoong Chon, Mar. Articles : Inhibitory Effect of Rutaecarpine on Thioacetamide (TAA)-induced Hepatic Fibrosis. Natural Product Sciences. 2014;20(4):262-8.	10
753	Jeong WK, Hyo K.Lee, Hyoung-KiJo, Jae MoonKim, Yongsoo. Principles and clinical application of ultrasound elastography for diffuse liver disease. Ultrasonography. 2014;33(3):149-60.	2
754	Kahled ME-Z, M. Abd El-ZaherMohamed Fawzy, Ramadan. Levels of Biogenic Amines in Cheeses and Their Impact on Biochemical and Histological Parameters in Rats. Applied Biological Chemistry. 2014;57(1):73-81.	8
755	Kang H, ChungsanKwon, Ki-RokLee, Kwangho. Study of a 13-weeks, Repeated, Intramuscular Dose, Toxicity Test of Sweet Bee Venom in Sprague-Dawley Rats. Journal of pharmacopuncture. 2014;17(2):73-9.	8
756	Kang H, ChungsanLee, SeungbaeKim, ByoungwooKwon, KirokLee, Kwangho. Study on a 4-Week Recovery Test of Sweet Bee Venom after a 13-Week, Repeated, Intramuscular Dose Toxicity Test in Sprague-Dawley Rats. Journal of pharmacopuncture. 2014;17(2):18-26.	8
757	Magda ME-M, A. MansourOlfat, HammamNoha, A. MehanaTaghreed, M. Hussein. Ameliorative Effect of Bone Marrow-Derived Stem Cells on Injured Liver of Mice Infected with Schistosoma mansoni. The Korean Journal of Parasitology. 2014;52(2):151-62.	8
758	Na JH, So WonKang, YunkooKoh, HongKim, Seung. The Clinical Significance of Serum Ferritin in Pediatric Non-Alcoholic Fatty Liver Disease. Pediatric gastroenterology, hepatology & nutrition. 2014;17(4):248-56.	2
759	Poortahmasebi V, Seyed MoayedKeyvani, HosseinNorouzi, MehdiMahmoodi, MahmoodJazayeri, Seyed Mohammad. Hepatic Steatosis: Prevalence and Host/Viral Risk Factors in Iranian Patients with Chronic Hepatitis B Infection. Asian Pacific journal of cancer prevention. 2014;15(9):3879-84.	2
760	Sul AR. Serum liver fibrosis test. JKMA : Journal of the Korean Medical Association = 대한의사협회지. 2014;57(8):704.	10
761	Sung Woo MS, ChungJi Ye, JungYoung Ae, KangMoo Suk, ParkYoung Sam, KimJoon, ChangSe Kyu, KimHyo Chae, PaikJun Won, CheongSong Yee, Kim. Poster Session : PS 1242 ; Pulmonology : A Case of Hemophagocytic Lymphohistiocytosis after Lung Transplantation. 대한내과학회 추계학술발표논문집. 2014;2014(1):311-.	7
762	Wang C-M, Shan-JenWu, Chi-HaoHu, Chien-MingCheng, Hui-WenChang, Jung-Su. Transient Knock Down of Grp78 Reveals Roles in Serum Ferritin Mediated Pro-inflammatory Cytokine Secretion in Rat Primary Activated Hepatic Stellate Cells. Asian Pacific journal of cancer prevention. 2014;15(2):605-10.	8
763	Wen Ting LL, ZhuYi, LiQuan, WuRen Tao, Gao. ORiginal Article : Mest Attenuates CCl4-Induced Liver Fibrosis in Rats by Inhibiting the Wnt/ β -Catenin Signaling Pathway. Gut and Liver. 2014;8(3):282-91.	10
764	Wenting L, ZhuYi, LiQuan, WuRentao, Gao. ORiginal Article : Mest Attenuates CCl4-Induced Liver Fibrosis in Rats by Inhibiting the Wnt/B-Catenin Signaling Pathway. Gut and Liver. 2014;8(3):282-91.	10
765	Wong GL-H. Prediction of fibrosis progression in chronic viral hepatitis. Clinical and molecular hepatology. 2014;20(3):228-36.	10
766	Wong GLH. Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol. 2014;20(3):228-36.	7

연번	서지정보	배제 사유
767	Wonseok KK, KimSeung Up, KimJun Yong, ParkDo Young, KimSang Hoon, AhnKwang Hyub, Han. The Diagnostic Accuracy of Red Cell Distribution Width-to-platelet Ratio in Assessment of Liver Fibrosis in Patients with Chronic Hepatitis B. 한국간담체외과학회 학술대회지. 2014;2014(4):63-.	7
768	Woo Sik J, HossainSeung Chun, Park. Mini-review : Toxicological Profiles of Poisonous, Edible, and Medicinal Mushrooms. Mycobiology. 2014;42(3):215-20.	7
769	Yi L, WuWenting, LiChuanlong, ZhuRentao, Gao. OOriginal Article : Mest Attenuates CCl4-Induced Liver Fibrosis in Rats by Inhibiting the Wnt/ β -Catenin Signaling Pathway. Gut and Liver. 2014;8(3):282-91.	8
770	Yi LT, LiChuan Long, ZhuQuan, WuRen Tao, Gao. Mest Attenuates CCl4-Induced Liver Fibrosis in Rats by Inhibiting the Wnt/ β -Catenin Signaling Pathway. Gut and Liver. 2014;8(3):282-91.	8
771	Yong Song G. Letter to the editor : Comments to Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease ; An Enhanced Model of BARD Score. Gut and Liver. 2014;8(2):228-.	7
772	Yong-Song G. Comments to Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score. Gut and Liver. 2014;8(2):228-.	7
773	Young Min Rah KMMANK. Toxic Hepatitis with Liver Fibrosis in a 67-year-old Man Who took Fritillaria thunbergii Miquel. The Medical Journal of Chosun University. 2014;39(4):306-8.	6
774	강현민, 임청산, 권기록. Study of a 13-weeks, Repeated, Intramuscular Dose, Toxicity Test of Sweet Bee Venom in Sprague-Dawley Rats. Journal of pharmacopuncture. 2014;17(2):73-9.	8
775	강현민, 이승배, 김병우, 권기록, 이광호. Study on a 4-Week Recovery Test of Sweet Bee Venom after a 13-Week, Repeated, Intramuscular Dose Toxicity Test in Sprague-Dawley Rats. Journal of pharmacopuncture. 2014;17(2):18-26.	8
776	곽금연. 특집 : 비알코올성 지방간(Non-alcoholic fatty liver disease, NAFLD) : 비알코올성 지방간의 진단. 당뇨병(JKD). 2014;15(2):82-92.	7
777	김경민, 윤인규, 김동열, 이윤상, 최우남. 발작성 심방세동 환자들에 대한 3D Inversion recovery turbo field echo기법에서 적절한 조영 후 지연시간에 대한 고찰. 대한자기공명기술학회지. 2014;24(-):44-51.	1
778	김문영. 특집 : 비알코올 지방간 질환의 진단. Korean Journal of Medicine(구 대한내과학회지). 2014;86(4):405-15.	7
779	김미나 안상훈. 만성B형간염 : 면역 관용기 환자, 치료할 것인가? Single Topic Symposium (STS). 2014;2014(1):34-40.	7
780	김영지, 이지범, 김성진, 원영호, 이승철, 원저 : 한국인 피부과환자에서 Methotrexate 치료효과 및 부작용. 대한피부과학회지. 2014;52(4):237-43.	1
781	김자경, 이동기, 이수연, 장혜영, 최준정, 이정일. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice. Experimental and molecular medicine. 2014;46(-):1-7.	8
782	나지훈, 강윤구, 고희, 김승. The Clinical Significance of Serum Ferritin in Pediatric Non-Alcoholic Fatty Liver Disease. Pediatric gastroenterology, hepatology & nutrition. 2014;17(4):248-56.	2
783	변상영, 김보리, 박현선, 윤현선, 조소연. Opitz G/BBB Syndrome 1예. 대한피부과학회지. 2014;52(9):677-8.	6
784	설아람. 혈청 간섬유화 검사. 대한의사협회지. 2014;57(8):704-9.	7
785	안현진, 남궁우, 마응천, Inhibitory Effect of Rutaecarpine on Thioacetamide (TAA)-induced Hepatic Fibrosis. Natural Product Sciences. 2014;20(4):262-8.	8
786	양현, 김보경, 유지연, 고은실, 장윤식, 정성진. 헤노흐-쇤라인 자색반과 동반된 IgG4 연관 요세관간질 신염. Korean Journal of Medicine(구 대한내과학회지). 2014;87(1):96-100.	1

연번	서지정보	배제 사유
787	이세환, 김홍수, 김영돈, 김상균, 김영석, 정승원, 장재영, 김부성. 알라닌아미노전달효소가 상승된 만성간질환 환자에서 Biphenyl Dimethyl Dicarboxylate와 Ursodeoxycholic Acid의 유효성과 안정성을 평가하는 무작위배정, 이중맹검, 다기관 제4상 임상시험. 대한소화기학회지. 2014;64(1):31-9.	5
788	정우경, 이형기, 조재문, 김용수. Principles and clinical application of ultrasound elastography for diffuse liver disease. ULTRASONOGRAPHY. 2014;33(3):149-60.	2
789	Alcohol, NAFLD, Other : Non-Invasive Measurement of Steatosis Grade by Controlled Attenuation Parameter Implemented on Fibroscan in Health Checkup Subjects. 춘·추계 학술대회 (KASL). 2013;2013(1):69-.	7
790	Alcohol, NAFLD, Other : Osthol Attenuated Liver Steatosis via Decrease Liver De Novo Triglyceride Synthesis not by Insulin Resistance: Multifaceted Effects of Cindium Monnieri Extract. 춘·추계 학술대회 (KASL). 2013;2013(1):50-1.	7
791	HBV : Reduction in the Liver Stiffness Value is Associated with HBeAg Loss in Chronic Hepatitis B Patients Receiving Continuous Oral Antiviral Therapy. 춘·추계 학술대회 (KASL). 2013;2013(1):86-7.	7
792	HCV, Acute, LT : Hepatic Stellate Cells Modulate Functions of Tregs in IFN γ -mediated Hepatitis of Mice. 춘·추계 학술대회 (KASL). 2013;2013(1):124-.	7
793	LC : Cell Type-Dependent Role of Class III Alcohol Dehydrogenase during Hepatic Fibrogenesis in Mice. 춘·추계 학술대회 (KASL). 2013;2013(1):118-.	7
794	LC : Efficacy of Immunological Measurement of Aspartate/ Alanine Aminotransferase with Monoclonal Antibodies in the Prediction of Liver Fibrosis. 춘·추계 학술대회 (KASL). 2013;2013(1):41-.	7
795	LC : Liver Stiffness Measurement Using Acoustic Radiation Force Impulse Elastography can Predict the Presence of Esophageal Varices in Patients with Compensated Liver Cirrhosis. 춘·추계 학술대회 (KASL). 2013;2013(1):113-4.	7
796	LC : Non-invasive Assessment of Fibrosis and Cirrhosis using Liver Fibrosis Measurement in Nonalcoholic Fatty Liver Disease. 춘·추계 학술대회 (KASL). 2013;2013(1):25-.	7
797	LC : Noninvasive Fibrosis Panels Predict 5-year Outcomes of Chronic Hepatitis B: Preliminary Study. 춘·추계 학술대회 (KASL). 2013;2013(1):115-.	7
798	LC : Risk Assessment of Clinical Outcomes in Asian Patients with Chronic B Viral Hepatitis using Enhanced Liver Fibrosis Test. 춘·추계 학술대회 (KASL). 2013;2013(1):65-.	7
799	LC : Which Noninvasive Hepatic Fibrosis Test Most Effectively Predicts Portal Pressure and Survival in Alcoholic Liver Disease Patients? 춘·추계 학술대회 (KASL). 2013;2013(1):23-4.	7
800	ORiginal Article : Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score. Gut and Liver. 2013;7(3):323-8.	10
801	Original Article : The usefulness of transient elastography, acoustic-radiation-force impulse elastography, and real-time elastography for the evaluation of liver fibrosis. Clinical and Molecular Hepatology(대한간학회지). 2013;19(2):156-64.	10
802	PARALLEL SYMPOSIUM 1 : MicroRNA and Cancer: Bioinformatics and NGS Perspective. 춘·추계 학술대회 (KASL). 2013;2013(1):213-.	7
803	Plenary Session I : Hepatic Vein Arrival Times Using a Microbubble Contrast Ultrasonography can Predict Disease Severity Non-invasively in Patients with Alcoholic Liver Disease. 춘·추계 학술대회 (KASL). 2013;2013(1):5-.	7
804	SPECIAL LECTURE 1 : Pathogenesis and Novel Therapeutic Targets of Alcoholic Liver Disease. 춘·추계 학술대회 (KASL). 2013;2013(1):205-.	7
805	Chung JH, Hyung SuKim, Sang GyuneLee, Yun NahKim, Young SeokJeong, Sung WonJang, Jae YoungLee, Sae HwanKim, Hong SooKim, Boo Sung. The usefulness of transient elastography, acoustic-radiation-force impulse elastography, and real-time elastography for the evaluation of liver fibrosis. Clin Mol Hepatol. 2013;19(2):156-64.	2

연번	서지정보	배제 사유
806	Eun Jin YK, KimSeung Up, KimHyon Suk, KimJun Yong, ParkDo Young, KimSang Hoon, AhnKwang Hyub, HanChae Yoon, Chon. LC : Risk Assessment of Clinical Outcomes in Asian Patients with Chronic B Viral Hepatitis using Enhanced Liver Fibrosis Test. 춘·추계 학술대회 (KASL). 2013;2013(1):65-.	7
807	Eun Ju CH, Leell Young, LeeMoon Young, KimJeong Ju, YooWon Mook, ChoiYoung Youn, ChoMin Jong, LeeYuri, ChoDong Hyeon, LeeYun Bin, LeeSu Jong, YuYoon Jun, KimChung,. LC : Which Noninvasive Hepatic Fibrosis Test Most Effectively Predicts Portal Pressure and Survival in Alcoholic Liver Disease Patients? 춘·추계 학술대회 (KASL). 2013;2013(1):23-4.	7
808	Hao PPL, M. J. Yu, G. R. Kim, I. H. Cho, Y. G.Kim, D. G. Isolation of pCAM+/CD133- hepatic progenitor cells. Molecules and cells. 2013;36(5):424-31.	10
809	Ho Hyun NW, JunHye Joon, JeonJai Sun, LeeWaqar Khalid, SaeedEun Kyung, Kim. Alcohol, NAFLD, Other : Osthol Attenuated Liver Steatosis via Decrease Liver De Novo Triglyceride Synthesis not by Insulin Resistance: Multifaceted Effects of Cindium Monnieri Extract. 춘·추계 학술대회 (KASL). 2013;2013(1):50-1.	7
810	Hyon Seung YS, LeeJin Seok, ByunYang Gun, SuhBin, GaoWon Il, Jeong. LC : Cell Type-Dependent Role of Class III Alcohol Dehydrogenase during Hepatic Fibrogenesis in Mice. 춘·추계 학술대회 (KASL). 2013;2013(1):118-.	7
811	Hyuk LW, LeeChoon Hee, Son. S-290 : 방사선치료 후 호전되었다가, 후유증으로 다시 발생한 상대정맥증후군 1예. 대한내과학회 추계학술발표논문집. 2013;2013(1):184-.	7
812	Jie L-K, NieJiu-Liang, ZhangFeng-Yan, LiuZhenzhen, WangZhi-Li, MaHui, He. Corn Peptides Protect Against Thioacetamide-Induced Hepatic Fibrosis in Rats. Journal of medicinal food. 2013;16(10):912-9.	8
813	Jong Ho CS, AhnSang Gyune, KimYun Nah, LeeYoung Seok, KimSung Won, JeongJae Young, JangSae Hwan, LeeHong Soo, KimBoo Sung, Kim. Original Article : The usefulness of transient elastography, acoustic-radiation-force impulse elastography, and real-time elastography for the evaluation of liver fibrosis. Clinical and Molecular Hepatology(대한간학회지). 2013;19(2):156-64.	2
814	Jung Ran CK, KimJung Il, LeeKyung Ah, LeeHyun Chung, ChungDa Hyun, JungKwan Sik, Lee. Alcohol, NAFLD, Other : Non-Invasive Measurement of Steatosis Grade by Controlled Attenuation Parameter Implemented on Fibroscan in Health Checkup Subjects. 춘·추계 학술대회 (KASL). 2013;2013(1):69-.	7
815	Ki Tae SH, LeeEui Yul, ChoiDong Joon, Kim. LC : Efficacy of Immunological Measurement of Aspartate/ Alanine Aminotransferase with Monoclonal Antibodies in the Prediction of Liver Fibrosis. 춘·추계 학술대회 (KASL). 2013;2013(1):41-.	7
816	Lee JE, Jeong Min Lee, Ye Ji Yoon, Jeong Hee Lee, Kyung Bun Han, Joon Koo Choi, Byung Ihn. The Effect of Gd-EOB-DPTA on the Stiffness Value of Magnetic Resonance Elastography in Evaluating Hepatic Fibrosis. J Korean Soc Magn Reson Med. 2013;17(3):215-23.	10
817	Lee TH, Seung Hye Yang, Ju Dong Kim, Donghee Ahmed, Monjur. Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score. Gut and liver. 2013;7(3):323-8.	10
818	Mi Sung PK, KimSeung Up, KimJun Yong, ParkDo Young, KimSang Hoon, AhnKwang Hyub, Han. LC : Prognostic Value of Combined Use of Liver Stiffness Measurement Using Transient Elastography and Fibrotest in Patients with Chronic Hepatitis B. 춘·추계 학술대회 (KASL). 2013;2013(1):114-.	7
819	Peipei H, 이미진, 유경란, 김인희, 조용곤,. Isolation of EpCAM+/CD133- Hepatic Progenitor Cells. Molecules and cells. 2013;36(5):424-31.	8
820	Qin NS, LeeHyon Seung, YiHyuk Soo, EunWon Il, Jeong. HCV, Acute, LT : Hepatic Stellate Cells Modulate Functions of Tregs in IFN γ -mediated Hepatitis of Mice. 춘·추계 학술대회 (KASL). 2013;2013(1):124-.	7
821	Ramon B. SPECIAL LECTURE 1 : Pathogenesis and Novel Therapeutic Targets of Alcoholic Liver Disease. 춘·추계 학술대회 (KASL). 2013;2013(1):205-.	7

연번	서지정보	배제 사유
822	Sanghyuk L. PARALLEL SYMPOSIUM 1 : MicroRNA and Cancer: Bioinformatics and NGS Perspective. 춘·추계 학술대회 (KASL). 2013;2013(1):213-.	7
823	Sung Won LC, NamEun Young, KimNa Young, KimJeong Won, JangSi Hyun, BaeJong Young, ChoiSeung Kew, Yoon. HBV : Reduction in the Liver Stiffness Value is Associated with HBeAg Loss in Chronic Hepatitis B Patients Receiving Continuous Oral Antiviral Therapy. 춘·추계 학술대회 (KASL). 2013;2013(1):86-7.	7
824	Tae Hoon LH, Han Ju Dong, Yang Dong Hee, Kim Mon Jur, Ahmed. Original Article : Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score. Gut and Liver. 2013;7(3):323-8.	10
825	Tae Hoon LH, HanJu Dong, YangDong Hee, Kim Monjur, Ahmed. Original Article : Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score. Gut and Liver. 2013;7(3):323-8.	10
826	Tae Hoon LH, Han Ju Dong, Yang Dong Hee, Kim Mon Jur, Ahmed. Original Article : Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score. Gut and Liver. 2013;7(3):323-8.	10
827	Won Ki HY, KimSoon Koo, BaikYoun Zoo, ChoHye Won, HwangJin Hyung, LeeMyeong Hun, ChaeSeung Yong, ShinJung Min, KimMee Yon, ChoSang Ok, Kwon. Plenary Session I : Hepatic Vein Arrival Times Using a Microbubble Contrast Ultrasonography can Predict Disease Severity Non-invasively in Patients with Alcoholic Liver Disease. 춘·추계 학술대회 (KASL). 2013;2013(1):5-.	7
828	Yehyun PU, KimBeom Kyung, KimJun Yong, ParkDo Young, KimSang Hoon, AhnKwang Hyub, Han. LC : Liver Stiffness Measurement Using Acoustic Radiation Force Impulse Elastography can Predict the Presence of Esophageal Varices in Patients with Compensated Liver Cirrhosis. 춘·추계 학술대회 (KASL). 2013;2013(1):113-4.	7
829	Yoshihiro O. [IR4-2] : Chronic inflammation and ectopic fat accumulation in the metabolic syndrome. International Congress of Diabetes and Metabolism. 2013;2013(0):44-.	7
830	Young Baek KH, KimHong Seok, ChoiYong, HwangYong Hoon, ChoiJun Jae, KimSeo Jung, WoongSoon Young, KoWon Hyeok, ChoeSo Young, Kwon. LC : Noninvasive Fibrosis Panels Predict 5-year Outcomes of Chronic Hepatitis B; Preliminary Study. 춘·추계 학술대회 (KASL). 2013;2013(1):115-.	7
831	Yun Nah LS, KimEun Sun, JungSeung Kew, YoonSi Hyun, BaeJong Young, ChoiMyeong Jun, SongChang Wook, KimSe Hyun, JoChang Don, LeeYoung Sok, LeeSang Wook, ChoiJin Mo, Yang. LC : Non-invasive Assessment of Fibrosis and Cirrhosis using Liver Fibrosis Measurement in Nonalcoholic Fatty Liver Disease. 춘·추계 학술대회 (KASL). 2013;2013(1):25-.	7
832	김문영. 간경변증과 문맥압항진증의 영상진단 : 도플러와 조영증강 초음파. Single Topic Symposium (STS). 2013;2013(1):1-10.	2
833	김민석, 김상균, 변진명, 윤라영, 한동훈, 문종주, 남재형, 김태진, 이세환, 정승원. 원저 : 원발성 담즙성 간경변증으로 진단되고 자가면역성 간염의 Feature를 보이는 한국인 환자에 대한 Simplified Scoring Criteria의 의미. Korean Journal of Medicine(구 대한내과학회지). 2013;84(2):211-20.	2
834	김지완, 김순중, 유광하, 이계영. S-311 : 폐를 침범한 IgG4 연관 자가 면역 질환 1예. 대한내과학회 추계학술발표논문집. 2013;2013(1):195-.	7
835	박건우, 정민웅, 오송희, 박종익, 박세령, 박형열. S-109 : 만성 C형 간염 환자에서 페그 인터페론 알파와 리바비린 병합요법으로 치료 후 발생한 돌발성 난청 1예. 대한내과학회 추계학술발표논문집. 2013;2013(1):94-.	7
836	박소정, 김호준. 조영증강 초음파 진단에서 호흡에 의한 움직임 보정 기법. 정보과학회논문지 : 소프트웨어 및 응용. 2013;40(3):176-81.	2
837	박희선. Hepatic Stiffness Measurement using Magnetic Resonance Elastography. Single Topic Symposium (STS). 2013;2013(1):26-7.	7
838	손춘희, 노미숙. P-108 : 폐암에 의한 상대정맥중후군 치료로 생긴 상대정맥 협착증. 대한결핵및호흡기학회 추계학술발표초록집. 2013;116(0):239-.	7

연번	서지정보	배제 사유
839	신승용, 조윤주, 김문영. S-100 : 초음파 및 조영 증강 초음파로 진단한 간담도 담관낭 선암의 예. 대한내과학회 추계학술발표논문집. 2013;2013(1):89-.	7
840	이무열, 이민, 정지영. 혈청 간섬유화 검사. 신의료기술평가 보고서. 2013;1(32):1-114.	7
841	이정은. The Effect of Gd-EOB-DPTA on the Stiffness Value of Magnetic Resonance Elastography in Evaluating Hepatic Fibrosis. Investigative Magnetic Resonance Imaging. 2013;17(3):215-23.	10
842	이정은, 이에지, 윤정희, 이경분, 한준구, 최병인. The Effect of Gd-EOB-DPTA on the Stiffness Value of Magnetic Resonance Elastography in Evaluating Hepatic Fibrosis. Investigative Magnetic Resonance Imaging. 2013;17(3):215-23.	2
843	이정은, 이에지, 윤정희, 이경분, 한준구, 최병인. 간 섬유화 평가를 위한 MR elastography의 경직도에 대한 Gd-EOB-DTPA의 영향. 대한자기공명의과학회지 = Journal of the Korean society of magnetic resonance in medicine. 2013;17(3):215-23.	10
844	이향선, 강태영, 최준정. S-586 : 혈청음성 류마티스 관절염과 B형 간염이 동반된 환자에서 발생한 특발성 후복막 섬유화증 1예. 대한내과학회 추계학술발표논문집. 2013;2013(1):332-.	7
845	장용호, 한성훈, 하태환, 김덕희, 류미진, 최예나, 백성석. S-566 : 전신경화증 환자에서 발생한 페아스페르길루스증 1예. 대한내과학회 추계학술발표논문집. 2013;2013(1):322-.	7
846	장효진, 현명수, 이경희, 고성애, 정다운, 정지윤, 구은주. S-486 : 원발성 폐암에서 동반된 단독 위전이 1예. 대한내과학회 추계학술발표논문집. 2013;2013(1):282-.	7
847	정우영, 김영선, 정윤정, 이규성, 신승수, 박광주, 황성철, 박주현. TP-88 : Plasmin 처리가 TGF- β 자극에 의한 섬유화를 억제하는 기전. 대한결핵및호흡기학회 추계학술발표초록집. 2013;116(0):226-.	7
848	지원준, 김호철, 이정수, 김동순. F-8 : 특발성 폐섬유화증 환자에서 GAP 병기 체계의 예측적 가치. 대한결핵및호흡기학회 추계학술발표초록집. 2013;116(0):110-.	7
849	최지호. Integrating systemic agents in clinic-based practice. 프로그램북(구 초록집). 2013;65(2):112-5.	7
850	황의동, 김영재, 임아영, 김송이, 정경수, 김은영, 정지예, 강영애, 박무석, 김영삼, 김세규, 장준. S-295 : 베체트병 환자에서 병발한 Ig G4 연관 폐질환의 1예. 대한내과학회 추계학술발표논문집. 2013;2013(1):187-.	7
851	Basic, HCC basic : O-029 ; Enhanced inactivation of immortalized hepatic stellate cell line by the synergistic effect of combination of HMG CoA reductase inhibitor and selective COX-2 inhibitor. 춘·추계 학술대회 (KASL). 2012;2012(1):27-.	7
852	HBV : PE-021 ; Hepatitis B surface antigen expression is associated with early recurrence in early stage hepatocellular carcinomas. 춘·추계 학술대회 (KASL). 2012;2012(-):75-.	7
853	HC, Acute : PE-112 : Combined effects of caspase inhibitor Nivocasan and lithospermate B on the inhibition of hepatic fibrosis in rats. 춘·추계 학술대회 (KASL). 2012;2012(1):114-5.	10
854	HC, Acute : PE-113 ; Validation of enhanced liver fibrosis test compared with liver stiffness and fibrotest for predicting liver fibrosis in chronic hepatitis B. 춘·추계 학술대회 (KASL). 2012;2012(1):115-.	10
855	HCC : PE-046 ; Utility of gadoteric acid-enhanced MRI in the surveillance for postoperative recurrence of hepatocellular carcinoma. 춘·추계 학술대회 (KASL). 2012;2012(1):86-.	7
856	Comparing 18F-Fluorodeoxyglucose Positron HCC : PE-048 ; Critical distance of tumor free effect in nonneoplastic parenchyme of hepatocellular carcinoma. 춘·추계 학술대회 (KASL). 2012;2012(-):87-.	10
857	HCV : PE-092 : A promising clinical utility of the controlled attenuation parameter (CAP) for noninvasive assessment of teatosis using Fibroscan®. 춘·추계 학술대회 (KASL). 2012;2012(1):104-5.	10
858	HCV, Alcoholic : PE-082 ; Relationship of IL28B gene polymorphism with liver fibrosis and hepatocellular carcinoma of chronic hepatitis C patients in Korea. 춘·추계 학술대회 (KASL). 2012;2012(1):100-.	7

연번	서지정보	배제 사유
859	HCV, Alcoholic : PE-092 ; A promising clinical utility of the controlled attenuation parameter (CAP) for noninvasive assessment of steatosis using Fibroscan®. 춘·추계 학술대회 (KASL). 2012;2012(-):104-5.	7
860	LC, Acute : O-056 ; The evaluation of effectiveness and safety for new therapy with bone marrow derived autologous mesenchymal stem cell for hepatic failure caused by alcoholic liver cirrhosis ? phase II study. 춘·추계 학술대회 (KASL). 2012;2012(1):38-9.	7
861	LC, Acute : PE-112 ; Combined effects of caspase inhibitor Nivocasan and lithospermate B on the inhibition of hepatic fibrosis in rats. 춘·추계 학술대회 (KASL). 2012;2012(-):114-5.	7
862	LC, Acute : PE-113 ; Validation of enhanced liver fibrosis test compared with liver stiffness and fibrotest for predicting liver fibrosis in chronic hepatitis B. 춘·추계 학술대회 (KASL). 2012;2012(-):115-.	7
863	LT, Other : O-065 : The results of protocol liver biopsy in patient with normal graft function who underwent liver transplantation due to hepatitis C virus related liver disease. 춘·추계 학술대회 (KASL). 2012;2012(-):43-.	10
864	LT, Others : O-065 ; The results of protocol liver biopsy in patient with normal graft function who underwent liver transplantation due to hepatitis C virus related liver disease. 춘·추계 학술대회 (KASL). 2012;2012(1):43-.	7
865	LT, Others : PE-131 ; A case of Caroli syndrome in adult. 춘·추계 학술대회 (KASL). 2012;2012(-):122-3.	7
866	Natural history and epidemiology of non-alcoholic fatty liver disease in Korea. 춘·추계 학술대회 (KASL). 2012;2012(1):127-34.	7
867	Beom Kyung KS, KimJun Yong, ParkDo Young, KimSang Hoon, AhnChae Yoon, ChonYoung Nyun, ParkKwang Hyub, HanSeung Up, Kim. HC, Acute : PE-113 ; Validation of enhanced liver fibrosis test compared with liver stiffness and fibrotest for predicting liver fibrosis in chronic hepatitis B. 춘·추계 학술대회 (KASL). 2012;2012(1):115-.	7
868	Beom Kyung KU, KimHyon Suk, KimJun Yong, ParkSang Hoon, AhnChae Yoon, ChonIn Rae, ChoDong Hoo, JohYoung Nyun, ParkKwang Hyub, HanDo Young, Kim. Plenary Session 1 : PS-1-3 ; Prospective validation of fibrotest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. 춘·추계 학술대회 (KASL). 2012;2012(1):3-4.	7
869	Chung YE, Ki Whang. Contrast Enhanced US in the Abdomen. J Korean Soc Ultrasound Med. 2012;31(4):203-12.	7
870	Do Young KI, ChungWeon Sang, RoYong Han, PaikYoung Nyun, ParkSang Hoon, AhnJung Gyu, ParkHee Dong, ParkKwan Sik, LeeKwang Hyub, Han. HC, Acute : PE-112 ; Combined effects of caspase inhibitor Nivocasan and lithospermate B on the inhibition of hepatic fibrosis in rats. 춘·추계 학술대회 (KASL). 2012;2012(1):114-5.	7
871	Hae Yoen JH, KimJing, JinKyoung Bun, LeeJa June, Jang. HCC : PE-048 ; Critical distance of tumor free effect in nonneoplastic parenchyme of hepatocellular carcinoma. 춘·추계 학술대회 (KASL). 2012;2012(1):87-.	7
872	Harry Y, ParkJeong Guil, LeeKyu Sung, RimPil Won, ParkSung Pyo, HongKwang Hyun, KoChang Il, KwonWon Hee, KimSeong Gyu, Hwang. HCV : PE-092 ; A promising clinical utility of the controlled attenuation parameter (CAP) for noninvasive assessment of steatosis using Fibroscan®. 춘·추계 학술대회 (KASL). 2012;2012(1):104-5.	7
873	Hong Kyu L, Cho Hee Sung, Lee Kun Il, Kim Hyoung Soo, Kim Seong Joon, Cho. Comparing 18F-Fluorodeoxyglucose Positron Emission Tomography and Video-assisted Thoracoscopic Surgery in the Evaluation of Small Pulmonary Nodules in Patients with a History of Malignancy. The Korean Journal of Thoracic and Cardiovascular Surgery. 2012;45(1):35-9.	10
874	Hye Young KW, LeeSukwon, SuhMin Su, ParkYoungrok, ChoiGeun, HongHae Won, LeeNam Joon, YiKyung Suk, Suh. LT, Others : O-065 ; The results of protocol liver biopsy in patient with normal graft function who underwent liver transplantation due to hepatitis C virus related liver disease. 춘·추계 학술대회 (KASL). 2012;2012(1):43-.	7

연번	서지정보	배제 사유
875	Jee Won HJ, YimHyun Jung, LeeSun Jae, LeeEileen, L. YoonSang Jun, SuhJi Hoon, KimJong Eun, YeonSoon Ho, UmKwan Soo, Byun. Basic, HCC basic : O-029 ; Enhanced inactivation of immortalized hepatic stellate cell line by the synergistic effect of combination of HMG CoA reductase inhibitor and selective COX-2 inhibitor. 춘·추계 학술대회 (KASL). 2012;2012(1):27-.	7
876	Jing J. HCC : PE-048 ; Critical distance of tumor free effect in nonneoplastic parenchyme of hepatocellular carcinoma. 춘·추계 학술대회 (KASL). 2012;2012(1):87-.	7
877	Jing JM, GawkHae Yeon, JungJa June, JangKyoung Bun, Lee. HBV : PE-021 ; Hepatitis B surface antigen expression is associated with early recurrence in early stage hepatocellular carcinomas. 춘·추계 학술대회 (KASL). 2012;2012(1):75-.	7
878	Lee H-K, Sung-WooLee, Hee-SungKim, Kun-IlKim, Hyung-SooCho, Seong-Joon. Comparing 18F-Fluorodeoxyglucose Positron Emission Tomography and Video-assisted Thoracoscopic Surgery in the Evaluation of Small Pulmonary Nodules in Patients with a History of Malignancy. The Korean journal of thoracic and cardiovascular surgery. 2012;45(1):35-9.	10
879	Lee HK, Sung Woo Lee, Hee Sung Kim, Kun Il Kim, Hyung Soo Cho, Seong Joon. Comparing 18F-Fluorodeoxyglucose Positron Emission Tomography and Video-assisted Thoracoscopic Surgery in the Evaluation of Small Pulmonary Nodules in Patients with a History of Malignancy. Korean J Thorac Cardiovasc Surg. 2012;45(1):35-9.	1
880	Moon Young KK, BaikYoon Ok, JangSo Yeon, ParkBo Ra, KimRyu Ho, YoelYong Kwan, Leell Young, LeeSang Ok, Kwon. LC, Acute : O-056 ; The evaluation of effectiveness and safety for new therapy with bone marrow derived autologous mesenchymal stem cell for hepatic failure caused by alcoholic liver cirrhosis ? phase II study. 춘·추계 학술대회 (KASL). 2012;2012(1):38-9.	7
881	So Yoon YH, KimIl Hwan, MoonKwon, YooSun Young, YiSung Ae, JungKi Nam, ShimHye Kyung, JungSeong Eun, KimWon Yung, ChoHye In, KimEun Mi, SongKyung Joo, Kwon. LT, Others : PE-131 ; A case of Caroli syndrome in adult. 춘·추계 학술대회 (KASL). 2012;2012(1):122-3.	7
882	Tae Yeob KH, Sohn. Natural history and epidemiology of non-alcoholic fatty liver disease in Korea. 춘·추계 학술대회 (KASL). 2012;2012(1):127-34.	7
883	Yang Won MW, PaikGeum Youn, GwakYong Han, PaikMoon Seok, ChoiJoon Hyeok, LeeKwang Cheol, KohByung Chul, Yoo. HCC : PE-046 ; Utility of gadoxetic acid-enhanced MRI in the surveillance for postoperative recurrence of hepatocellular carcinoma. 춘·추계 학술대회 (KASL). 2012;2012(1):86-.	7
884	Young Kul JY, ParkMin Young, RimIn Ku, YoMin Su, HaJu Seung, KimJu Won, LeeOh Sang, KwonYun Soo, KimDuck Joo, ChoiJu Hyun, Kim. HCV, Alcoholic : PE-082 ; Relationship of IL28B gene polymorphism with liver fibrosis and hepatocellular carcinoma of chronic hepatitis C patients in Korea. 춘·추계 학술대회 (KASL). 2012;2012(1):100-.	7
885	김여향, 강석진, 정지영, 이희정, 현명철. 청소년 폐결핵의 임상적 및 영상학적 특징 : 재활동성 결핵과의 관련성. Pediatric allergy and respiratory disease. 2012;22(2):163-70.	1
886	곽낙원, 이진우, 박영식, 이상민, 임재준, 유철규, 김영환, 한성구, 이창훈,. CPFЕ, 특발폐섬유증, 폐기종의 폐암 발생 위험률 비교. 대한결핵및호흡기학회 추계학술발표초록집. 2012;114(0):166-.	7
887	김상찬, 김현욱, 최지혜, 장재영, 최을수. 개에서 발생한 장간막 점액육종의 한 증례. 한국임상수의학회지. 2012;29(2):173-6.	8
888	남수정, 조재용, 이혜승, 최기영,장 자준, 윤유석, 한호성. Chemotherapy-Associated Hepatopathy in Korean Colorectal Cancer Liver Metastasis Patients: Oxaliplatin-Based Chemotherapy and Sinusoidal Injury. Journal of Pathology and Translational Medicine. 2012;46(1):22-9.	2
889	박찬애, 한정민. O-5 : 소변에서 발견된 방광주혈흡충란 1예. 임상미생물검사학회 초록집. 2012;2012(1):27-.	7

연번	서지정보	배제 사유
890	도경현, 오동규, 이상민, 한승봉, 김동순. 특발성폐섬유증 환자에서 폐기종 동반 여부가 노력성폐활량(FVC) 감소 및 생존에 미치는 영향 - 임상연구와 관련된 관점에서의 분석. 대한결핵및호흡기학회 추계학술발표초록집. 2012;114(0):248-.	1
891	유병철, 정승원, 장재영, 구소미, 김상균, 김영석, 전찬홍, 진윤미. 전신성 경화증과 동반된 자가면역성 간염에 의한 간경변. 대한소화기학회지. 2012;59(1):48-52.	6
892	이병춘, 김현진, 정양화, 최준호, 이원홍, 차현정. 간 섬유화 진단을 위한 Liver Shear Wave Elastography의 유용성. 대한초음파의료영상학회지. 2012;3(1):9-14.	2
893	정용은. 복부 조영증강 초음파. ULTRASONOGRAPHY. 2012;31(4):203-12.	10
894	정용은, 김기황. 복부 조영증강 초음파. ULTRASONOGRAPHY. 2012;31(4):203-12.	7
895	고재경, 황성환, 박진모, 박정훈. 성인의 조갑하에 발생한 황색육아종. 대한피부과학회지. 2012;50(10):928-30.	1